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Multiple myeloma 
Multiple myeloma is characterized by the accumulation of monoclonal plasma cells in the 
bone marrow (Figure 1). The neoplastic cells are long-lived cells with a low proliferative 
index, and produce a monoclonal immunoglobulin (M-component, paraprotein). The 
amount of the M-component in the serum is a reliable measure of tumor burden and can 
therefore be used as an excellent tumor marker. In about 20% of the myeloma patients 
only light chains are produced which are secreted in the urine as Bence Jones proteins, 
and 2% of the patients have nonsecretory myeloma characterized by the absence of 
detectable monoclonal protein in serum and urine. The tumor cells and the M-component 
are responsible for a number of organ dysfunctions and symptoms including bone disease, 
renal failure, increased susceptibility to infection, anemia, and sometimes clotting 
abnormalities or manifestations of hyperviscosity. Myeloma is an incurable disease and 
accounts for 1% of all cancers and more than 10% of all malignant hematologic diseases. 
The incidence of myeloma is 4 per 100,000 per year and the median age of diagnosis is 68 
years. Survival of myeloma patients ranges from as short as 2 months to greater than 80 
months after diagnosis and depends on a variety of prognostic factors including plasma 
cell labeling index 1, level of β2-microglobulin 2, plasmablastic morphology 3, and 
cytogenetics 4-7.  
 
Cytogenetics  
Chromosome 14q32 translocations seem to be important in the pathogenesis of myeloma 
and are detected in the majority of the patients 8,9. These translocations result in the 
deregulation of expression of oncogenes by juxtaposing them near one of the IgH 
enhancers. Primary translocations are early events, occur in germinal center B cells as a 
result of errors in IgH switch recombination, or less often somatic hypermutation, and are 
characterized by the absence of clonal heterogeneity. These translocations are also 
detected in patients with monoclonal gammopathy of undetermined significance (MGUS) 
10,11, and therefore it is supposed that they are not sufficient for malignant transformation, 
but may be initial clone-immortalizing events. Secondary translocations occur during 
tumor progression, are usually complex, involve other mechanisms than aberrant class 
switch recombination or somatic hypermutation, are less often IgH associated, and 
characterized by the presence of intraclonal heterogeneity 12-14. There are 4 recurrent 
primary translocations that together account for 40% of all translocations: 
t(11;14)(q13;q32) (cyclin D1) 15, t(4;14)(p16;q32) (MMSET; FGFR3) 16,17, 
t(6;14)(p21;q32) (cyclin D3) 18, and t(14;16)(q32;q23) (c-maf) 19. The t(4;14) 
translocation is associated with a poor prognosis, whereas the t(11;14) predicts good 
clinical outcome 19-21. The biologic consequences regarding apoptosis, drug resistance, 
and proliferation of these translocations are at the moment poorly understood. 
Deregulation of Cyclin D1 as a result of the t(11;14) translocation may lead to loss of cell 
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cycle control 22, and c-Maf can transform fibroblasts 5. Expression of the fibroblast growth 
factor receptor-3 (FGFR3) as a result of the t(4;14) translocation leads to activation of the 
MAPK pathway 23,24 and FGFR3 signaling can substitute for interleukin-6 (IL-6) for the 
growth and survival of an IL-6-dependent myeloma cell line 25. In addition, FGFR3 can 
transform hematopoietic cells 26 and fibroblasts 23,24. Furthermore, expression of FGFR3 
in myeloma cells resulted in dexamethasone-resistance, probably through the up-
regulation of Bcl-XL 27. Disease progression is characterized by an increasing number of 
chromosomal abnormalities (c-Myc) 28,29, activating mutations of genes such as FGFR3 
and Ras 17,30-34, and changes in expression of genes (p16INK4a) 35,36, enabling the tumor to 
survive and proliferate independently of the bone marrow microenvironment. 
Monosomy of chromosome 13 or deletion of chromosome 13q14 is observed in 
about 50% of the patients and is associated with poor response to therapy and a short 
progression free and overall survival 5,7,37,38. The gene or genes that are deleted on 
chromosome 13 and are responsible for the poor prognosis have yet to be defined.  
 
 
 
Figure 1. Bone marrow aspiration of a myeloma patient. Smear of bone marrow aspirate, with extensive 
infiltration by polymorphous plasma cells.  
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Drug resistance 
High-dose therapy followed by autologous stem cell transplantation has improved 
response rate and survival when compared with conventional chemotherapy 39. However, 
in all myeloma patients the disease ultimately relapses and becomes resistant to 
subsequent drug treatments. In myeloma, many mechanisms of drug resistance exist and 
insight in these mechanisms is essential to make progress in the therapy of myeloma. 
These mechanisms include alterations in drug transport by proteins such as P-glycoprotein 
40-43 and lung resistance protein (LRP) 44,45. Inhibition of drug efflux from cancer cells 
with P-glycoprotein inhibitors has demonstrated variable success in clinical trials 40,46. 
Mutations or deletions in the target genes may also be involved, an example of which is 
expression of a truncated glucocorticoid receptor (GR), which was associated with steroid 
resistance 47,48. Furthermore, altered expression of target genes such as DNA 
Topoisomerase II and the glucocorticoid receptor 47,49,50, and enhanced detoxification of 
drugs by enzymes such as glutathione S-transferase or by elevated levels of glutathione 51 
may contribute to chemoresistance. Increased rates of repair of damage to DNA have also 
been shown to be a mechanism of clinical resistance to melphalan 52. However, since 
cytotoxic agents induce cell death through the triggering of apoptosis 53, inhibition of 
drug-induced apoptosis has been suggested as a major contributor of drug resistance in 
myeloma 54,55. 
 
Deregulation of apoptosis in myeloma 
Defects in the regulation of programmed cell death resulting in a survival advantage play 
an important role in the accumulation of slowly proliferating myeloma cells in the bone 
marrow. Furthermore, failure of myeloma cells to undergo programmed cell death may 
result in resistance to chemotherapeutic agents. Several studies have demonstrated the 
importance of the bone marrow microenvironment in promoting myeloma cell growth, 
survival, and drug resistance. Growth factors such as IL-6 and insulin-like growth factor I 
(IGF-I), which are predominantly produced by bone marrow stromal cells result in 
dysfunction of growth and survival pathways, and may render myeloma cells resistant to a 
variety of cytotoxic agents. For example, IGF-I and IL-6 protect against drug-induced 
apoptosis via PI-3K signaling and NF-κB activation. Furthermore, adhesion of myeloma 
cells to extracellular matrix components protects against a variety of cytotoxic agents.  
Various studies have demonstrated constitutive activation of growth and survival 
signaling pathways in myeloma tumor cells, which may be, at least in part, due to 
interactions between myeloma cells and the bone marrow microenvironment. However, 
deregulation of oncogenes and tumor suppressor genes as a result of mutations (Ras, 
FGFR3) or alterations in expression (PTEN, deletion of chromosome 13q14, Mcl-1) may 
also be involved in the activation of pathways leading to a variety of cellular processes 
including drug resistance, survival, and proliferation of myeloma tumor cells. 
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Micro-environment 
Myeloma cells secrete IL-1β, tumor necrosis factor-α (TNF-α), vascular endothelial 
growth factor (VEGF), and IL-6 56-59 and binding of myeloma cells to bone marrow 
stromal cells triggers the secretion of IL-6, IGF-I, VEGF, and transforming growth factor-
β (TGF-β) from bone marrow stromal cells 60,61. Myeloma cells also produce cytokines 
(TNF-α, TGF-β, VEGF) that can further upregulate IL-6 secretion in bone marrow 
stromal cells 56,62,63. Furthermore, enhanced osteoclastic bone resorption induced by 
myeloma cells results in the release of diverse cytokines and growth factors from the 
extracellular matrix. In addition, the osteoclast itself is a potent producer of IL-6 64. These 
findings indicate that there is a symbiotic relationship between myeloma cells and the 
bone marrow microenvironment. These cytokines not only contribute to the expansion of 
the myeloma tumor clone through the promotion of survival, proliferation, and 
angiogenesis, but also contribute to bone destruction and block the apoptotic effects of 
various cytotoxic agents (Figure 2). IL-6 is one of the most important growth factors for 
myeloma cells, and is predominantly produced in a paracrine way by bone marrow 
stromal cells, but also by activated osteoclasts 65-67. IL-6 induces myeloma cell 
proliferation and inhibits apoptosis, and overrides the apoptotic signals mediated by 
cytotoxic drugs 68. Binding of IL-6 to the IL-6 receptor triggers the activation of at least 3 
signaling pathways; the JAK/STAT pathway 69, the Ras/mitogen-activated protein kinase 
(MAPK) pathway 70,71, and the phosphatidylinositol-3 kinase (PI-3K) pathway 72. 
Activation of the JAK/STAT 73 and PI-3K pathways 74 is implicated in protection against 
apoptosis, whereas activation of the Ras-MAPK 70 and PI-3K pathways 74 induces 
proliferation. Blocking of the IL-6 receptor can overcome drug resistance of myeloma 
cells 75. IGF-I is also an important growth factor for myeloma cells and stimulates 
proliferation and protects myeloma tumor cells against death induced by dexamethasone 
72,76-80. IGF-I stimulation leads to activation of both the MAPK and the PI-3K pathways, 
but the PI-3K pathway was demonstrated to be the major regulator of both apoptosis and 
proliferation, with only minimal contributions to either by the MAPK cascade 76,81. IGF-I 
is produced in the liver, and also by osteoblasts in the bone marrow microenvironment 
82,83. Finally, adhesion of myeloma tumor cells to extracellular matrix proteins such as 
fibronectin via β1 integrins 84,85 or bone marrow stromal cells 86,87 reduces the sensitivity 
of tumor cells to a variety of chemotherapeutic agents (cell adhesion-mediated drug 
resistance; CAM-DR).  
 
Ras 
Ras proteins (H-, K-, and N-Ras) have been shown to play a key role in signal 
transduction pathways leading to survival or growth, and in malignant transformation. Ras 
proteins cycle between an inactive guanosine 5’-diphosphate (GDP)-bound state and an  
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Figure 2. Growth factors activate signaling pathways leading to proliferation, survival, and resistance to 
cytotoxic agents. Myeloma cell proliferation is mediated through activation of MAPK, PI-3K, and NF-κB 
signaling pathways. Survival is mediated by activation of JAK/STAT, NF-κB, and PI-3K pathways. Inhibition of 
drug-induced apoptosis is an important mechanism of drug resistance in myeloma.  
 
 
active guanosine 5’-triphosphate (GTP)-bound state. Regulatory proteins that control the 
GDP/GTP cycling rate of Ras include GTPase-activating proteins (GAPs), which enhance 
the rate of GTP hydrolysis to GDP, and guanine nucleotide exchange factors (GEFs), 
which induce the dissociation of GDP to allow association of GTP 88. Active GTP-bound 
Ras modulates the activity of effector proteins including Raf-1 and PI-3K. Point mutations 
at codons 12, 13, or 61 lead to a constitutive active GTP-bound state.  
In multiple myeloma, Ras plays an important role in the control of both 
proliferation, apoptosis, and drug resistance. In myeloma cells, IL-6 triggers the transition 
of Ras from the inactive GDP-bound form to the active GTP-bound form and activates the 
MAPK pathway, leading to proliferation 70,89. This suggests that Ras proteins transduce 
proliferation signals through their activation of Raf-MAPK pathway, but they are also 
involved in the transduction of survival and growth signals through pathways such as PI-
3K/Akt and NF-κB 90. Ras mutations are found in many human cancers 91, including 
multiple myeloma. The frequency of Ras mutations is 39% in patients with newly 
diagnosed disease 30, and increases to 64-70% in patients with advanced disease 31,32. 
Furthermore, Ras mutations are absent in patients with MGUS 92,93. This suggests that 
mutations of Ras represent a progression event and not an initiating event. The presence 
of Ras mutations at diagnosis is associated with an adverse outcome, a poor response to 
therapy 31, and a shorter survival 30. In vitro studies showed that Ras mutations are 
associated with IL-6-independent growth 94,95, and provided resistance against apoptosis 
NF-κB
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P42/44 MAPK
MEK
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induced by cytotoxic agents such as dexamethasone, doxorubicin, and melphalan 86,95,96 
through the constitutive activation of MAPK, PI-3K, and NF-κB signaling pathways 90. 
The role of other small GTP-binding proteins including the Rho family members such as 
Rac-1, RhoA, and Cdc42 in the regulation of myeloma cell growth and drug resistance is 
currently unknown. 
 
Nuclear factor-κB 
Nuclear factor-κB (NF-κB) is a transcription factor involved in the regulation of a variety 
of cellular processes including apoptosis, differentiation, and inflammatory responses and 
is typically a heterodimer of p50 and p65 subunits 97. In most cell types, NF-κB resides in 
the cytosol and is inactivated by its association with IκB family inhibitors. Activators of 
NF-κB such as TNF-α, result in the activation of IκB kinase (IKK), which phosphorylates 
IκB in a site-specific way. This leads to the ubiquitination-dependent degradation of IκB 
by the 26S proteasome 98. The direct consequence is the translocation of NF-κB from the 
cytoplasm into the nucleus, where it binds to specific DNA sequences in the promoters of 
target genes leading to stimulation of their transcription. 
Various reports have indicated constitutive activity of NF-κB in myeloma 
patients’ samples and in myeloma cell lines 99-101. Maintenance of constitutive activity of 
NF-κB was associated with resistance of myeloma cell lines to dexamethasone 99. 
Inhibition of NF-κB activity induced apoptosis, inhibited proliferation, potentiated the 
cytotoxic effects of chemotherapeutic agents, and abrogated the protective effect of IL-6 
on dexamethasone- and thalidomide derivatives-induced growth inhibition 100-102. 
Furthermore, adhesion of myeloma cells to bone marrow stromal cells and TNF-α 
secreted by myeloma cells trigger the transcription and secretion of the important growth 
and survival factor IL-6 through the activation of NF-κB in the stromal cells 103,104. These 
results indicate that NF-κB plays an important role in myeloma cell survival, proliferation, 
and drug resistance. In myeloma cell lines, the proteasome inhibitor PS-341 (Velcade, 
Bortezomib) has been shown to induce apoptosis, to inhibit proliferation, and to sensitize 
myeloma cells to conventional chemotherapeutic agents which was, at least in part, due to 
inhibition of NF-κB activity 102,105-107. These results provided the framework for clinical 
trials of PS-341. These clinical studies have shown that PS-341 has activity against 
refractory multiple myeloma 108,109.  
 
PI-3K/Akt pathway 
Activation of PI-3K results in the generation of phosphatidylinositol (PI) phosphates 
including PIP3. One target of PI-3K and the phospholipids is Akt (protein kinase B; PKB). 
The phospholipid molecules bind to the pleckstrin-homology domain of Akt, resulting in 
its translocation to the cell membrane and phosphorylation at serine and threonine 
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residues by PDK 1 and 2. This phosphorylation of Akt leads to the efficient activation of 
Akt kinase activity 110-112. Activated Akt subsequently phosphorylates several substrates, 
including BAD, glycogen synthase kinase-3, and the Forkhead family of transcription 
factors. 
Constitutive activation of PI-3K and Akt was found in myeloma cell lines 72 and 
in myeloma cells from patients, whereas Akt activation was not observed in non-
malignant hematopoietic cells from the same patients 72,113. Various studies have shown 
that the myeloma growth and survival factors IL-6 and IGF-I can activate the PI-3K/Akt 
pathway in myeloma cells 72,74,81,114,115. These growth factors may therefore contribute to 
the activation of the PI-3K/Akt pathway in myeloma cells in vivo. However, loss-of-
function mutations in PTEN may also be involved. The tumor suppressor PTEN is an 
important negative regulator of PI-3K/Akt activation. It dephosphorylates PI-3K products 
such as PIP3 and leads to a concomitant reduction in Akt activity 116,117. Loss of PTEN 
expression was found in myeloma cell lines 115. Induction of proliferation, survival, and 
protection against cytotoxic agents mediated by IGF-I and IL-6 were, at least in part, 
dependent on the activation of a PI-3K-dependent pathway 72,74,81. Activation of Akt by 
PI-3K may be responsible for the proliferative and anti-apoptotic effects of PI-3K, since 
expression of a dominant-negative Akt gene in myeloma cells or pharmacologic inhibition 
of Akt resulted in a decreased number of cells in S phase and increase in apoptosis 113,118. 
In addition, expression of constitutively active Akt protected myeloma cells against both 
novel and conventional anti-tumor agents 118. Downstream targets of Akt that are involved 
in the control of survival and proliferation of myeloma cells include p70S6 kinase and the 
Forkhead family of proteins 74,81,90,115. 
 
Bcl-2 family proteins and regulation of apoptosis 
The Bcl-2 family consists of anti-apoptotic (Bcl-2, Bcl-XL, Bcl-W, Bfl-1, Mcl-1, A1) and 
pro-apoptotic (Bax, Bak, Bid, Bcl-XS, Bad, Bik, Bim, Hrk) family members. The ratio of 
death agonists to death antagonists determines whether a cell will survive or die after an 
apoptotic signal. Alterations in the highly regulated expression of anti- and pro-apoptotic 
Bcl-2 family proteins can contribute to the development of cancer. Deregulated 
overexpression of anti-apoptotic Bcl-2 family members may result in an extended 
survival. These cells are at risk for the acquisition of additional genetic changes, and 
subsequent malignant transformation. Moreover, the ratio of anti- and pro-apoptotic Bcl-2 
family members determines the susceptibility of cancer cells towards a variety of 
cytotoxic agents 119,120. Anti-apoptotic Bcl-2 family proteins do not affect drug transport 
or drug-induced DNA damage, however, tumor cells with elevated levels of these proteins 
have a reduced susceptibility to apoptosis induction during drug treatment and can repair 
drug-induced damage when administration of the drug is stopped.  
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Bcl-2 family proteins contain at least one of four conserved Bcl-2 homology 
(BH) domains designated BH1, BH2, BH3, and BH4 121-123. Part of the Bcl-2 family 
proteins also possesses a carboxyl-terminal hydrophobic domain, which is important for 
membrane docking 124. Anti-apoptotic Bcl-2 family members are localized in the 
mitochondrial outer membrane, the endoplasmic reticulum, or nuclear membrane 125-128. A 
substantial fraction of the pro-apoptotic Bcl-2 family members, however, reside in the 
cytosol or localize to the cytoskeleton 129-131. Following a death signal, these pro-apoptotic 
proteins undergo a change of conformation and translocate to mitochondria. Moreover, 
part of the pro-apoptotic proteins can also integrate in the mitochondrial outer membrane. 
For example, in viable cells Bax is predominantly localized in the cytosol or loosely 
attached to membranes, but following a death signal Bax translocates to the outer 
membrane of mitochondria and becomes an integral membrane protein 130,132. Bid is 
cleaved at its amino-terminus following TNF-α/Fas signaling by activated caspase-8 and 
the truncated Bid form moves to mitochondria 133-136. It is hypothesized that following 
translocation of pro-apoptotic proteins to mitochondria, the activity of the anti-apoptotic 
Bcl-2 family members is neutralized through the formation of heterodimers. In addition, 
the pro-apoptotic members with hydrophobic core α helices such as Bax and Bid can 
become integral mitochondrial membrane proteins and may form selective channels for 
cytochrome c release and other factors from the intermembrane space 120,137-139. 
Alternatively, these proteins may alter the activity of pre-existing channels such as the 
permeability transition pore (PTP) 140-142. Opening of the PTP results in mitochondrial 
depolarization, uncoupling of oxidative phosphorylation, and mitochondrial swelling 
leading to the rupture of the mitochondrial outer membrane and release of cytochrome c 
143. The anti-apoptotic Bcl-2 family proteins inhibit apoptosis by neutralizing the function 
of pro-apoptotic Bcl-2 family members, or by suppression of the activity of components 
of the PTP, or a combination of these 144. Cytochrome c in the cytosol binds to Apaf-1 and 
induces a conformational change in Apaf-1 allowing it to associate with caspase-9, 
resulting in activation of caspase-9 which, in turn, activates effector caspase-3 145, 
resulting in the cleavage of key proteins (Figure 3) 146. This leads to cellular changes that 
occur during apoptosis including DNA fragmentation, chromatin condensation, membrane 
blebbing, cell shrinkage, and disassembly of the cell into membrane-enclosed vesicles 
(apoptotic bodies). Caspases cleave other caspase family members, signal transduction 
proteins, cytoskeletal proteins, chromatin modifying proteins (eg, polyADP ribosyl 
polymerase, PARP), DNA repair proteins, and inhibitory subunits of endonucleases 
specifically at aspartic acid residues 147. One group of substrates of the effector caspases 
includes the anti-apoptotic Bcl-2 family members 148,149. Cleavage not only inactivates 
these proteins, but also creates a form that promotes apoptosis, suggesting a positive feed-
back loop. Some studies have reported that anti-apoptotic Bcl-2 family proteins can also 
inhibit the ability of Apaf-1 to activate caspase-9 150. The anti-apoptotic family member 
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Bcl-XL can bind Apaf-1 and some pro-apoptotic Bcl-2 family proteins have been shown 
to dissociate this complex 151-154. The inhibitor of apoptosis (IAP) proteins such as 
survivin and XIAP can inhibit activated caspases and activation of pro-caspases, and 
thereby prevent apoptosis 155. Their role in myeloma, however, is unknown. Another 
apoptogenic protein that is released from mitochondria is Smac/DIABLO. Once released, 
Smac/DIABLO interacts with and neutralizes XIAP, an inhibitor of caspase-3 and -9, 
thereby facilitating caspase activation 156,157.  
 
Figure 3. Cytochrome c-mediated activation of Apaf-1, results in the activation of a downstream caspase 
program. The ratio of anti-apoptotic and pro-apoptotic Bcl-2 family proteins determines the susceptibility of 
cells to a death signal. 
 
 
Bcl-2 in myeloma 
Bcl-2 was identified at the t(14;18) chromosome translocation breakpoint. This 
translocation is present in about 90% of follicular lymphomas and in up to 30% in diffuse 
large B-cell lymphomas 158-160. This translocation results in the juxtaposition of Bcl-2 
normally located on chromosome 18, with transcriptional enhancer regions in 14q32, thus 
deregulating the expression of Bcl-2 and giving the B cells containing this translocation a 
survival advantage. Although these B cells have a low growth fraction, the increased life 
span results in clonal expansion. Several studies have demonstrated significant Bcl-2 
expression in malignant cells of patients with myeloma 161-167, however the t(14;18) 
translocation is not present in myeloma cells. This indicates that other mechanisms such 
as hypomethylation of the Bcl-2 gene 168, constitutive activity of NF-κB which induces 
Bcl-2 transcription 169,170, or loss of the p53 tumor suppressor which inhibits Bcl-2 gene 
expression 171,172, may be involved. Overexpression of Bcl-2 in B cells through use of an 
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immunoglobulin gene enhancer in transgenic mice prolongs the life span of plasma cells 
and B cells 173,174, and in combination with abnormal expression of other oncogenes such 
as c-myc, contributes to the development of immature pre-B cell lymphoma, large cell 
lymphoma, or plasmacytoma in the mice 175,176. Altogether these data suggest a role for 
Bcl-2 in the etiology of myeloma and non-Hodgkin’s lymphomas.  
There are several lines of evidence that suggest that Bcl-2 plays a role in drug 
resistance in myeloma. Bcl-2 overexpression using gene transfer approaches rendered 
myeloma cells more resistant to a variety of cytotoxic drugs 177,178, and protected against 
IL-6 deprivation-induced apoptosis 179. In addition, Bcl-2 protein levels increased 
following exposure of cell lines to doxorubicin, which may account for the relative 
resistance to a second doxorubicin exposure 178. Also in leukemia and solid tumor cell 
lines, Bcl-2 levels correlate with relative sensitivity to various chemotherapeutic agents 
and γ-radiation 123.  
High expression of Bcl-2 in malignant cells of patients with acute myeloid 
leukemia and high-grade B cell lymphoma is associated with poor response to therapy 
180,181. In myeloma, the prognostic significance of Bcl-2 expression is currently unclear. In 
3 studies no correlation between Bcl-2 expression, which was determined by 
immunohistochemistry or immunofluoresence, and response to chemotherapy or survival 
was observed 163,164,167. All these studies, however, suffer from small sample size. 
Moreover, the expression of other anti- and pro-apoptotic Bcl-2 family proteins was not 
evaluated. Finally, one study showed that high levels of Bcl-2 expression were associated 
with resistance to interferon therapy 163. Larger studies using flow cytometric analysis to 
objectively quantify Bcl-2 expression are required to further assess the prognostic 
significance of Bcl-2. In summary, in myeloma the role of Bcl-2 in drug resistance is still 
unclear and needs further clarification.  
 
Other Bcl-2 family proteins in myeloma 
Bcl-XL is expressed in myeloma cells, and appears to be up-regulated in specimens taken 
from patients at the time of relapse, when compared to expression levels at initial 
diagnosis. In addition, Bcl-XL expression correlated with decreased response rates in 
patient groups treated with either melphalan and prednisone or with vincristine, 
Adriamycin, and dexamethasone 182. However, down-regulation of Bcl-XL protein 
expression in myeloma cell lines did not induce apoptosis or enhance chemosensitivity 183, 
suggesting that Bcl-XL is not involved in drug resistance in myeloma, but serves as an 
indicator of chemoresistance. Bcl-XS is a protein that arises through alternate splicing of 
Bcl-X 184, but is not expressed in myeloma cells 182. 
In normal cells Mcl-1 expression is rapidly up-regulated during critical events 
such as changes in proliferation, differentiation, and cellular stress 185, suggesting that its 
function is to provide short-term, rapidly inducible enhancement of cell viability 186. Mcl-
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1 is expressed during specific stages of B cell development. Expression is low in naive B 
cells and memory B cells, while expression is prominent in germinal center B cells 187,188. 
The expression of Bcl-2 follows a reciprocal pattern. Germinal center B cells undergo 
affinity maturation and the majority of the cells die by apoptosis, in contrast to Bcl-2 
positive naive and memory B cells, which survive for an extended period of time. Mcl-1 is 
supposed to promote survival of germinal center B cells for a short period of time, to 
allow the selection of clones with appropriate antibody affinity. However, deregulated or 
constitutive expression of Mcl-1, as opposed to the transient expression in normal cells, 
may result in enhanced survival over the long term and tumorigenic conversion and may 
attribute to resistance of tumor cells to cytotoxic drugs. In cell lines, Mcl-1 promotes cell 
viability under a variety of apoptosis-inducing conditions including exposure to cytotoxic 
agents and the withdrawal of required growth factors 189,190. Furthermore, overexpression 
of Mcl-1 has been correlated with failure to achieve complete remission in B-cell chronic 
lymphocytic leukemia (B-CLL) patients treated with chemotherapy 191. Overexpression of 
Mcl-1 in transgenic mice prolongs the life span of myeloid and lymphoid (B and T) cells 
at both mature and immature stages of differentiation 192 and contributes to the 
development of follicular B-cell lymphoma and diffuse large-cell lymphoma in 
approximately 85% of the mice after a follow-up of 2 years 193.  
Mcl-1 is overexpressed in myeloma cells, when compared with normal plasma 
cells 194. In part of the myeloma cell lines, Mcl-1 and Bcl-XL are coregulated by the 
important growth and survival factor IL-6 195. The JAK-STAT signal transduction 
pathway seems to be responsible for the up-regulation of Bcl-XL and Mcl-1 by IL-6 73,196. 
In the majority of myeloma cell lines and myeloma patients’ samples, however, Mcl-1 
regulation is IL-6-independent and not controlled by the JAK-STAT, MAPK, or PI-3K 
signaling pathways 197, whereas these signaling pathways have been shown to stimulate 
Mcl-1 transciption in a variety of other cell lines. Down-regulation of Mcl-1 induced 
apoptosis in myeloma cells 183,198,199 and sensitized myeloma cells towards cytotoxic 
agents 183. This indicates that Mcl-1 is an important regulator of survival and 
chemosensitivity in myeloma cells. The role of the other Bcl-2 family proteins in multiple 
myeloma remains to be elucidated. 
 
Mevalonate pathway and prenylation 
Deregulated or elevated activity of HMG-CoA reductase, which is the rate-limiting 
enzyme of the mevalonate pathway, has been demonstrated in a variety of human cancers 
including leukemia and lymphoma 200,201. Furthermore, inhibition of the mevalonate 
pathway induces apoptosis and inhibits proliferation in acute myeloid leukemia cells 202. 
The role of the mevalonate pathway in myeloma is unknown.  
Cells obtain cholesterol from 2 sources: 1) exogenously from low-density 
lipoprotein (LDL) which enters the cell via receptor-mediated endocytosis; and 2) 
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endogenously from synthesis within the cell from acetyl-CoA through the mevalonate 
pathway (Figure 4). Other non-sterol products of the mevalonate pathway include 
dolichol, required for glycoprotein synthesis; the polyisoprenoids side chains of heme A 
and ubiquinone, involved in oxidative respiration; isopentenyladenine, present in some 
tRNAs; and the isoprenoids farnesylpyrophosphate (FPP) and 
geranylgeranylpyrophosphate (GGPP), required for protein prenylation 203. The 
mevalonate pathway is highly regulated and this is achieved through regulation of 3-
hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) synthase, HMG-CoA reductase, and 
LDL receptors. In the absence of LDL, cells maintain high activites of HMG-CoA 
synthase and HMG-CoA reductase resulting in the increased synthesis of mevalonate for 
the production of cholesterol and non-sterol products. When LDL is present, the activities 
of these enzymes decline, and mevalonate is used for the production of non-sterol end-
products. Furthermore, the LDL receptor gene is repressed when intracellular pools of 
sterols increase. When there is both excess of mevalonate and sterols, the residual activity 
of HMG-CoA reductase is abolished and mevalonate production is stopped 203.  
Many proteins such as Ras and Rho family proteins require prenylation, a lipid 
posttranslational modification, for proper cellular localization. Prenylation is essential for 
the full biologic activity of the proteins 204-206. H-, N-, and K-Ras require farnesylation, 
and Rac-1, Cdc42, and RhoA require geranylgeranylation for their function 207-210. 
However, in cells treated with farnesyl transferase inhibitors, K-Ras can be alternatively 
geranylgeranylated 211,212. Farnsesyl transferase (FTase) catalyzes the transfer of a farnesyl 
group from FPP, whereas geranylgeranyl transferases (GGTase) I and II catalyze the 
transfer of a geranylgeranyl moiety derived from GGPP to cysteines at the carboxy-
terminus of the protein. Prenylated proteins share characteristic carboxy-terminal 
consensus sequences, and can be separated in proteins with a CAAX (C, cysteine; A, 
aliphatic amino acid; X any amino acid) motif and proteins with a CC or CXC sequence. 
When the X in the CAAX sequence is methionine, serine, cysteine, or glutamine, the 
cysteine will be farnesylated; when X is leucine, it will be gerananylgeranylated by 
GGTase I. GGTase II transfers the geranylgeranyl moieties to both cysteine residues of 
the CC or CXC motifs 209,210,213,214.  
Statins block cholesterol synthesis by inhibition of HMG-CoA reductase, and are 
therefore widely used for the treatment of hypercholesterolemia 215. Statins also deplete 
intracellular pools of FPP and GGPP, thereby preventing the posttranslational prenylation 
of small GTP-binding proteins involved in diverse cellular processes including the 
regulation of apoptosis and proliferation 216,217. In various cancer cell lines and purified 
tumor cells from acute myeloid leukemia patients statins induce apoptosis, inhibit 
proliferation, and sensitize tumor cells to a variety of cytotoxic drugs through the 
inhibition of the mevalonate pathway 216,217. Furthermore, pravastatin prolonged the 
survival of patients with advanced hepatocellular carcinoma 218.  
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Figure 4. The mevalonate pathway. The mevalonate pathway leads to the formation of cholesterol. Other non-
sterol products of the mevalonate pathway include dolichol, required for glycoprotein synthesis; the 
polyisoprenoids side chains of heme A and ubiquinone, involved in oxidative respiration; isopentenyladenine, 
present in some tRNAs; and the isoprenoids farnesylpyrophosphate (FPP) and geranylgeranylpyrophosphate 
(GGPP), required for protein prenylation. 
 
 
Scope of this thesis 
The study of drug resistance and cell survival in myeloma cells has resulted in the 
identification of a number of potential targets for antimyeloma therapy. Among those are 
proteins participating in signaling pathways regulating growth and survival. Biologically-
based therapies that are currently being explored in myeloma include recombinant 
osteoprotegerin (OPG), inhibitors of NF-κB such as the proteasome inhibitor PS-341 
(Velcade), farnesyl transferase inhibitors to target Ras mutations, and thalidomide and its 
analogs to target both the myeloma cell and its microenvironment. Development of 
therapeutic agents that augment the apoptotic effects of conventional chemotherapeutic 
agents represents a strategy to reverse chemoresistance in patients with multidrug resistant 
disease.  
In this study, we investigated the role of Bcl-2 protein in the regulation of 
survival and chemoresistance of myeloma cells using an antisense strategy. First, 
preclinical studies were performed to determine the role of Bcl-2 in the regulation of 
apoptosis and drug resistance in myeloma tumor cells. Based on the outcome of these in 
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vitro studies, a phase 2 trial was designed to evaluate the effect of Bcl-2 protein down-
regulation on the therapeutic efficacy of VAD chemotherapy in refractory myeloma 
patients.  
Targeting the mevalonate pathway may be a new therapeutic strategy to overcome 
resistance to conventional therapies in multiple myeloma. We investigated the importance 
of the mevalonate pathway for the regulation of growth, survival, and drug resistance in 
myeloma tumor cells. 
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Abstract 
 
An antisense oligodeoxynucleotide (ODN) complementary to the first 6 codons of the 
Bcl-2 mRNA, G3139 (oblimersen sodium; Genasense), has been shown to down-regulate 
Bcl-2 and produce responses in a variety of malignancies including drug-resistant 
lymphoma. Incubation of ex vivo purified plasma cells from patients with multiple 
myeloma (MM) with carboxyfluorescein (FAM)-labeled antisense ODNs resulted in a 
time- and dose-dependent uptake in the cytoplasm and nucleus. No major differences in 
uptake of Bcl-2 antisense ODNs were observed among patients’ samples. Incubation of 
purified myeloma plasma cells with G3139, but not solvent or reverse polarity control 
ODNs, resulted in a reduction (>75%) of Bcl-2 mRNA levels after 2 and 4 days, as 
measured by Real-Time PCR. Treatment with G3139 led to a sequence-specific reduction 
of Bcl-2 protein levels within 4 days of exposure in 10 out of 11 clinical samples from 
patients with chemosensitive and multidrug resistant disease, without significant reduction 
of α-actin, Bax, Bcl-XL, or Mcl-1 proteins. This resulted in a significantly enhanced 
sensitivity of the myeloma tumor cells to dexamethasone or doxorubicin-induced 
apoptosis. G3139 can consistently enter myeloma cells, down-regulate the expression of 
Bcl-2, and enhance the efficacy of myeloma therapy. These data support further clinical 
evaluation of G3139 therapy in multiple myeloma.  
 
Keywords     
Bcl-2, antisense oligodeoxynucleotide, multiple myeloma, chemosensitization, drug 
resistance
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Introduction 
 
Although chemotherapy is initially effective in the majority of patients with multiple 
myeloma (MM), they all eventually develop multidrug resistant disease. Different 
mechanisms contribute to the drug resistant phenotype of myeloma tumor cells 1. These 
mechanisms include decreased accumulation of the cytotoxic drug in cells due to 
increased efflux 2-6, altered drug metabolism 7, and altered intracellular targets of the drug 
8-11. However, there is increasing evidence that cytotoxic drugs exert their effects through 
the triggering of apoptotic pathways and that prevention of drug-induced apoptosis is 
associated with multidrug resistant disease 12,13. Several studies have demonstrated that 
interleukin-6 (IL-6) 14-16, Ras mutations 16-18, adhesion of myeloma plasma cells to bone 
marrow stromal cells 19,20 or extracellular matrix components 21, and the anti-apoptotic 
proteins Bcl-XL 22,23, Mcl-1 24,25, and Bcl-2 26,27, inhibit apoptosis of myeloma plasma 
cells.  
Bcl-2 overexpression was first identified in the translocation t(14;18) observed in 
follicular lymphoma. Despite the low incidence (0-15%) of this translocation in MM, 
overexpression of Bcl-2 is found in the majority of myeloma patients and plasma cell lines 
28-34. Bcl-2 protects against apoptosis by forming heterodimers with pro-apoptotic Bcl-2 
family members such as Bax and Bad, and by preventing both cytochrome c release from 
mitochondria and activation of caspases 35,36. Overexpression of Bcl-2 protein in myeloma 
cell lines confers protection from apoptosis induced by IL-6 deprivation 37, 
dexamethasone 27, etoposide, or doxorubicin 26 and may therefore contribute to tumor cell 
survival and a multidrug resistant phenotype. For these reasons, abrogating the anti-
apoptotic effect of Bcl-2 protein may increase chemosensitivity and reverse 
chemoresistance in myeloma tumor cells. 
Antisense oligodeoxynucleotides (ODNs) are short single-stranded DNA 
molecules that are complementary to a known target mRNA. This results in a sequence-
specific hybridization of the antisense ODNs with their target mRNAs, which prevents 
translation or recruits endogenous RNase H to cleave the mRNA backbone 38. G3139 
(oblimersen sodium; Genasense) is an 18-mer phosphorothioate antisense ODN, directed 
against the first 6 codons of Bcl-2 mRNA. Several in vitro studies and studies using tumor 
xenograft models in mice demonstrate that antisense-mediated Bcl-2 down-regulation 
induces apoptosis 39-45 and reverses chemoresistance 46-51. In a Phase I study in relapsed 
non-Hodgkin’s lymphoma patients 52,53 and in a Phase I-II study in patients with advanced 
melanoma 54, objective antitumor responses without significant toxicity were reported for 
G3139 as a single agent or G3139 combined with dacarbazine, respectively. 
In this study, we show that G3139 decreases Bcl-2 mRNA and protein levels in 
myeloma plasma cells resulting in an enhanced susceptibility towards dexamethasone and 
doxorubicin-induced apoptosis.  
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Materials and methods 
 
Reagents 
Dexamethasone was purchased from Sigma (St Louis, MO, USA) and doxorubicin from 
Pharmacia & Upjohn (Woerden, The Netherlands). 
 
ODNs 
Phosphorothioate antisense oligodeoxynucleotides used in this study, were provided by 
Genta Inc. (Berkeley Heights, NJ, USA). The sequence of Bcl-2 antisense ODN 
(GenasenseTM; oblimersen sodium; G3139), corresponding to the first 6 codons of the 
open reading frame of Bcl-2 mRNA was 5’-TCT CCC AGC GTG CGC CAT-3’. Reverse 
polarity ODNs (G3622; sequence, 5’-TAC CGC GTG CGA CCC TCT-3’) were used as a 
control. The ODNs were dissolved in Iscove’s Modified Dulbecco’s Medium (IMDM) 
and stored at –80oC until use. ODNs were administered to cells in free form in the absence 
of cationic lipids. 
 
Patients  
Myeloma plasma cells were obtained from bone marrow aspirates taken from the posterior 
iliac crest in 14 patients and from peripheral blood in one patient (patient 3) with plasma 
cell leukemia after obtaining informed consent. The clinical characteristics of these 
patients are shown in Table 1. The plasma cell percentage in the patient samples varied 
from 6-54% of the mononuclear cells as determined by co-expression of CD38 (anti-
CD38-FITC, Immunotech, Marseille, France) and CD138 (anti-CD138-PE, Immunotech) 
by flow cytometric analysis (FACSCalibur, Becton Dickinson, Erembodegem, Belgium 
(BDIS)). Myeloma plasma cells were purified ex vivo from mononuclear cells obtained by 
Ficoll-Paque (Amersham; Pharmacia BiotechAB, Uppsala, Sweden) density 
centrifugation, by magnetic cell sorting (MACS) based on CD138 expression 55. To this 
end, mononuclear cells were subsequently labeled with anti-CD138 (Immunotech) and rat 
anti-mouse IgG1 microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany) and then 
separated using a high gradient magnetic separation column placed in a strong magnetic 
field (Miltenyi), exactly following the instructions of the manufacturer. Samples obtained 
in this way contained >95% plasma cells as determined by analysis of CD38/CD138 co-
expression. For experiments, myeloma cells were resuspended in RPMI-1640 (GIBCO, 
Breda, The Netherlands) supplemented with 10% fetal calf serum (FCS) (Integro, 
Zaandam, The Netherlands), 100 IU/ml penicillin, 100 µg/ml streptomycin, and 10 µM β-
mercaptoethanol.  
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Table 1. Clinical characteristics of multiple myeloma patients 
 
Flow cytometric analysis of ODN-uptake  
For the time-course studies, cells (1 X 106 cells/ml) were incubated with 5 µM FAM-
labeled antisense or unlabeled antisense ODNs for various periods of time. For the dose-
response study, cells were incubated with 0, 0.05, 0.1, 0.5, 1, 5, or 10 µM FAM-labeled or 
unlabeled antisense ODNs for 24 hours. After incubation, cells were harvested, washed 3 
times in ice-cold PBS, and incubated with an ice-cold solution of 0.2 M acetic acid and 
0.5 M NaCl (pH 2.5) at 4oC for 10 minutes to remove membrane-bound ODN as 
described by Haigler et al 56. After acid-salt elution, the cells were washed in PBS and 
incubated with propidium iodide (Calbiochem, La Jolla, CA, USA; 5 µg/ml). Green 
fluorescence of propidium iodide negative cells was determined by flow cytometric 
analysis (BDIS). The relative amount of intracellular ODNs was expressed as the ratio of 
the mean fluorescence intensities of FAM-labeled antisense and unlabeled antisense 
treated cells.  
  
Viability assay 
Viability of cells was examined by means of the 3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium bromide (MTT) assay as described previously 57. Purified myeloma 
plasma cells were seeded in a concentration of 1 X 106/ml in a 96-well flat bottom plate 
(100 µl/well) (Nunc, Roskilde, Denmark) and treated with 10 µM ODNs. After 2, 4, or 7 
Patient Age/Sex Stage M-component type Disease status 
1 46/F III-A κ-LC Untreated 
2 50/M III-A IgG-λ Untreated 
3 76/F III-B non-secretory Relapse after MP 
4 58/M III-A IgG-λ Relapse after autoPBSCT 
5 49/F II-A IgG-κ Untreated 
6 73/M I-A IgG-λ MP refractory 
7 69/M II-A IgA-κ VAD refractory 
8 52/M III-A IgG-κ VAD/Thalidomide sensitive 
9 58/F III-A IgG-κ MP refractory 
10 54/F II-A IgG-κ VAD sensitive 
11 59/M II-B IgG-κ MP-Dexamethasone-Thalidomide refractory 
12 63/M III-B IgA-κ VAD refractory 
13 63/M III-A κ-LC VAD refractory 
14 61/M III-A IgG-κ VAD sensitive 
15 69/M III-B IgG-λ VAD refractory 
 The patients were classified according to the Durie-Salmon staging system 64. The M-component type was
determined by immunofixation. Bone marrow plasma cell percentage was determined by simultaneous
detection of CD38 and CD138 in bone marrow mononuclear cells by flow cytometric analysis. Plasma cell
monoclonality was established by means of immunofluorescence microscopy based on heavy- and light-chain
expression.  
M, male; F, female; Ig, immunoglobulin; LC, light chain; κ, kappa; λ, lambda; MP, melphalan and prednisone;
autoPBSCT, autologous peripheral blood stem cell transplantation; VAD, vincristine, doxorubicin, and
dexamethasone. 
 
  
Bcl-2 antisense chemosensitizes myeloma plasma cells 
42 
days, 25 µl of MTT (5 mg/mL) was added to each well. After an incubation of 2 hours at 
37oC the reaction was stopped by the addition of 100 µl 20% sodium dodecyl sulphate 
(SDS; Boehringer Mannheim, Mannheim, Germany) / 0.025 M HCl / 0.35 M HAc in a 
mixture of (1:1; v/v) N,N-dimethylformamide (Merck, Darmstadt, Germany) and distilled 
water. After an overnight incubation at 37oC the optical density of the samples was 
determined at 570 nm.  
 
Apoptosis assessment by Annexin V staining  
Purified myeloma plasma cells (5 X 105 in 0.5 ml) were treated with 10 µM ODNs in a 
48-well plate (Nunc). After 2, 4, or 7 days, cells were harvested, washed in ice cold PBS 
and directly stained with Annexin V-FITC (Nexins Research, Kattendijke, The 
Netherlands) and propidium iodide (PI). After an incubation for 10 minutes at 4oC, the 
cells were subsequently analyzed by flow cytometry as described previously 58. Apoptotic 
cells were defined as early apoptotic cells (Annexin V positive and PI negative) and late 
apoptotic cells (Annexin V positive and PI positive). 
 
Real-Time PCR 
Total RNA was isolated from cells (2 X 106 in 2 ml), which were incubated with solvent 
control or 10 µM ODNs for 2 or 4 days, using RNAzol (Campro, Veenendaal, The 
Netherlands) according to the manufacturer’s instructions. For cDNA synthesis 1 µg of 
RNA was incubated with 750 U/ml AMV Reverse Transcriptase (Promega, Madison, WI, 
USA), 100 µg/ml Hexamer primer (Roche, Almere, The Netherlands), 1 mM of dATP, 
dTTP, dGTP and dCTP (Amersham Pharmacia Biotech Inc, Little Chalfont, UK), and 
1350 U/ml RNAguard (Amersham) in a total volume of 20 µl for 90 minutes at 42oC. 
Bcl-2 and porphobilinogen deaminase (PBGD) cDNAs were amplified using 
primers and probes that were selected with the Primer Express Applications-Based Primer 
Design Software (Applied Biosystems, Nieuwerkerk a/d IJssel, The Netherlands). For 
Bcl-2, the sequences of the primers were 5’-CGC CCT GTG GAT GAC TGA GT-3’ and 
5’-GGG CCG TAC AGT TCC ACA A-3’ and for PBGD 5’-GGC AAT GCG GCT GCA 
A-3’ and 5’-GGG TAC CCA CGC GAA TCA C-3’. The sequences of the Bcl-2 and 
PBGD TaqMan probes (Applied Biosystems) were 5’-CTG AAC CGG CAC CTG CAC 
ACC TG-3’ and 5’-CAT CTT TGG GCT GTT TTC TTC CGC C-3’, respectively. The 
probes were labeled at the 5’ end with the reporter dye molecule (FAM and VIC for the 
Bcl-2 and PBGD probes, respectively) and at the 3’ end with the quencher dye molecule 
(TAMRA). The PCR reactions (50 µl total volume; 5 µl 10 X ROX buffer (Applied 
Biosystems), 3 mM MgCl2 for Bcl-2 or 5 mM for PBGD, 1 µl cDNA, 12.5 pmol of each 
of the Bcl-2 or 15 pmol of each of the PBGD primers, 10 pmol Bcl-2 or PBGD probe, 25 
U/ml AmpliTaq gold polymerase (Applied Biosystems), 0.8 mM of dATP, dTTP, dGTP 
and dCTP (Amersham)) were heated to 95oC for 10 minutes and then amplified for 40 
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cycles at 95oC for 15 seconds and 60 seconds at 60oC by using the ABI Prism 7700 
Sequence Detection system. Relative quantitation of gene expression was performed as 
described in the manual using the comparative CT (treshold cycle) method. Relative Bcl-2 
mRNA levels were normalized to PBGD mRNA levels and presented as a percentage of 
solvent control treated cells.  
 
Western blot analysis 
Cells (1.5 X 106 cells in 1.5 ml) were incubated for 2 or 4 days in growth medium with 
ODNs (10 µM). After harvesting, whole cell lysates were made by washing cells twice in 
ice-cold PBS and then resuspending them in lysis buffer (10 mM Tris-HCl (pH 7.6), 150 
mM NaCl, 1% Triton X-100, and a cocktail of protease inhibitors (Boehringer 
Mannheim)) at 4oC for 20 minutes. Insoluble material was removed by centrifugation at 
14 000 r.p.m. for 6 minutes at 4oC. Protein concentrations were determined by the BCA 
assay (Pierce, Rockford, IL, USA). Samples containing equal amounts of protein were 
mixed with 2 X Laemmli sample buffer (0.125 M Tris (pH 6.9) with 4% SDS, 20% 
Glycerol, and 10% β-mercaptoethanol) and boiled for 5 minutes. Proteins were 
subsequently fractionated in 12% SDS-PAGE at room temperature and electrically 
transferred from the gel to a PVDF-membrane (Biorad, Hercules, CA, USA). After 
blocking in 0.1% Tween-20, 5% skimmed powder milk, 2% BSA in 10 mM Tris and 150 
mM NaCl, the membranes were incubated with anti-Bcl-2 (Dako, Glostrup, Denmark), 
anti-Bax (Immunotech), anti-Mcl-1 (Santa Cruz Biotechnology Inc, Santa Cruz, CA, 
USA), or anti-Bcl-XL/S (Santa Cruz). Antibody binding was visualized with enhanced 
chemoluminescence (Amersham) detection with hyperfilm ECL (Amersham) after 
incubation with a horseradish peroxidase (HRP)-conjugated secondary antibody (Dako). 
Membranes incubated with anti-Bcl-2, anti-Bax, anti-Mcl-1, or anti-Bcl-XL/S were 
extensively washed in PBS and reprobed with anti-α-actin (Sigma). Relative amounts of 
protein expression were determined by densitometry and normalized to α-actin 
expression.  
 
Statistical analysis  
Data analysis was performed using the SPSS statistical software package (SPSS Inc, 
Chicago, IL, USA). A two-sided Student’s t-test or a Welch’s t-test in case of unequal 
variances, was used to determine differences between groups. Differences were 
considered statistically significant when P < 0.05. Data are plotted as means ± standard 
error of the mean (s.e.m.). 
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Results 
 
Uptake of antisense ODNs 
Uptake of Bcl-2 antisense ODNs was studied in purified myeloma plasma cells from 
patients 1, 2, 3, and 4. Myeloma cells were purified from mononuclear cells from bone 
marrow aspirates of patients 1, 2, and 4, and from peripheral blood of patient 3 with 
secondary plasma cell leukemia by MACS based on CD138 expression. Plasma cell 
percentage in all cases was >95% after purification (data not shown). Myeloma cells were 
incubated with 5 µM FAM-labeled or unlabeled Bcl-2 antisense ODNs for various periods 
of time. Figure 1A shows a time-dependent increase in ODN-uptake. ODN-uptake was 
higher for myeloma cells from patients 1 and 3 compared to cells from patients 2 and 4. 
For all 4 patients’ samples ODN-uptake was highest during the first 48 hours of 
incubation. During the following 48 hours ODNs accumulated at a significantly lower 
rate. The concentration-dependent uptake of antisense ODNs was studied by incubating 
myeloma cells from patient 4 with 0, 0.05, 0.1, 0.5, 1, 5, or 10 µM FAM-labeled or 
unlabeled antisense ODNs for 24 hours. Figure 1B demonstrates that uptake was more 
efficient at lower concentrations of ODN in medium.  
 
Figure 1. Dose- and time-dependent uptake of Bcl-2 antisense ODNs. Plasma cells from myeloma patients 1, 
2, and 4 were purified from bone marrow mononuclear cells and from patient 3 with secondary plasma cell 
leukemia from peripheral blood mononuclear cells by MACS based on CD138 expression. Plasma cell 
percentage was >95% after purification. Myeloma plasma cells were (A) incubated with 5 µM unlabeled or 
FAM-labeled antisense ODNs for various periods of time or (B) with various concentrations of unlabeled or 
FAM-labeled Bcl-2 antisense ODNs for 24 hours. The relative amount of intracellular ODNs was studied by 
flow cytometry and expressed as the ratio of the mean fluorescence intensities of FAM-labeled antisense and 
unlabeled antisense treated cells (MFR). Experiments were performed in triplicate. Data are presented as mean ± 
s.e.m. 
 
 
Effect of Bcl-2 antisense ODNs on Bcl-2 mRNA levels in ex vivo purified myeloma 
plasma cells 
Real-Time PCR was performed to examine Bcl-2 mRNA levels in purified myeloma 
plasma cells from patients 8 and 12. In myeloma cells from patient 8, Bcl-2 mRNA levels 
normalized to PBGD mRNA levels, were reduced by 10 µM (60.6 µg/mL) antisense 
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ODNs by 92.5%, when compared to the solvent control after 4 days of treatment. Reverse 
polarity ODNs did not significantly decrease Bcl-2 mRNA levels in cells from patient 8 
(4.8%; P < 0.01). Treatment of myeloma cells from patient 12 with 10 µM Bcl-2 antisense 
for 2 and 4 days reduced Bcl-2 mRNA levels normalized to PBGD mRNA levels by 89.4 
and 77.2%, compared to 2.2% (P < 0.01) down-regulation and 14.1% (P < 0.01) induction 
in reverse polarity-treated cells, respectively (Figure 2A). This indicates that there is a 
sequence-specific inhibition of Bcl-2 mRNA by Bcl-2 antisense ODNs. 
 
 
Figure 2. Sequence-specific reduction of Bcl-2 mRNA and protein levels by Bcl-2 antisense ODNs in 
purified myeloma tumor cells from patient 12. Plasma cells were purified from bone marrow mononuclear 
cells by MACS based on CD138 expression (purity >95%). Cells from patients 12 were treated for 2 or 4 days 
with solvent control (0), 10 µM antisense (AS), or 10 µM reverse polarity (RP) ODNs. (A) Bcl-2 and PBGD 
mRNA levels were determined by Real-Time PCR. Bcl-2 mRNA levels normalized to PBGD, were expressed as 
a percentage of the solvent control values. The experiment was performed once in triplicate. Shown are the mean 
± s.e.m. and the significance (P values). (B) After protein isolation, Bcl-2, Mcl-1, Bcl-XL, and Bax were 
determined by Western blot analysis. Blots were reprobed with anti-α-actin to confirm the presence of equal 
amounts of protein in each lane. 
 
 
Effect of Bcl-2 antisense ODNs on Bcl-2 protein levels in ex vivo purified myeloma 
plasma cells 
Western blot analysis was performed to determine the effect of the ODNs on Bcl-2 protein 
expression. Myeloma cells from 11 myeloma patients (patients 5-15) were purified from 
bone marrow mononuclear cells by MACS based on CD138 expression. The ex vivo 
purified plasma cells were incubated with solvent control, 10 µM antisense, or 10 µM 
reverse polarity ODNs. Myeloma cells were treated for 2 and 4 days in all cases with the 
exception of cells from patients 7, 9, 10, and 13 which were treated for 4 days only 
because of insufficient myeloma cells. Expression of Bcl-2 and Bax was found in all  
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Figure 3. Sequence-specific and time-dependent down-regulation of Bcl-2 protein levels by Bcl-2 antisense 
ODNs in purified myeloma cells from patients, whereas protein levels of Bax were not affected. The 
reduction of Bcl-2 protein levels ranged from 8-18% and 42-84% in the 6 out of 7 and 10 out of 11 responding 
patients after 2 and 4 days of treatment, respectively. Plasma cells from myeloma patients 5-15 were purified 
from bone marrow mononuclear cells by MACS based on CD138 expression. Plasma cell percentage was >95% 
after purification. Ex vivo purified myeloma plasma cells were incubated with solvent control, 10 µM Bcl-2 
antisense (AS), or 10 µM reverse polarity (RP) ODNs for 2 or 4 days. After protein isolation, Bcl-2, Bax, and α-
actin were determined by Western blot analysis. In 8 patients’ samples, Western blot analysis was performed 
once; in 3 patients’ samples 2 times, with identical results. Bcl-2 and Bax protein levels were quantitated by 
densitometry analysis of the protein bands and normalized to α-actin. Bcl-2 and Bax protein levels are expressed 
as a percentage of the solvent control values. 
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cases. After 2 days of treatment Bcl-2 protein levels were slightly decreased in antisense-
treated cells in 6 out of 7 patients. However, after 4 days of incubation Bcl-2 protein 
expression was significantly down-regulated by antisense ODNs in all 11 patients’ 
samples, except in myeloma cells from patient 5. On day 2 Bcl-2 levels were not changed 
in myeloma cells derived from patient 14. In contrast, on day 4 Bcl-2 protein levels were 
significantly diminished in Bcl-2 antisense-treated cells from patient 14, when compared 
to solvent or reverse polarity control-treated cells.  
 
Figure 4. Bcl-2 antisense enhances sensitivity of purified myeloma tumor cells from patients to 
doxorubicin-induced cell death. Plasma cells from myeloma patients 9, 11, and 13 were purified from bone 
marrow mononuclear cells by MACS based on CD138 expression (purity >95%). The myeloma tumor cells were 
incubated for 4 days with solvent control, 10 µM Bcl-2 antisense, or 10 µM reverse polarity ODNs. Then cells 
were resuspended in RPMI-1640 with 10% FCS and incubated for 2 days with doxorubicin (0.5 to 20 X 10-7 M). 
The percentage of viable cells, relative to the untreated cells, was measured by using the MTT assay. The 
experiment was performed once in triplicate. Data are presented as mean ± s.e.m. *: P < 0.05; **: P < 0.005 
(Bcl-2 antisense treatment vs reverse polarity control treatment). 
 
 
Densitometry analysis after normalization for α-actin, demonstrated a reduction 
of Bcl-2 protein levels that ranged from 8 to 18% and 42 to 84% in the 6 out of 7 and 10 
out of 11 responding patients after 2 and 4 days of treatment, respectively (Figure 3). This 
was in contrast to reverse polarity ODNs and solvent control, which did not affect Bcl-2 
protein expression indicating a sequence-specific effect (Figure 3). For example, treatment 
of myeloma cells from patient 9 with Bcl-2 antisense for 4 days reduced Bcl-2 protein 
levels by 72%, compared to an increase of 6% in reverse polarity treated cells. Antisense 
treatment did not result in a significant change in the levels of α-actin or the pro-apoptotic 
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Bcl-2 family protein Bax (Figure 3). In addition, protein levels of the anti-apoptotic Bcl-2 
family members Mcl-1 and Bcl-XL were not affected by Bcl-2 antisense treatment, as 
determined in myeloma patients 7, 8, 12, 14, and 15. Bcl-XS expression was not detected 
in the different patients’ samples. Figure 2B shows a representative example of an 
antisense-mediated Bcl-2 protein down-regulation in myeloma plasma cells derived from 
patient 12, while Bcl-XL, Bax, Mcl-1, and α-actin protein levels remained unchanged. 
 
 
 
Figure 5. Bcl-2 antisense enhances sensitivity of purified myeloma tumor cells from patients to 
dexamethasone-induced cell death. Plasma cells from myeloma patients 9, 11, 13, and 15 were purified from 
bone marrow mononuclear cells by MACS based on CD138 expression (purity >95%). The myeloma tumor cells 
were incubated for 4 days with solvent control, 10 µM Bcl-2 antisense, or reverse polarity ODNs. Then cells 
were resuspended in RPMI-1640 with 10% FCS and incubated for 2 days with dexamethasone (0.5 to 100 X 10-7 
M). The percentage of viable cells, relative to the untreated cells, was measured by using the MTT assay. The 
experiment was performed once in triplicate. Data are presented as mean ± s.e.m. *: P < 0.05; **: P < 0.005 
(Bcl-2 antisense treatment vs reverse polarity control treatment). 
 
 
Bcl-2 antisense ODNs chemosensitize ex vivo purified myeloma plasma cells  
MTT assay was used to determine the effect of Bcl-2 antisense ODNs on cell viability of 
ex vivo purified plasma cells derived from myeloma patients 1-15. Although treatment 
with 10 µM Bcl-2 antisense resulted in down-regulation of Bcl-2 mRNA and protein 
levels, it did not reduce cell viability after 2, 4, and 7 days when compared to solvent, or 
reverse polarity control-treated cells (data not shown).  
We also tested whether the Bcl-2 protein down-regulation resulted in an 
increased susceptibility of myeloma plasma cells to dexamethasone or doxorubicin-
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induced apoptosis. Ex vivo purified myeloma cells from myeloma patients were treated for 
4 days with solvent control, 10 µM antisense, or reverse polarity control ODNs. This was 
followed by a 2 day incubation with various concentrations of dexamethasone (0.5 to 100 
X 10-7 M) (patients 9, 11, 13, and 15) or doxorubicin (0.5 to 20 X 10-7 M) (patients 9, 11, 
and 13). In all 4 patients’ samples a significant reduction of Bcl-2 protein expression was 
detected after 4 days of treatment with Bcl-2 antisense (Figure 3). Reduction of cell 
viability by doxorubicin or dexamethasone was significantly higher in myeloma cells 
which were pre-treated with antisense ODNs when compared to solvent or reverse 
polarity control pre-treated cells (Figure 4 and 5). For instance, doxorubicin (4 X 10-7 M) 
reduced cell viability of plasma cells from patient 13, relative to untreated controls with 
99% in antisense pre-treated cells, whereas the reduction was 35% (P = 0.012) in solvent 
control and 49% (P = 0.03) in reverse polarity control pre-treated cells (Figure 4). The 
reduction in cell viability of myeloma plasma cells from patient 13 after addition of 10 X 
10-7 M dexamethasone was 85% in antisense pre-treated cells, compared to 39% (P = 
0.001) and 42% (P = 0.001) in solvent and reverse polarity control pre-treated cells, 
respectively (Figure 5). The results obtained by MTT assay were confirmed by flow 
cytometric detection of apoptotic cells by using the Annexin V assay as shown in figure 6 
for patient 12.  
 
 
 
 
Discussion 
 
Bcl-2 is expressed in the majority of myeloma patients and myeloma cell lines 28-34. Gene 
transfection experiments show that overexpression of Bcl-2 renders myeloma cell lines 
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Figure 6. Bcl-2 antisense enhances
sensitivity of purified myeloma tumor cells
from patient 12 to dexamethasone-induced
apoptosis. Plasma cells from myeloma patient
12 were purified from bone marrow
mononuclear cells by MACS based on CD138
expression (purity >95%). The myeloma
tumor cells were incubated for 4 days with
solvent control (0), 10 µM Bcl-2 antisense
(AS), or reverse polarity ODNs (RP). Then
cells were resuspended in RPMI-1640 with
10% FCS and incubated for 2 days with
dexamethasone (50 X 10-7 M) or solvent
control. The percentage of apoptotic cells was
determined by flow cytometric analysis using
the Annexin V assay. The experiment was
performed once in triplicate. Data are
presented as mean ± s.e.m. 
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resistant to the induction of apoptosis by various cytotoxic drugs 26,27. In addition, 
exposure of plasma cell lines to doxorubicin increases Bcl-2 protein levels, which may 
account for the relative resistance to a second doxorubicin exposure 26. This suggests that 
Bcl-2 overexpression protects myeloma tumor cells from apoptosis induced by cytotoxic 
drugs, and that modulation of Bcl-2 protein levels may enhance the susceptibility to 
antimyeloma agents and reverse chemoresistance.  
Bcl-2 gene expression can be specifically manipulated by using antisense ODNs 
targeting the Bcl-2 mRNA. G3139 is a phosphorothioate antisense ODN rendering it 
resistant to nuclease digestion, directed against the first 6 codons of the Bcl-2 mRNA. In 
this study, we show that treatment with G3139 reduced Bcl-2 protein in a time-dependent 
and sequence-specific manner in purified myeloma cells from patients, while α-actin, Bcl-
XL, Mcl-1, and Bax levels remained unchanged. G3139 treatment decreased Bcl-2 protein 
levels in myeloma cells both in patients with chemosensitive and refractory disease. The 
reduction of Bcl-2 protein by G3139 was mediated by a sequence-specific reduction of 
Bcl-2 mRNA, as the control, PBGD, mRNA levels remained unchanged. This suggests 
that the decrease of Bcl-2 mRNA levels is a sequence-specific effect, possibly due to 
degradation of the target mRNA by RNase H, an enzyme that hydrolyzes the RNA moiety 
of RNA-DNA complexes 38. The phosphorothioate DNA oligonucleotide is resistant to 
RNase H cleavage and can therefore hybridize with other Bcl-2 mRNA molecules. 
However, it can not be excluded that other mechanisms, such as inhibition of transcription 
initiation or elongation, inhibition of RNA transport, interference with binding to 
ribosomes, and the inability of the ribosomal complex to scan the message may also 
contribute to the inhibition of Bcl-2 protein expression by Bcl-2 antisense ODNs 38. 
G3139 treatment alone did not reduce cell viability of myeloma plasma cells 
from patients despite the significant reduction of Bcl-2 protein levels. It is possible that 
other anti-apoptotic proteins such as Bcl-XL 22,23 or Mcl-1, which is an important survival 
protein in myeloma 24,25, substitute for Bcl-2 after its down-regulation resulting in 
protection against apoptosis. In ex vivo purified myeloma tumor cells, however, we show 
that an antisense-mediated down-regulation of Bcl-2 protein resulted in a significantly 
enhanced susceptibility to dexamethasone or doxorubicin-induced apoptosis. Importantly, 
chemosensitization was observed in myeloma plasma cells from both patients with 
refractory and chemosensitive disease, and in samples with low in vitro sensitivity to 
dexamethasone or doxorubicin. Interestingly, Bcl-2 antisense ODNs sensitized myeloma 
cells more efficiently to dexamethasone, in comparison to doxorubicin. This may suggest 
that Bcl-2 is a more important regulator of response to dexamethasone. Some reports 
indicate different nonantisense effects of antisense ODNs. For instance, products of 
enzymatic degradation of ODNs can influence cell proliferation 59. Moreover, G3139 
contains 2 unmethylated CpG motifs within the ODN sequence which are known to 
activate NK cells and macrophages 60, and to stimulate B cells 61. Phosphorothioate ODNs 
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have also been shown to competitively inhibit a variety of nucleases and polymerases 62. 
However, in contrast to G3139, the phosphorothioate reverse polarity control ODN 
(G3622) which contains the same nucleotides and also 2 CpG motifs did not enhance the 
sensitivity of myeloma cells to dexamethasone or doxorubicin-induced apoptosis. These 
data support an antisense mechanism for the chemosensitizing activity of G3139. 
Chemosensitization by an antisense-mediated Bcl-2 protein reduction was also detected in 
myeloma cells which were purified from bone marrow mononuclear cells by negative 
selection based on absence of CD45 expression on myeloma cells (data not shown), which 
excludes the possibilty that chemosensitization is a phenomenon that can only be observed 
in positively selected myeloma cells. Determination of apoptosis by flow cytometric 
detection of Annexin V staining and exclusion of propidium iodide by cells confirmed the 
results obtained from MTT assay, concerning chemosensitization and the absence of a 
direct cytotoxic effect of G3139. These results indicate that manipulation of Bcl-2 protein 
levels by treating patients with G3139 may enhance sensitivity to dexamethasone or 
doxorubicin-containing regimens, and induce more durable responses.  
Antisense ODNs must cross cell membranes in order to hybridize with their 
target mRNA. Uptake of Bcl-2 antisense was studied in plasma cells from 4 myeloma 
patients by using flow cytometry. Although phosphorothioate modified Bcl-2 antisense 
ODNs have a high polyanionic charge and molecular weight, they were rapidly taken up 
by cells. No major differences in uptake of Bcl-2 antisense ODNs were observed among 
patients. A recent study reported that ODN-uptake at low concentrations is predominantly 
via receptor-mediated endocytosis while at higher concentrations, a fluid phase 
endocytosis mechanism appears to predominate 38,63. This may explain the dose-dependent 
uptake of fluorochrome-labeled G3139 observed in myeloma cells. 
In summary, uptake of G3139 resulted in a sequence-specific reduction of Bcl-2 
mRNA and protein levels in ex vivo purified myeloma plasma cells. In clinical samples 
from myeloma patients, Bcl-2 down-regulation alone did not induce apoptosis, but it did 
enhance the sensitivity of myeloma plasma cells to dexamethasone and doxorubicin. Our 
findings suggest that Bcl-2 protein plays a significant role in multidrug resistance, and that 
treatment with cytotoxic antimyeloma agents following down-regulation of Bcl-2 by 
G3139 may reduce the induction of or reverse the effect of multidrug resistance. This 
approach is currently undergoing evaluation in clinical trials.    
 
 
References 
 
 1.  Dalton, W. S. and Jove, R. Drug resistance in multiple myeloma: approaches to circumvention. 
Semin.Oncol., 26: 23-27, 1999. 
 2.  Epstein, J., Xiao, H. Q., and Oba, B. K. P-glycoprotein expression in plasma-cell myeloma is associated 
with resistance to VAD. Blood, 74: 913-917, 1989. 
  
Bcl-2 antisense chemosensitizes myeloma plasma cells 
52 
 3.  Sonneveld, P., Durie, B. G., Lokhorst, H. M., Marie, J. P., Solbu, G., Suciu, S., Zittoun, R., Lowenberg, 
B., and Nooter, K. Modulation of multidrug-resistant multiple myeloma by cyclosporin. The Leukaemia 
Group of the EORTC and the HOVON. Lancet, 340: 255-259, 1992. 
 4.  Grogan, T. M., Spier, C. M., Salmon, S. E., Matzner, M., Rybski, J., Weinstein, R. S., Scheper, R. J., 
and Dalton, W. S. P-glycoprotein expression in human plasma cell myeloma: correlation with prior 
chemotherapy. Blood, 81: 490-495, 1993. 
 5.  Raaijmakers, H. G., Izquierdo, M. A., Lokhorst, H. M., de Leeuw, C., Belien, J. A., Bloem, A. C., 
Dekker, A. W., Scheper, R. J., and Sonneveld, P. Lung-resistance-related protein expression is a 
negative predictive factor for response to conventional low but not to intensified dose alkylating 
chemotherapy in multiple myeloma. Blood, 91: 1029-1036, 1998. 
 6.  Filipits, M., Drach, J., Pohl, G., Schuster, J., Stranzl, T., Ackermann, J., Konigsberg, R., Kaufmann, H., 
Gisslinger, H., Huber, H., Ludwig, H., and Pirker, R. Expression of the lung resistance protein predicts 
poor outcome in patients with multiple myeloma. Clin.Cancer Res., 5: 2426-2430, 1999. 
 7.  Linsenmeyer, M. E., Jefferson, S., Wolf, M., Matthews, J. P., Board, P. G., and Woodcock, D. M. 
Levels of expression of the mdr1 gene and glutathione S-transferase genes 2 and 3 and response to 
chemotherapy in multiple myeloma. Br.J.Cancer, 65: 471-475, 1992. 
 8.  Moalli, P. A., Pillay, S., Weiner, D., Leikin, R., and Rosen, S. T. A mechanism of resistance to 
glucocorticoids in multiple myeloma: transient expression of a truncated glucocorticoid receptor mRNA. 
Blood, 79: 213-222, 1992. 
 9.  Ishikawa, H., Kawano, M. M., Okada, K., Tanaka, H., Tanabe, O., Sakai, A., Asaoku, H., Iwato, K., 
Nobuyoshi, M., and Kuramoto, A. Expressions of DNA topoisomerase I and II gene and the genes 
possibly related to drug resistance in human myeloma cells. Br.J.Haematol., 83: 68-74, 1993. 
 10.  Krett, N. L., Pillay, S., Moalli, P. A., Greipp, P. R., and Rosen, S. T. A variant glucocorticoid receptor 
messenger RNA is expressed in multiple myeloma patients. Cancer Res., 55: 2727-2729, 1995. 
 11.  Futscher, B. W., Foley, N. E., Gleason-Guzman, M. C., Meltzer, P. S., Sullivan, D. M., and Dalton, W. 
S. Verapamil suppresses the emergence of P-glycoprotein-mediated multi-drug resistance. Int.J.Cancer, 
66: 520-525, 1996. 
 12.  Solary, E., Droin, N., Bettaieb, A., Corcos, L., Dimanche-Boitrel, M. T., and Garrido, C. Positive and 
negative regulation of apoptotic pathways by cytotoxic agents in hematological malignancies. 
Leukemia, 14: 1833-1849, 2000. 
 13.  O'Gorman, D. M. and Cotter, T. G. Molecular signals in anti-apoptotic survival pathways. Leukemia, 
15: 21-34, 2001. 
 14.  Hardin, J., MacLeod, S., Grigorieva, I., Chang, R., Barlogie, B., Xiao, H., and Epstein, J. Interleukin-6 
prevents dexamethasone-induced myeloma cell death. Blood, 84: 3063-3070, 1994. 
 15.  Lichtenstein, A., Tu, Y., Fady, C., Vescio, R., and Berenson, J. Interleukin-6 inhibits apoptosis of 
malignant plasma cells. Cell Immunol., 162: 248-255, 1995. 
 16.  Rowley, M., Liu, P., and Van Ness, B. Heterogeneity in therapeutic response of genetically altered 
myeloma cell lines to interleukin 6, dexamethasone, doxorubicin, and melphalan. Blood, 96: 3175-3180, 
2000. 
 17.  Neri, A., Murphy, J. P., Cro, L., Ferrero, D., Tarella, C., Baldini, L., and Dalla-Favera, R. Ras oncogene 
mutation in multiple myeloma. J.Exp.Med., 170: 1715-1725, 1989. 
 18.  Billadeau, D., Liu, P., Jelinek, D., Shah, N., LeBien, T. W., and Van Ness, B. Activating mutations in 
the N- and K-ras oncogenes differentially affect the growth properties of the IL-6-dependent myeloma 
cell line ANBL6. Cancer Res., 57: 2268-2275, 1997. 
 19.  Grigorieva, I., Thomas, X., and Epstein, J. The bone marrow stromal environment is a major factor in 
myeloma cell resistance to dexamethasone. Exp.Hematol., 26: 597-603, 1998. 
 20.  Cheung, W. C. and Van Ness, B. The bone marrow stromal microenvironment influences myeloma 
therapeutic response in vitro. Leukemia, 15: 264-271, 2001. 
  
Chapter 2 
53 
 21.  Damiano, J. S., Cress, A. E., Hazlehurst, L. A., Shtil, A. A., and Dalton, W. S. Cell adhesion mediated 
drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. 
Blood, 93: 1658-1667, 1999. 
 22.  Gauthier, E. R., Piche, L., Lemieux, G., and Lemieux, R. Role of bcl-X(L) in the control of apoptosis in 
murine myeloma cells. Cancer Res., 56: 1451-1456, 1996. 
 23.  Tu, Y., Renner, S., Xu, F., Fleishman, A., Taylor, J., Weisz, J., Vescio, R., Rettig, M., Berenson, J., 
Krajewski, S., Reed, J. C., and Lichtenstein, A. BCL-X expression in multiple myeloma: possible 
indicator of chemoresistance. Cancer Res., 58: 256-262, 1998. 
 24.  Zhang, B., Gojo, I., and Fenton, R. G. Myeloid cell factor-1 is a critical survival factor for multiple 
myeloma. Blood, 99: 1885-1893, 2002. 
 25.  Derenne, S., Monia, B., Dean, N. M., Taylor, J. K., Rapp, M. J., Harousseau, J. L., Bataille, R., and 
Amiot, M. Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival 
protein of human myeloma cells. Blood, 100: 194-199, 2002. 
 26.  Tu, Y., Xu, F. H., Liu, J., Vescio, R., Berenson, J., Fady, C., and Lichtenstein, A. Upregulated 
expression of BCL-2 in multiple myeloma cells induced by exposure to doxorubicin, etoposide, and 
hydrogen peroxide. Blood, 88: 1805-1812, 1996. 
 27.  Gazitt, Y., Fey, V., Thomas, C., and Alvarez, R. Bcl-2 overexpression is associated with resistance to 
dexamethasone, but not melphalan, in multiple myeloma cells. Int.J.Oncol., 13: 397-405, 1998. 
 28.  Hamilton, M. S., Barker, H. F., Ball, J., Drew, M., Abbot, S. D., and Franklin, I. M. Normal and 
neoplastic human plasma cells express bcl-2 antigen. Leukemia, 5: 768-771, 1991. 
 29.  Pettersson, M., Jernberg-Wiklund, H., Larsson, L. G., Sundstrom, C., Givol, I., Tsujimoto, Y., and 
Nilsson, K. Expression of the bcl-2 gene in human multiple myeloma cell lines and normal plasma cells. 
Blood, 79: 495-502, 1992. 
 30.  Sangfelt, O., Osterborg, A., Grander, D., Anderbring, E., Ost, A., Mellstedt, H., and Einhorn, S. 
Response to interferon therapy in patients with multiple myeloma correlates with expression of the Bcl-
2 oncoprotein. Int.J.Cancer, 63: 190-192, 1995. 
 31.  Ong, F., van Nieuwkoop, J. A., Groot-Swings, G. M., Hermans, J., Harvey, M. S., Kluin, P. M., and 
Kluin-Nelemans, J. C. Bcl-2 protein expression is not related to short survival in multiple myeloma. 
Leukemia, 9: 1282-1284, 1995. 
 32.  Harada, N., Hata, H., Yoshida, M., Soniki, T., Nagasaki, A., Kuribayashi, N., Kimura, T., Matsuzaki, 
H., and Mitsuya, H. Expression of Bcl-2 family of proteins in fresh myeloma cells. Leukemia, 12: 1817-
1820, 1998. 
 33.  Puthier, D., Pellat-Deceunynck, C., Barille, S., Robillard, N., Rapp, M. J., Juge-Morineau, N., 
Harousseau, J. L., Bataille, R., and Amiot, M. Differential expression of Bcl-2 in human plasma cell 
disorders according to proliferation status and malignancy. Leukemia, 13: 289-294, 1999. 
 34.  Renner, S., Weisz, J., Krajewski, S., Krajewska, M., Reed, J. C., and Lichtenstein, A. Expression of 
BAX in plasma cell dyscrasias. Clin.Cancer Res., 6: 2371-2380, 2000. 
 35.  Gross, A., McDonnell, J. M., and Korsmeyer, S. J. BCL-2 family members and the mitochondria in 
apoptosis. Genes Dev., 13: 1899-1911, 1999. 
 36.  Kroemer, G. and Reed, J. C. Mitochondrial control of cell death. Nat.Med., 6: 513-519, 2000. 
 37.  Schwarze, M. M. and Hawley, R. G. Prevention of myeloma cell apoptosis by ectopic bcl-2 expression 
or interleukin 6-mediated up-regulation of bcl-xL. Cancer Res., 55: 2262-2265, 1995. 
 38.  Gewirtz, A. M., Sokol, D. L., and Ratajczak, M. Z. Nucleic acid therapeutics: state of the art and future 
prospects. Blood, 92: 712-736, 1998. 
 39.  Campos, L., Sabido, O., Rouault, J. P., and Guyotat, D. Effects of BCL-2 antisense 
oligodeoxynucleotides on in vitro proliferation and survival of normal marrow progenitors and leukemic 
cells. Blood, 84: 595-600, 1994. 
  
Bcl-2 antisense chemosensitizes myeloma plasma cells 
54 
 40.  Cotter, F. E., Johnson, P., Hall, P., Pocock, C., al Mahdi, N., Cowell, J. K., and Morgan, G. Antisense 
oligonucleotides suppress B-cell lymphoma growth in a SCID-hu mouse model. Oncogene, 9 : 3049-
3055, 1994. 
 41.  Pepper, C., Thomas, A., Hoy, T., Cotter, F., and Bentley, P. Antisense-mediated suppression of Bcl-2 
highlights its pivotal role in failed apoptosis in B-cell chronic lymphocytic leukaemia. Br.J.Haematol., 
107: 611-615, 1999. 
 42.  Miyake, H., Tolcher, A., and Gleave, M. E. Antisense Bcl-2 oligodeoxynucleotides inhibit progression 
to androgen-independence after castration in the Shionogi tumor model. Cancer Res., 59: 4030-4034, 
1999. 
 43.  Schlagbauer-Wadl, H., Klosner, G., Heere-Ress, E., Waltering, S., Moll, I., Wolff, K., Pehamberger, H., 
and Jansen, B. Bcl-2 antisense oligonucleotides (G3139) inhibit Merkel cell carcinoma growth in SCID 
mice. J.Invest Dermatol., 114: 725-730, 2000. 
 44.  Guinness, M. E., Kenney, J. L., Reiss, M., and Lacy, J. Bcl-2 antisense oligodeoxynucleotide therapy of 
Epstein-Barr virus-associated lymphoproliferative disease in severe combined immunodeficient mice. 
Cancer Res., 60: 5354-5358, 2000. 
 45.  Tortora, G., Caputo, R., Damiano, V., Bianco, R., Fontanini, G., Cuccato, S., De Placido, S., Bianco, A. 
R., and Ciardiello, F. Combined blockade of protein kinase A and bcl-2 by antisense strategy induces 
apoptosis and inhibits tumor growth and angiogenesis. Clin.Cancer Res., 7: 2537-2544, 2001. 
 46.  Zangemeister-Wittke, U., Schenker, T., Luedke, G. H., and Stahel, R. A. Synergistic cytotoxicity of bcl-
2 antisense oligodeoxynucleotides and etoposide, doxorubicin and cisplatin on small-cell lung cancer 
cell lines. Br.J.Cancer, 78: 1035-1042, 1998. 
 47.  Jansen, B., Schlagbauer-Wadl, H., Brown, B. D., Bryan, R. N., van Elsas, A., Muller, M., Wolff, K., 
Eichler, H. G., and Pehamberger, H. bcl-2 antisense therapy chemosensitizes human melanoma in SCID 
mice. Nat.Med., 4: 232-234, 1998. 
 48.  Gleave, M. E., Miayake, H., Goldie, J., Nelson, C., and Tolcher, A. Targeting bcl-2 gene to delay 
androgen-independent progression and enhance chemosensitivity in prostate cancer using antisense bcl-
2 oligodeoxynucleotides. Urology, 54: 36-46, 1999. 
 49.  Konopleva, M., Tari, A. M., Estrov, Z., Harris, D., Xie, Z., Zhao, S., Lopez-Berestein, G., and Andreeff, 
M. Liposomal Bcl-2 antisense oligonucleotides enhance proliferation, sensitize acute myeloid leukemia 
to cytosine-arabinoside, and induce apoptosis independent of other antiapoptotic proteins. Blood, 95: 
3929-3938, 2000. 
 50.  Klasa, R. J., Bally, M. B., Ng, R., Goldie, J. H., Gascoyne, R. D., and Wong, F. M. Eradication of 
human non-Hodgkin's lymphoma in SCID mice by BCL-2 antisense oligonucleotides combined with 
low-dose cyclophosphamide. Clin.Cancer Res., 6: 2492-2500, 2000. 
 51.  Lopes de Menezes, D. E., Hudon, N., McIntosh, N., and Mayer, L. D. Molecular and pharmacokinetic 
properties associated with the therapeutics of bcl-2 antisense oligonucleotide G3139 combined with free 
and liposomal doxorubicin. Clin.Cancer Res., 6: 2891-2902, 2000. 
 52.  Webb, A., Cunningham, D., Cotter, F., Clarke, P. A., di Stefano, F., Ross, P., Corbo, M., and 
Dziewanowska, Z. BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet, 349: 
1137-1141, 1997. 
 53.  Waters, J. S., Webb, A., Cunningham, D., Clarke, P. A., Raynaud, F., di Stefano, F., and Cotter, F. E. 
Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with 
non-Hodgkin's lymphoma. J.Clin.Oncol., 18: 1812-1823, 2000. 
 54.  Jansen, B., Wacheck, V., Heere-Ress, E., Schlagbauer-Wadl, H., Hoeller, C., Lucas, T., Hoermann, M., 
Hollenstein, U., Wolff, K., and Pehamberger, H. Chemosensitisation of malignant melanoma by BCL2 
antisense therapy. Lancet, 356: 1728-1733, 2000. 
 55.  Jego, G., Robillard, N., Puthier, D., Amiot, M., Accard, F., Pineau, D., Harousseau, J. L., Bataille, R., 
and Pellat-Deceunynck, C. Reactive plasmacytoses are expansions of plasmablasts retaining the capacity 
to differentiate into plasma cells. Blood, 94: 701-712, 1999. 
  
Chapter 2 
55 
 56.  Haigler, H. T., Maxfield, F. R., Willingham, M. C., and Pastan, I. Dansylcadaverine inhibits 
internalization of 125I-epidermal growth factor in BALB 3T3 cells. J.Biol.Chem., 255: 1239-1241, 
1980. 
 57.  Roovers, D. J., van Vliet, M., Bloem, A. C., and Lokhorst, H. M. Idarubicin overcomes P-glycoprotein-
related multidrug resistance: comparison with doxorubicin and daunorubicin in human multiple 
myeloma cell lines. Leuk.Res., 23: 539-548, 1999. 
 58.  van de Donk, N. W., Kamphuis, M. M., Lokhorst, H. M., and Bloem, A. C. The cholesterol lowering 
drug lovastatin induces cell death in myeloma plasma cells. Leukemia, 16: 1362-1371, 2002. 
 59.  Koziolkiewicz, M., Gendaszewska, E., Maszewska, M., Stein, C. A., and Stec, W. J. The 
mononucleotide-dependent, nonantisense mechanism of action of phosphodiester and phosphorothioate 
oligonucleotides depends upon the activity of an ecto-5'-nucleotidase. Blood, 98: 995-1002, 2001. 
 60.  Ballas, Z. K., Rasmussen, W. L., and Krieg, A. M. Induction of NK activity in murine and human cells 
by CpG motifs in oligodeoxynucleotides and bacterial DNA. J.Immunol., 157: 1840-1845, 1996. 
 61.  Yi, A. K., Chang, M., Peckham, D. W., Krieg, A. M., and Ashman, R. F. CpG 
oligodeoxyribonucleotides rescue mature spleen B cells from spontaneous apoptosis and promote cell 
cycle entry. J.Immunol., 160: 5898-5906, 1998. 
 62.  Stein, C. A. Does antisense exist? Nat.Med., 1: 1119-1121, 1995. 
 63.  Beltinger, C., Saragovi, H. U., Smith, R. M., LeSauteur, L., Shah, N., DeDionisio, L., Christensen, L., 
Raible, A., Jarett, L., and Gewirtz, A. M. Binding, uptake, and intracellular trafficking of 
phosphorothioate-modified oligodeoxynucleotides. J.Clin.Invest, 95: 1814-1823, 1995. 
 64.  Durie, B. G. Staging and kinetics of multiple myeloma. Semin.Oncol., 13: 300-309, 1986. 
 
 
 
  
Bcl-2 antisense chemosensitizes myeloma plasma cells 
56 
 
 
 
 
 
  57 
 
 
 
 
 
Chapter 3 
 
 
 
 
 
G3139, a Bcl-2 antisense oligodeoxynucleotide, may 
overcome drug resistance in VAD refractory myeloma 
 
 
Niels W.C.J. van de Donk, Okke de Weerdt, Gerda Veth, Marijke Eurelings, Esther van 
Stralen, Stanley R. Frankel, Anton Hagenbeek, Andries C. Bloem, and Henk M. Lokhorst  
 
 
 
 
 
 
 
 
 
 
Submitted 
 
 
  
Bcl-2 antisense in refractory myeloma 
58 
Abstract 
 
Expression of Bcl-2 in multiple myeloma is associated with resistance to 
chemotherapeutic drugs. Conversely, suppression of Bcl-2 enhanced the chemosensitivity 
of myeloma cells in vitro. G3139 is an antisense oligodeoxynucleotide targeted to the first 
6 codons of the Bcl-2 mRNA. In this study, G3139 was delivered as a continous 
intravenous infusion for 7 days at a fixed dose of 7 mg/kg/day in combination with VAD 
chemotherapy. Ten patients with refractory myeloma participated in this trial, including 8 
patients with VAD refractory disease, 1 patient with thalidomide refractory disease, and 6 
patients with disease refractory to thalidomide/dexamethasone. The combination of 
G3139 and VAD was feasible and well tolerated. Seven patients (70%) responded 
including 4 patients (40%) with a partial response and 3 patients (30%) with a minor 
response. Baseline Bcl-2 protein levels in bone marrow myeloma cells, Ki-67 growth 
fraction, and presence of deletion of chromosome 13 were not predictive of response. 
Median progression free survival was 6 months (range, 2 to 7+ months) and median 
overall survival has not been reached. G3139 down-regulated Bcl-2 protein levels in 
peripheral blood circulating myeloma cells, B cells, T cells, and monocytes. There was a 
trend towards correlation between decrease in circulating B and T cells and reduction of 
Bcl-2 protein levels in these cells. These results indicate that G3139 may overcome 
classical resistance and restore sensitivity of myeloma tumor cells to VAD chemotherapy.
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Introduction 
 
Multiple myeloma is characterized by the accumulation of monoclonal plasma cells in the 
bone marrow. The emergence of drug-resistant disease is the primary cause of treatment 
failure in myeloma. Well established mechanisms of drug resistance for myeloma tumor 
cells in vitro are mutations or altered expression of target genes 1-4, increased drug 
metabolism 5, changes in drug accumulation 6-11, and increased repair of drug-induced 
damage 12. Recent studies have demonstrated that defects in apoptotic pathways contribute 
significantly to resistance of cancer cells to chemotherapeutic drugs 13-15. Tumor cells, 
which are unable to undergo programmed cell death are therefore resistant to 
chemotherapeutic agents. 
Bcl-2 is a potent enhancer of cell viability through the inhibition of apoptotic 
death in various cell lines. Bcl-2 is expressed in myeloma cell lines and in myeloma 
patients' samples despite the absence of molecular evidence of Bcl-2 rearrangements 16-22. 
Bcl-2 inhibits apoptosis by forming inactivating heterodimers with pro-apoptotic Bcl-2 
family proteins, and by preventing the collapse of the mitochondrial transmembrane 
potential, cytochrome c release from mitochondria into the cytosol, and caspase activation 
23-25. Overexpression of Bcl-2 in transgenic mice prolongs the life span of plasma cells and 
in combination with abnormal expression of other oncogenes such as c-myc, contributes 
to the development of immature pre-B cell lymphoma, large cell lymphoma or 
plasmacytoma in 40-60% of the mice 26,27. This suggests a role for Bcl-2 in the etiology of 
myeloma. Gene transfer-mediated overexpression of Bcl-2 in myeloma cells has been 
reported to block the process of chemotherapy-induced apoptosis 28,29. In addition, Bcl-2 
protein levels increased following exposure of cell lines to doxorubicin, which may 
account for the relative resistance to a second doxorubicin exposure 28. We and others 
have shown that specific down-regulation of Bcl-2 protein by Bcl-2 antisense 
oligodeoxynucleotides (ODNs) restored chemosensitivity in chemoresistant myeloma cell 
lines and in primary myeloma cells from patients 30-32.   
G3139 is a 18-mer fully phosphorothioated antisense ODN targeted to the first 6 
codons of the Bcl-2 mRNA. Preclinical studies showed that G3139 was effectively taken 
up by myeloma cells, decreased Bcl-2 mRNA levels and protein levels, and sensitized 
myeloma cells to chemotherapeutic agents including dexamethasone and doxorubicin 31,32. 
Furthermore, G3139 as a single agent has resulted in tumor regression in patients with 
relapsed non-Hodgkin’s lymphoma (NHL) 33,34, and studies in patients with metastatic 
melanoma 35, chemorefractory small-cell lung cancer 36, metastatic hormone-refractory 
prostate cancer 37, and in refractory/relapsed acute leukemia 38 showed that G3139 can be 
administered safely in combination with chemotherapy. Based upon these data we 
initiated a phase 2 study of G3139 in combination with vincristine, adriamycin, and 
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dexamethasone (VAD) in patients with heavily pretreated multiple myeloma including 
patients with disease resistant to VAD, thalidomide, and other chemotherapy regimens. 
   
 
Patients, materials, and methods 
 
Criteria for enrollment 
Patients up to 75 years of age with multiple myeloma refractory to or relapsing after 
completion of at least 2 lines of chemotherapy which included VAD chemotherapy and 
with satisfactory venous access for 7-day infusion were eligible for the study. Criteria for 
exclusion were World Health Organization (WHO) performance status 4; severe cardiac, 
pulmonary, neurologic, metabolic, or psychiatric disease; absolute neutrophil count 
<1000/mm3 and platelets <50000/mm3; need for transfusion support; inadequate liver 
function; creatinine clearance <40 ml/min; prior malignant disease except nonmelanoma 
skin tumors or stage 0 cervical carcinoma; therapy for myeloma within 3 weeks prior to 
start G3139 in combination with VAD; active uncontrolled infections; known 
hypersensitivity to phophorothiate-containing oligodeoxynucleotides, dexamethasone, or 
doxorubicin; and use of any investigational therapy within 4 weeks prior to registration. 
Approval was obtained from the University Medical Center Utrecht institutional review 
board for these studies (01/227-E). Written informed consent was obtained from all 
patients before inclusion. The study was performed according to the Helsinki agreement.  
 
Study protocol 
G3139 (Genasense, oblimersen sodium; Genta, Inc., Berkeley Heights, NJ, USA; 5'-TCT 
CCC AGC GTG CGC CAT-3') was delivered as a continous intravenous infusion through 
a separate line using a portable pump on days 1 to 7 at a dose of 7 mg/kg/day. Infusion 
sites were changed when early signs of inflammation were observed. VAD was started at 
day 4 of the G3139 infusion. The VAD regimen consisted of daily doses of 0.4 mg 
vincristine and 9 mg/m2 doxorubicin on days 4 to 7 and were administered by rapid 
intravenous infusion as described previously 39. Dexamethasone (40 mg) was given orally 
on days 4 to 7 on even cycles and on days 4 to 7, 12 to 15, and 20 to 23 on odd cycles of 
VAD. The treatment cycles were repeated at 4-week intervals. Three courses of treatment 
were planned per patient, but additional courses could be administered in the case of 
response. Antibacterial and anti-fungal prophylaxis was given according to local 
guidelines. Adverse events were graded according to the National Cancer Institute (NCI) 
Common Toxicity Criteria (CTC) version 2.0 (http://ctep.info.nih.gov). 
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Evaluation of response 
Response evaluation was performed according to the Blade criteria 40. Partial response 
(PR) was defined as 50% or more reduction of monoclonal immunoglobulins (M-protein) 
in serum and/or urine or more than 50% reduction of bone marrow infiltration in 
nonsecretory myeloma. Minor response (MR) was defined as 25 to 50% reduction of M-
protein in serum and/or urine or 25 to 50% reduction of bone marrow infiltration in 
nonsecretory myeloma. Complete response (CR) was defined as no M-protein measurable 
in serum and/or 10 times concentrated urine by immunofixation analysis and less than 5% 
plasma cells which had to be polyclonal by immunofluorescence staining. Patients with a 
reduction of less than 25% of M-protein in serum and/or urine or of bone marrow 
infiltration were considered to be refractory. Relapse from CR was defined as recurrence 
of M-protein in serum and/or urine measured by immunofixation on at least 2 occasions. 
Progression from PR or MR was defined as an increase in serum and/or urine M-protein 
levels or bone marrow infiltration by more than 25% on 2 consecutive measurements or 
any increase of M-protein in the presence of clinical evidence of disease progression.  
 
Immuno-FISH analysis 
To detect a (partial) deletion of chromosome 13, FISH analysis using the commercially 
available SpectrumOrange-conjugated probe LSI13 (Rb1) (Vysis, Downers Grove, IL, 
USA) was performed according to the manufacturer’s guidelines with minor 
modifications and combined with immunological staining of the cytoplasmatic Ig light 
chains to positively identify plasma cells as described previously 41. Signals of the probe 
were detected by standard procedures. We intended to analyze a total of 100 plasma cells 
in each patient. A patient was considered as having deletion of chromosome 13 when the 
percentage of plasma cells with a deletion exceeded 20%. 
 
Quantification of Bcl-2 by flow cytometry 
Bcl-2 and Bax protein levels were determined in myeloma plasma cells (CD38+ CD138+ 
CD45±) in bone marrow prior to start of G3139 treatment and in peripheral blood 
circulating myeloma cells (CD38+, CD138+, CD45±), CD3+ cells, CD19+ cells, and CD14+ 
cells at day 0, 4, and 7 of the treatment cycle by flow cytometry. Peripheral blood or bone 
marrow mononuclear cells, which were obtained by Ficoll-Paque (Amersham; Pharmacia 
BiotechAB, Uppsala, Sweden) density centrifugation, (1 x 106) were fixed and 
permeabilized using FACS Lysing Solution (FLS, 10% in aqua destillata; Becton 
Dickinson, Erembodegem, Belgium (BDIS)) and subsequently incubated with anti-Bcl-2-
FITC (IgG1, Dako, Glostrup, Denmark) antibody or the isotype and subclass matched 
control antibody. All incubations were performed at room temperature for 30 minutes. 
Cells were then incubated with mouse serum for 15 minutes at room temperature, and 
subsequently incubated with CD3-PE (BDIS), CD14-APC (BDIS), and CD19-Percp 
Cy5.5 (BDIS) or with CD38-APC (BDIS), CD138-PE (Immunotech, Marseille , France), 
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and CD45-PERCP (BDIS) for 15 minutes at room temperature, and analyzed on a 
FACSCalibur (BDIS). Between different steps the cells were washed with PBS. The mean 
fluorescence ratio (MFR), defined as the ratio of the mean fluorescence intensities (MFI) 
of primary antibody and isotype control stained cells was used as a measure for Bcl-2 
expression.  
 
Flow cytometric analysis of lymphocyte subsets 
Lymphocyte populations were analyzed using four-colour flow cytometry at day 0, 4, and 
7 of each treatment cycle. Peripheral blood, collected in sodium heparine, was stained at 
room temperature with a panel of antibodies, lysed using FACS Lysing Solution (BDIS), 
washed with PBS, and analyzed on a FACSCalibur (BDIS). The following antibody 
combinations were used to analyze the lymphocyte populations: CD3, CD16+56, CD45, 
CD19, and CD8, CD4, CD45, CD3. CD3, CD4, CD8, CD19, and CD45 were obtained 
from BDIS and CD16+56 was derived from Immunotech. B cells were defined as CD3- 
CD19+, natural killer cells as CD3- CD16+/CD56+, CD8 cells as CD3+ CD8+, and CD4 
cells as CD3+ CD4+. Absolute counts of a certain lymphocyte population were calculated 
by multiplying the total white blood cell (WBC) count by the frequency of that population 
in the lymphocyte gate and by the fraction of total WBCs included in the lymphocyte gate.   
 
Statistical analysis 
Data analysis was performed using the SPSS statistical software package (SPSS, Chicago, 
IL, USA). Correlations were calculated by using the Spearmann test. The Mann-Whitney 
U-test was used to determine differences in case of continuous variables. The Fisher’s 
exact test for two by two tables was used to determine differences in case of categorial 
variables. Correlations were considered significant when P < 0.05. Progression free and 
overall survival were computed by Kaplan Meier survival analysis. 
  
 
Results 
 
Patient characteristics 
A total of 10 patients were enrolled in this study. Clinical characteristics are shown in 
Table 1. There were 5 males and 5 females. Median age was 56 years, with a range of 39 
to 64 years. All patients were heavily pretreated and had received a median of 4 previous 
chemotherapy regimens (range, 2 to 6). Eight patients (80%) had VAD refractory disease, 
6 (60%) had thalidomide/dexamethasone refractory disease, and 1 patient (10%) had 
thalidomide refractory disease. Five patients had received high-dose chemotherapy with 
autologous hematopoietic stem-cell support, and one of these patients received a second 
cycle of high-dose chemotherapy for relapse. Two patients had received an allograft. The 
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median number of cycles of G3139 and VAD was 2.5. Five patients received 2 cycles of 
treatment, and went off study because of progression during treatment or because of 
infection (patient 10). Three cycles were administered to 3 patients. Two patients received 
4 or 6 treatment cycles. A total of 29 cycles of G3139 and VAD have been administered. 
 
         Table 1. Clinical characteristics  
 
Toxicity 
At the start of treatment, anemia was present in 8 patients (6 grade 1, and 2 grade 2), 
leucopenia was present in 4 (1 grade 1, 3 grade 2), neutropenia in 4 (1 grade 1, 2 grade 2, 
1 grade 3), lymphopenia in 2 (1 grade 1, 1 grade 2), and grade 1 thrombocytopenia in 2 
patients. Hematological toxicity during the first cycle and during all cycles is shown in 
Table 2.  
 
Table 2. Hematological toxicity in patients treated with G3139 and VAD  
 
No. of patients with event of common toxicity criteria during first cycle (all cycles; n=29) 
Toxicity Grade 1 Grade 2 Grade 3 Grade 4 
Leucopenia 0 (6) 1 (4) 1 (2) 1 (3) 
Neutropenia 0 (3) 1 (1) 1 (3) 1 (3) 
Lymphopenia 1 (2) 1 (1) 3 (8) 1 (2) 
Thrombocytopenia 3 (7) 1 (1) 0 (4) 1 (2) 
Anemia 7 (17) 2 (6) 0 (1) 0 
 
Characteristic  
Total number of patients enrolled 10 
Gender  
  Male 5 
   Female 5 
Age (years)  
   Median 56 
   Range 39-64 
Deletion of chromosome 13 (%) 77.8  
Ki-67 (%)  
    Median 2 
     Range 0-70  
Number of prior chemotherapy regimens  
   2 1 
   3 1 
   4 4 
   5 2 
   6 2 
Number of cycles completed  
   2 5 
   3 3 
   4 1 
   6 1 
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Non-hematological adverse events included fatigue in 5 patients (grade 1 in 3 
patients, and grade 2 in 2 patients) (Table 3). Nine patients had a grade 1 local 
inflammatory reaction around the infusion site. One patient (patient 5) developed skin and 
subcutaneous tissue necrosis (grade 3) during administration of G3139 before start of 
chemotherapy. This was likely the consequence of extravasation of G3139 at cycle 1. The 
local skin inflammation around the infusion site required change of the infusion site every 
2 or 3 days in all patients. Furthermore, 3 patients (5, 9, 10) underwent placement of a 
central venous catheter. One of these patients (patient 5) developed a catheter-related 
venous thrombosis and patient 10 had a catheter-related infection. These events were 
likely related to G3139 and VAD treatment. Patients 4 and 10 developed a grade 3 
infection. 
 
Table 3. Non-hematological toxicity in patients treated with G3139 and VAD 
 
Disease response 
Four patients (40%) achieved a partial response and 3 patients (30%) achieved a minor 
response, indicating that 70% of the patients responded to the combination of G3139 and 
VAD (Table 4). Of the 7 responders, 5 had VAD refractory disease (Table 4). This group 
of 5 included 3 patients who sequentially received VAD alone followed by the 
combination of G3139 and VAD (patients 5, 9, and 10). In addition, 3 of the 7 responding 
patients had thalidomide/dexamethasone refractory disease and 1 had thalidomide 
refractory disease. Patient 2 had VAD and thalidomide/dexamethasone refractory disease 
and obtained only a minor response after allogeneic stem cell transplantation, but 
achieved a partial response on the current protocol (Table 4). Three patients did not 
respond. Deletion of chromosome 13 (del13) was present in 7 out 9 evaluable patients 
(77.8%). Del13 was present in 5 out 6 responding and in 2 out 3 non-responding patients. 
The Ki-67 growth fraction was not predictive of response. Among the responding patients, 
5 had anemia at base line. Hemoglobin levels increased in 3 patients, decreased in 1 
patient, and remained unchanged in 1 patient. Responses were also associated with 
increases in Karnofsky performance-status scores in 4 (57%) patients and improvement of 
pain in 7 (100%) patients. Four out 7 responding patients relapsed, whereas response 
persists in 3 patients. Median progression free survival of these patients was 6 months 
(range, 2 to more than 7 months) without any further therapy before relapse occurred. 
No. of patients with event of common toxicity criteria during first cycle (all cycles; n=29) 
Toxicity Grade 1 Grade 2 Grade 3 Grade 4 
Fatigue 3 (13) 2 (4) 0 0 
Thrombosis 0 0 0 (1) 0 
Catheter-related infection 0 0 0 (1) 0 
Infection 0 0 0 (2) 0 
Renal 2 (5) 0 0 0 
Injection site reaction 9 (23)  0 1 (1) 0 
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Three patients had died of progressive disease. The median overall survival for all patients 
to date exceeds 12 months (range, 3 to more than 16 months). Although not significant, 
achievement of response was associated with longer overall survival when compared to 
non-responding patients (P = 0.17). 
 
Table 4. Previous treatment and outcome of G3139 combined with VAD  
 
 
Bcl-2 protein levels in bone marrow myeloma cells 
In 9 patients, Bcl-2 was determined in bone marrow myeloma cells by flow cytometry 
prior to start of therapy. No material for analysis was available from patient 2. Bcl-2 
protein levels, expressed as mean fluorescence ratio, varied among patients (median 12.2; 
range: 2.4 to 27.4). No association between Bcl-2 protein levels and response was 
observed.  
 
Effect of treatment on Bcl-2 protein levels in peripheral blood circulating myeloma 
cells, B cells, T cells, and monocytes 
In peripheral blood from patients 3, 4, 5, 6, 9, and 10 more than 0.01% circulating 
myeloma cells were detected (range: 0.01 to 4.0%), enabling analysis of Bcl-2 protein 
levels in these cells. In the other patients the level of peripheral blood infiltration was too 
low, to reliably quantify Bcl-2 protein expression. Bcl-2 protein expression was 
determined by flow cytometry at day 0 before treatment and at day 4 of G3139 infusion 
prior to initiation of VAD. After 4 days of G3139 treatment Bcl-2 protein levels in 
circulating myeloma cells were reduced in 4 out 6 patients (median change: -13.3%) 
(Table 5). Bcl-2 protein expression was also determined by flow cytometry in peripheral 
blood T cells (CD3+), B cells (CD19+), and monocytes (CD14+). This analysis was 
performed during cycle 1 (patients 1, 2, 6, 7, 9, and 10) or cycle 2 (patients 3, 5, and 8). 
Treatment for 4 days with G3139 resulted in a reduction of Bcl-2 protein levels in B cells 
in 9 out 9 patients when compared with baseline values (median change: -25.0%). In 
monocytes, Bcl-2 protein levels were reduced in 8 out 9 patients on day 4 (median 
Patient Cycles completed Previous therapy and outcome of G3139+VAD therapy 
1 2 VAD PR---IDM refr---VAD refr---CVP refr---Thal+dexa refr---G3139+VAD refr 
2 3 VAD refr---Thal+dexa refr—alloSCT MR---G3139+VAD PR 
3 6 VAD refr---IDM refr---autoSCT PR---Thal+dexa refr---G3139+VAD PR 
4 2 VAD PR---IDM PR---autoSCT PR---Thal+dexa refr---G3139+VAD MR 
5 3 VAD refr---IDM PR---autoSCT CR---VAD refr---G3139+VAD PR 
6 2 VAD refr---IDM PR---TAD PR---autoSCT PR---Thal+dexa refr---G3139+VAD refr 
7 4 VAD PR---IDM PR---autoSCT CR---VAD PR---autoSCT PR---Thal refr---G3139+VAD PR 
8 2 VAD PR---IDM CR---VAD refr---Thal+dexa refr---G3139+VAD refr 
9 3 VAD PR---IDM PR---alloSCT PR---TAD PR---DLI refr---VAD refr---G3139+VAD MR 
10 2 MP refr---VAD refr---G3139+VAD MR 
 VAD, vincristine, doxorubicin, and dexamethasone; IDM, intermediate-dose melphalan; CVP,
cyclophosphamide, vincristine, and prednisone; Thal, thalidomide; dexa, dexamethasone; alloSCT, allogeneic
stem cell transplantation; autoSCT, autologous stem cell transplantation; TAD, thalidomide, doxorubicin, and
dexamethasone; DLI, donor lymphocyte infusion; MP, melphalan and prednisone; MR, minor response; PR,
partial response; CR, complete response; refr, refractory. 
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change: -21.8%). Bcl-2 protein levels were reduced in T cells in 6 out 9 patients on day 4 
(median change: -16.4%) (Table 5). There was no significant association between Bcl-2 
protein down-regulation in peripheral blood circulating myeloma cells, B cells, T cells, or 
monocytes and response to G3139 in combination with VAD chemotherapy. 
 
Table 5. Effect of G3139 on Bcl-2 protein levels at day 4 (presented as the change 
from baseline (day 0) in %) 
 
Effect of treatment on circulating leucocytes and thrombocytes 
In 8 patients, the effect of treatment on numbers of circulating lymphocytes, monocytes, 
granulocytes, and thrombocytes in peripheral blood was determined on day 0, 4, 7, and 28 
of cycle 1 (patients 2, 4, 6, 7, 9, and 10) or cycle 2 (patients 3 and 8) (Table 6). The largest 
effect was observed in B cells, which showed mean reductions of 50.9% on day 4 and 
36.5% on day 7, when compared with baseline numbers. There was a minor reduction of 
T cells on day 4 and a more profound reduction on day 7. This was due to a decrease of 
both CD4+ and CD8+ T cells. NK cells either increased (n=5) or decreased (n=3) after 4 
days of G3139 treatment. However, on day 7 natural killer (NK) cells were reduced in all 
patients. Both on day 4 and 7, a reduction in monocytes was observed. G3139 did not 
affect granulocytes on day 4, but on day 7 there was a significant increase in the number 
of granulocytes, which was probably related to administration of dexamethasone. 
Thrombocytes were reduced on day 4 and day 7. T cells (CD4 and CD8) and monocytes 
returned to baseline or near baseline values on day 28 prior to start of the following course 
of G3139 and VAD. However, B cells and thrombocytes did not fully recover, and NK 
cells and granulocytes were increased on day 28. Although not significant, there was a 
trend for correlation between Bcl-2 protein reduction in B or T cells and reduction of B 
cells (day 4: R=0.643; P = 0.119, day 7: R=0.657; P = 0.156) or T cells (day 4: R=0.739; 
P = 0.058, day 7: R=0.771; P = 0.072). No association was observed between Bcl-2 
down-regulation in monocytes and reduction of monocytes. 
 
 
 Patient   B cells   T cells Monocytes Myeloma cells   
1   - 16.3   13.8 -21.8   
2   - 3.6   -5.1 -11.1   
3   - 62.8   -19.3 -8.3 5.5   
4     1.9   
5   - 27.6   -16.4 -22.2 - 19.7   
6   - 25.0   -25.1 -25.0 - 25.6   
7   - 5.3   2.0 -19.5   
8   - 14.8   15.5 15.7   
9   - 33.6   -18.0 -27.7 - 26.4   
10   - 37.4   -19.3 -47.3 - 6.9   
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Table 6. Effect of G3139 combined with VAD on numbers of circulating leucocytes and 
thrombocytes (presented as the change from baseline in %) 
 
 
Discussion 
 
In this study, we evaluated the effect of Bcl-2 antisense in combination with VAD 
chemotherapy in heavily pretreated multiple myeloma patients who failed previous 
therapy. G3139 was administered as a continuous intravenous infusion on days 1 to 7 at a 
dose of 7 mg/kg/day. VAD was started at day 4 of the G3139 infusion. The sequential 
order was based on preclinical data indicating that in purified myeloma cells the 
maximum decrease in Bcl-2 protein expression was typically observed after 4 days of 
treatment with G3139 31. In this study, 7 of the 10 patients (70%) responded including 4 
patients (40%) with a partial response and 3 (30%) with a minor response. Of the 7 
responders 5 had VAD refractory disease. This group of 5 included 3 patients who 
sequentially received VAD followed by the combination of G3139 and VAD. Responses 
were associated with increased hemoglobin levels and performance status, and 
improvements in disease symptoms including pain. These data indicate that Bcl-2 
antisense may overcome classical drug resistance and restore the sensitivity of myeloma 
tumor cells to VAD chemotherapy. Median progression free survival was 6 months, which 
is usual for this category of patients 42,43, and the median overall survival has not been 
reached. Response did not appear to be correlated with Ki-67 growth fraction or Bcl-2 
protein levels in bone marrow myeloma tumor cells at baseline. Furthermore, it is 
remarkable that responsiveness to G3139 in combination with VAD chemotherapy did not 
correlate with the presence of deletion of chromosome 13, which is a strong unfavourable 
prognostic factor in myeloma. 
 This study showed that G3139 and VAD could be administered safely in heavily 
pretreated myeloma patients. Also in patients with refractory/relapsed acute leukemia 38, 
metastatic melanoma 35, chemorefractory small-cell lung cancer 36, or metastatic hormone-
 Day 4 Day 7 Day 28 
Cell type Mean (%) Range (%) Mean (%) Range (%) Mean (%) Range (%) 
B cells -50.9 -90 to -1.1 -36.5 -95.8 to 3.4 -32.8 -88.8 to 60.0 
T cells -20.4 -78.5 to 54.1 -43.4 -78.9 to 36.8 -7.5 -55.3 to 63.2 
CD4+ T cells -11.6 -65.3 to 66.1 -45.4 -84.2 to 31.3 -1.1 -59.8 to 107.1 
CD8+ T cells -21.5 -95.9 to 49.6 -37.4 -71.6 to 47.6 5.4 -54.2 to 71.2 
NK cells 3.3 -51.3 to 54.4 -40.3 -62.5 to -13.2 22.8 -65.0 to 100.0 
Granulocytes -5.3 -50.0 to 26.4 172.5 4.1 to 293.1 55.7 0.0 to 122.4 
Monocytes -27.1 -67.7 to 72.2 -28.9 -45.2 to -12.3 6.3 -20.9 to 43.1 
Thrombocytes -14.9 -26.8 to 2.6 -20.5 -38.9 to 3.6 -19.3 -75.9 to 1.6 
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refractory prostate cancer 37, the combination of G3139 with chemotherapy was feasible. 
In the current study, the clinically most significant adverse event of G3139 was a local 
inflammatory reaction around the infusion site. This was also observed in NHL patients 
who were treated with a continuous subcutaneous infusion of G3139 33,34. Hematological 
toxicity may be primarily attributable to VAD chemotherapy and was predominantly 
observed in patients with cytopenias at baseline. Patient 8 developed grade 2 anemia, 
grade 3 leucopenia, neutropenia, and thrombopenia, and grade 4 lymphopenia, which 
were probably due to advanced infiltration of bone marrow. Thrombocytopenia and 
fatigue were observed during G3139 infusion that precedes VAD chemotherapy and are 
adverse events that were also reported in trials evaluating other phosphorothioate 
oligodeoxynucleotides 44,45, suggesting that these effects resulted from non-sequence 
specific effects and can be attributed to the phosphorothioate backbone of the 
oligodeoxynucleotide molecule.   
G3139 treatment for 4 days moderately reduced Bcl-2 protein levels in peripheral 
blood circulating myeloma cells, B cells, T cells, and monocytes in the majority of the 
patients. Similar moderate reductions of Bcl-2 were found in other studies evaluating 
G3139 34,35,38. No significant association was found between Bcl-2 down-regulation in 
peripheral blood myeloma cells, B cells, T cells, or monocytes and response to G3139 in 
combination with VAD. G3139 administration alone preceding chemotherapy resulted in 
a transient reduction of absolute numbers of circulating lymphocytes, monocytes, and 
thrombocytes, but did not alter the number of circulating neutrophils or NK cells. We 
further show for the first time that the decline in circulating lymphocytes is due to 
reduction of B cells and to a lesser extent of T cells (CD4 and CD8). After completion of 
the treatment course there was a full recovery of the number of circulating T cells and 
monocytes and a partial recovery of platelets and B cells. This is in agreement with 
studies indicating that Bcl-2 is not essential for survival of pluripotent hematopoietic stem 
cells 46, and therefore Bcl-2 down-regulation by G3139 treatment will not result in a loss 
of renewal potential for normal hematopoietic cells. The transient reduction of B cells and 
T cells by G3139 is likely related to a sequence-specific Bcl-2 down-regulation in these 
cells. First, survival of mature B and T (CD4 and CD8) cells has been shown to be 
critically dependent on Bcl-2 protein expression 46. Furthermore, there was a trend 
towards a correlation between down-regulation of Bcl-2 protein in B and T cells and 
decline of circulating lymphocytes. Moreover, although lymphopenia was also reported in 
other studies evaluating G3139 34,35,37, there have been no reports of lymphopenia in 
clinical trials of other phosphorothioate antisense molecules developed to inhibit other 
targets 44,45.  
In conclusion, G3139 induced significant clinical responses when combined with 
VAD chemotherapy in patients with (VAD) refractory disease. The combination of Bcl-2 
antisense and VAD chemotherapy was feasible and well tolerated. The results of this trial 
warrant exploration of Bcl-2 antisense in earlier-stage disease. 
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Abstract 
 
Lovastatin is an irreversible inhibitor of HMG-CoA reductase and blocks the production 
of mevalonate, a critical compound in the production of cholesterol and isoprenoids. 
Isoprenylation of target proteins, like the GTP-binding protein Ras, is essential for their 
membrane localization and subsequent participation in intracellular signaling cascades. 
Lovastatin effectively decreased the viability of plasma cells from cell lines (n=10) and 
myeloma patients’ samples (n=8) in a dose- and time-dependent way. Importantly, co-
incubation of lovastatin with dexamethasone had a synergistic effect in inducing plasma 
cell cytotoxity. This effect was not the consequence of a change in the protein expression 
levels of Bcl-2 or Bax induced by lovastatin. The decrease in plasma cell viability was the 
result of induction of apoptosis and inhibition of proliferation. Mevalonate effectively 
reversed the cytotoxic and cytostatic effects of lovastatin in plasma cells. The cytotoxic 
activity of lovastatin was higher in Pgp expressing cell lines, but did not correlate with the 
multidrug resistance (MDR)-related proteins LRP, Bcl-2 and Bax. Lovastatin treatment 
resulted in a shift of Ras localization from the membrane to the cytosol that was reversed 
by mevalonate. The data presented in this paper warrant study of lovastatin alone or in 
combination with therapeutic drugs, in the treatment of myeloma patients.   
 
 
Keywords: lovastatin, HMG-CoA reductase, multiple myeloma, multidrug resistance, 
apoptosis, isoprenylation 
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Introduction 
  
The enzyme 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase catalyzes the 
reduction of HMG-CoA to mevalonate, which is an intermediate in the synthesis of 
cholesterol, essential for membrane integrity; of dolichol, required for glycoprotein 
synthesis; of polyisoprenoids side chains of heme A and ubiquinone, involved in oxidative 
respiration; and of isopentyl-adenine, present in some tRNAs. Furthermore mevalonate is 
also a precursor of the isoprenoids farnesylpyrophosphate and 
geranylgeranylpyrophosphate 1. These isoprenoids are used for posttranslational 
modification of a variety of proteins, including Ras and Ras-related GTP binding proteins. 
Isoprenylation is essential for membrane attachment 2 and participation of the modified 
proteins in signal transduction processes 3-7.  
Lovastatin is a potent competitive inhibitor of HMG-CoA reductase and is widely 
used for the treatment of hypercholesterolemia 8. Lovastatin blocks the enzymatic 
conversion of HMG-CoA to mevalonate and subsequently the synthesis of downstream 
mevalonate products. In this way lovastatin interferes with isoprenylation and the 
subsequent membrane localization of G proteins like Ras and Ras-related proteins 9,10. 
Lovastatin inhibits the proliferation of several tumor cells by inducing a growth arrest at 
the G1/S boundary 10,11. Furthermore, lovastatin has a chemosensitizing capacity in cancer 
cells, rendering tumor cells susceptible to chemotherapeutic drugs 12-18 and can directly 
induce apoptosis as has been documented for several tumor cell lines 10,15,19,20 and tumor 
cells from patients with acute myeloid leukemia 19, possibly via down-regulation of the 
anti-apoptotic protein Bcl-2 15. The observation that long-term treatment of 
hypercholesterolemia patients with statins was associated with fewer cancer deaths 21, 
suggests that lovastatin interferes with processes involved in tumorigenesis.   
Multiple myeloma is a plasma cell tumor localized in the bone marrow. Although 
the majority of the patients respond to initial treatment, almost all patients relapse and die 
from multidrug resistant disease. Interleukin-6 (IL-6) is the most important growth and 
survival factor in myeloma 22-24. Through binding to the IL-6 receptor, IL-6 activates the 
JAK-STAT 25 and Ras-MAPK 23 pathways, resulting in proliferation and protection from 
apoptosis of plasma cells. Activating Ras mutations are associated with IL-6-independent 
growth 26 and are associated with a dexamethasone and doxorubicin-resistant phenotype 
27. 
Since lovastatin effectively interferes with the membrane localization of Ras and 
its subsequent involvement in signaling processes 20,28, and knowing the importance of 
Ras signaling cascades in myeloma, we investigated the ability of lovastatin to induce 
apoptosis in myeloma cell lines and purified myeloma plasma cells. The results imply that 
lovastatin alone or in combination with chemotherapeutic drugs might be an effective 
therapy in multiple myeloma. 
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Materials and methods 
 
Reagents 
Lovastatin was a generous gift from Merck, Sharp & Dohme Research Laboratories 
(Rahway, NJ, USA) and prepared as described previously 29. Dexamethasone and 
mevalonate were purchased from Sigma (St Louis, MO, USA).  
 
Cell lines and culture conditions 
Plasma cell lines RPMI-8226 and U266 were obtained from the American Tissue Culture 
Collection (ATCC) and L363 from the German Collection of Microorganisms and Cell 
Cultures (GCMC). Plasma cell lines UM-1 and UM-3 were obtained after prolonged in 
vitro culture of bone marrow aspirates of myeloma patients and have been described 
before 30. The plasma cell line UM-6 was obtained under identical conditions as described 
above. UM-6 cells express high levels of plasma cell associated antigens CD38, CD138 
and cytoplasmic IgAkappa, as determined by flow cytometric analysis and 
immunofluorescence microscopy, respectively. Analysis using ASO-PCR established the 
clonal relationship between UM-6 and the original myeloma tumor (data not shown). The 
doxorubicin-resistant cell lines RPMI-DOX40 (DOX40) and RPMI-DOX6 (DOX6) were 
kind gifts of Dr W. Dalton (University of South Florida, Tampa, FL, USA) and Dr R. 
Scheper (Free University, Amsterdam, The Netherlands), respectively. The IL-6-
dependent plasma cell line XG-1 (XG-1+) was a kind gift of Dr B. Klein (Institut for 
Molecular Genetics, Montpellier, France) 31. An IL-6-independent variant (XG-1-) was 
selected by limiting dilution of XG-1+ cells in the absence of IL-6. Cell lines were 
cultured in RPMI-1640 (GIBCO, Breda, The Netherlands) supplemented with 10% fetal 
calf serum (FCS) (Integro, Zaandam, The Netherlands), 100 IU/ml penicillin, 100 µg/ml 
streptomycin and 10 µM β-mercaptoethanol (growth medium). The IL-6-dependent cell 
lines XG-1+ and UM-6 were cultured in the continuous presence of exogenous IL-6 (1.25 
ng/ml rhIL-6 (Roche, Almere, The Netherlands)) and the RPMI-DOX6 cell line was 
cultured in the continuous presence of 6 X 10-8 M doxorubicin. 
Myeloma plasma cells were purified from mononuclear cells obtained by Ficoll-
Paque (Amersham; Pharmacia BiotechAB, Uppsala, Sweden) density centrifugation from 
bone marrow aspirates of 7 myeloma patients and peripheral blood of one patient with 
primary plasma cell leukemia after obtaining informed consent. The plasma cell 
percentage in the patient samples varied from 4 - 46% of the mononuclear cells (see Table 
2) as determined by simultaneous detection of CD38 (anti-CD38-FITC, Immunotech, 
Marseille, France) and CD138 (anti-CD138-PE, Immunotech) by flow cytometric analysis 
(FACSCalibur, Becton and Dickinson, Erembodegem, Belgium (BDIS)). Myeloma 
plasma cells were purified ex vivo by magnetic cell sorting (MACS) based on CD138 
expression 32. To this end, mononuclear cells were subsequently labeled with anti-CD138 
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(Immunotech) and rat anti-mouse IgG1 microbeads (Miltenyi Biotec, Bergisch Gladbach, 
Germany) and then separated using a high gradient magnetic separation column placed in 
a strong magnetic field (Miltenyi), exactly following the instructions of the manufacturer. 
Samples obtained in this way contained >95% plasma cells as determined by analysis of 
CD38/CD138 co-expression. For experiments myeloma cells were resuspended in growth 
medium (see above). 
   
In vitro cell cultures 
Viability assay Viability of cells was examined by means of the 3-[4,5-dimethylthiazol-2-
yl]-2,5-diphenyltetrazolium bromide (MTT) assay as described previously 33. In short, 
cells were seeded in a concentration of 0.3 X 106/ml for the plasma cell lines or 1 X 
106/ml for the purified myeloma cells and NBM mononuclear cells in a 96-well flat 
bottom plate (100 µl/well) (Nunc, Roskilde, Denmark) and treated with different 
concentrations lovastatin (0, 1, 5, 10, 20, 40, 60, 80, 100 and 150 µM). After 2 or 4 days, 
25 µl of MTT (5 mg/ml) was added to each well. After an incubation of 2 hours at 37oC 
the reaction was stopped by the addition of 100 µl 20% sodium dodecyl sulphate (SDS; 
Boehringer Mannheim, Mannheim, Germany) / 0.025 M HCl / 0.35 M HAc in a mixture 
of (1:1; v/v) N,N-dimethylformamide (Merck, Darmstadt, Germany) and aqua destillata. 
After an overnight incubation at 37oC the optical density of the samples was determined at 
570 nm.  
Cell proliferation assay Cells (3 X 104) were seeded in 96-well flat bottom plates (Nunc) 
in 100 µl growth medium with different concentrations lovastatin (0, 1, 5, 10, 20, 40, 60, 
80, 100 and 150 µM). After 32 and 80 hours, 3H-thymidine (Amersham, Little Chalfont, 
UK) (1 µCi/well) was added for the remaining 16 hours of the assay. 3H-thymidine 
incorporation was analyzed by liquid scintillation counting as described previously 34. 
Apoptosis assessment by Annexin V staining Mononuclear cells (3 X 105 in 0.5 ml) were 
incubated with different concentrations lovastatin (0, 5, 10, 40, 100 and 150 µM) in a 48-
well plate (Nunc). After 2 or 4 days, cells were harvested, washed in ice cold PBS and 
directly stained with Annexin V-FITC (Nexins Research, Kattendijke, The Netherlands) 
and propidium iodide (PI). After an incubation for 10 minutes at 4oC, the cells were 
subsequently analyzed by flow cytometry as described previously 30. Apoptotic cells were 
defined as early apoptotic cells (Annexin V positive and PI negative) and late apoptotic 
cells (Annexin V positive and PI positive). 
Apoptosis assessment by the TUNEL assay Cells were incubated with lovastatin as 
described above. DNA strand breaks in apoptotic cells were detected by incorporation of 
FITC-labeled deoxyuridine triphosphate (UTP-FITC) into fragmented DNA by terminal 
deoxynucleotidyl transferase (TdT) (Boehringer Mannheim). Briefly, cells were 
subsequently washed in 1% bovine serum albumin (BSA) in PBS at 4oC, fixated in 4% 
paraformaldehyde solution for 1 hour at room temperature, permeabilized in 0.1% Triton 
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X-100 in 0.1% sodiumcitrate solution for 2 minutes at 4oC and incubated with UTP-FITC 
and TdT for 1 hour at 37oC in the dark. Cells were analyzed by flow cytometry. 
 
Expression of MDR-related proteins 
For flow cytometric detection of intracellular Bcl-2, Bax and LRP, cells (0.5 - 1 X 106) 
were fixed and permeabilized using FACS Lysing Solution (FLS, 10% in aqua destillata; 
BDIS) and subsequently incubated with anti-Bcl-2-FITC (IgG1, Dako, Glostrup, 
Denmark), anti-Bax (IgG2b, Immunotech) or anti-LRP (IgG2b, a kind gift of Dr R. 
Scheper) antibodies or their isotype and subclass matched control antibodies, followed by 
incubation with goat anti-mouse IgG F(ab’)2-FITC (Dako) for detection of Bax and LRP. 
All incubations were performed at room temperature for 30 minutes except staining for 
LRP that was performed at 4oC for 60 minutes. Between different steps the cells were 
washed with PBS. Membrane Pgp expression was determined by using the MRK16 
antibody (kindly provided by Dr R. Scheeper) as described before 33. The mean 
fluorescence ratio (MFR), defined as the ratio of the mean fluorescence intensities (MFI) 
of primary antibody and isotype control stained cells was used as a measure for the Bcl-2, 
Bax, LRP or Pgp protein expression.  
 
Western blotting 
Cells (1 X 106 cells in 1.5 ml) were incubated for varying lengths of time in growth 
medium with lovastatin (0, 10 or 30 µM) in the presence or absence of 100 µM 
mevalonate. After harvesting, whole cell lysates were made by washing cells twice in ice-
cold PBS and then resuspending them in lysis buffer (10 mM Tris-HCl [pH 7.6], 150 mM 
NaCl, 1% Triton X-100 and a cocktail of protease inhibitors (Boehringer Mannheim)) at 
4oC for 20 minutes. Insoluble material was removed by centrifugation at 14 000 r.p.m. for 
6 minutes at 4oC. When membrane and cytosolic protein fractions were analyzed, cells 
were suspended in extraction solution (10% glycerol, 20 mM Hepes, 1 mM MgCl2, 1 mM 
EDTA, 1 mM DTT and a cocktail of protease inhibitors (Boehringer Mannheim)). The 
lysate was sonificated twice for 5 seconds and centrifuged at 4oC for 30 minutes at 48 000 
g. The supernatant contained the proteins of the cytosolic fraction. The insoluble material 
was subsequently resuspended in solubilization buffer (1% NP-40, 20 mM Hepes, 20 mM 
MgAc, 5 mM NaF, 0.2 mM EDTA, 0.8 mM EGTA, 1 mM DTT and a cocktail of protease 
inhibitors). After 2 rounds of sonification for 10 seconds, an incubation for 30 minutes at 
4oC and a centrifugation step at 4oC for 30 minutes at 48 000 g, proteins of the membrane 
fraction were present in the supernatant. 
Protein concentrations were determined by the BCA assay (Pierce, Rockford, IL, 
USA). Samples containing equal amounts of protein were mixed with 2 X Laemmli 
sample buffer (0.125 M Tris pH 6.9 with 4% SDS, 20% Glycerol and 10% β-
mercaptoethanol) and boiled for 5 minutes. Proteins were subsequently fractionated in 
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10% SDS-PAGE at room temperature and electrically transferred from the gel to PVDF-
membrane (Biorad, Hercules, CA, USA). After blocking in 0.1% Tween-20, 5% skimmed 
powder milk, 2% BSA in 10 mM Tris and 150 mM NaCl, the membranes were incubated 
with anti-Bcl-2 (Dako) or anti-Ras (Transduction Laboratories, BDIS). Antibody binding 
was visualized with enhanced chemoluminescence (Amersham) detection with hyperfilm 
ECL (Amersham) after incubation with a horseradish peroxidase (HRP)-conjugated 
secondary antibody (Dako). Membranes incubated with anti-Bcl-2 or anti-Ras were 
extensively washed in PBS and reprobed with anti-Bax (Dako) and anti-α-actin (Sigma) 
or anti-γ-adaptin (Sigma) and anti-ICAM-1 (clone F7.11 35)), respectively. The level of 
protein expression was determined by densitometry following normalization for α-actin 
expression.  
 
Statistics  
Data analysis was performed using the SPSS statistical software package (SPSS Inc, 
Chicago, IL, USA). A two-sided Student’s t-test or a Welch’s t-test in case of unequal 
variances, was used to determine differences between groups. The correlation between 
lovastatin sensitivity and MDR-related proteins was calculated by using the Spearmann 
test. Differences and correlations were considered statistically significant when P < 0.05. 
Data are plotted as means ± standard error of the mean (s.e.m.). 
 
 
Results 
 
Lovastatin reduces cell viability in plasma cell lines and in ex vivo purified myeloma 
plasma cells by inhibition of HMG-CoA reductase 
The effect of lovastatin on cell viability was examined on 10 plasma cell lines by using 
the MTT assay. In vitro incubation with lovastatin decreased cell viability in all plasma 
cell lines tested in a time- (data not shown) and dose-dependent way, as shown in Figure 
1A for 3 representative cell lines. The concentration of lovastatin that reduced cell 
viability of the plasma cell lines with 50% (MTT50) or 75% (MTT25) after 4 days of in 
vitro culture ranged from 0.8 – 13.3 µM (MTT50) and 1.8 – 18.8 µM (MTT25) (Table 1). 
Lovastatin inhibits the enzyme HMG-CoA reductase that catalyzes the conversion of 3-
hydroxy-3-methylglutaryl CoA to mevalonate. To examine whether the reduction in 
myeloma cell viability was mediated by an inhibition of HMG-CoA reductase activity, we 
investigated whether mevalonate rescued plasma cells from lovastatin-induced cell death. 
Co-incubation with mevalonate significantly diminished the effect of lovastatin on plasma 
cell lines, as shown in Figure 1B for U266 cells.  
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Figure 1. Effect of lovastatin alone or in combination with mevalonate on viability of plasma cell lines. (A) 
Three representative plasma cell lines were incubated for 4 days with different concentrations of lovastatin or 
solvent control. (B) U266 cells were incubated with lovastatin for 4 days in the presence or absence of 100 µM 
mevalonate. Cell viability was examined by using the MTT assay as compared with control cells treated with 
solvent control. Experiments were performed at least 3 times in triplo. Data are presented as mean ± s.e.m. **: P 
< 0.005. 
 
 
Myeloma plasma cells were purified from bone marrow aspirates from 7 
myeloma patients and peripheral blood from 1 patient with primary plasma cell leukemia 
(for clinical data of these patients see Table 2) based on CD138 expression using magnetic 
beads. This isolation method resulted in cell samples that contained >95% plasma cells 
(data not shown). Lovastatin also effectively induced tumor cell death in these ex vivo 
purified myeloma plasma cells in a dose- and time-dependent fashion (Figure 2A). 
Lovastatin sensitivity differed among the myeloma patients’ samples. MTT50 and MTT25 
were in the range of 6.0 to 63.4 and 8.9 to >150 µM, respectively (Table 2). The reduction 
of viability of myeloma tumor cells from patients by lovastatin was significantly reversed 
by co-treatment with mevalonate (shown for cells from patient 5 in Figure 2B).  
 
Figure 2. Effect of lovastatin alone or in combination with mevalonate on viability of ex vivo purified 
plasma cells. (A) Ex vivo purified myeloma plasma cells from myeloma bone marrow samples (n=7) and 
peripheral blood from one patient with primary plasma cell leukemia were incubated for 4 days with different 
concentrations of lovastatin or solvent control. (B) Purified myeloma tumor cells from patient 5 were incubated 
with lovastatin for 4 days in the presence or absence of 100 µM mevalonate. Cell viability was examined by 
using the MTT assay as compared with control cells treated with solvent control. Experiments were performed 
once in triplo. Data are presented as mean ± s.e.m. *: P < 0.05 ; **: P < 0.005. 
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Table 1. Expression of MDR-related proteins and effect of lovastatin on cell viability in 
10 plasma cell lines 
 
 
Table 2. Clinical data and effect of lovastatin on cell viability of purified myeloma cells  
 
 
Lovastatin induces apoptosis and inhibits proliferation  
The effect of lovastatin on plasma cell proliferation and induction of apoptosis was 
investigated in three plasma cell lines that differed in their lovastatin sensitivity (RPMI-
Cell line Pgp LRP Bcl-2 Bax Bcl-2/Bax MTT50 MTT25 
RPMI-8226 1.62 4.77 19.20 18.06 1.06 5.11 9.13 
DOX6 22.30 6.61 11.05 17.49 0.63 1.65 4.94 
DOX40 67.30 4.20 25.30 43.39 0.58 0.84 1.80 
UM-1 2.15 9.92 18.53 33.18 0.56 4.57 8.67 
UM-3 1.59 2.62 17.38 19.42 0.89 13.34 17.38 
UM-6 1.48 0.99 9.87 8.45 1.17 8.46 16.42 
XG-1- 1.53 2.44 12.20 41.63 0.29 3.36 4.56 
XG-1+ 1.71 3.00 8.51 20.64 0.41 2.79 4.10 
U266 1.55 6.07 19.87 23.89 0.83 9.68 18.48 
L363 0.97 7.33 17.52 35.29 0.50 10.37 18.78 
 
Patient Disease MTT50 
(µM) 
MTT25 
(µM) 
Age/Sex Stage 
diagnosis
M-protein Plasma cell
(%) 
Treatments Disease status 
1 MM 22.48 >150 49/M III-B IgG-κ 4 alloBMT plateau 
2 MM 63.40 >150 57/M II-B IgG-κ 11 MP-dexa-Thal relapse 
3 MM 5.96 8.94 59/M III-B IgA-κ 28 VAD-MP relapse 
4 MM 6.20 9.30 60/M III-A κ-LC 16 autoPBSCT-Thal relapse 
5 MM 11.78 22.58 57/M III-A IgG-λ 39 none untreated/active 
6 MM 29.66 144.8 65/F III-A IgG-κ 13 autoPBSCT relapse 
7 MM 7.51 16.23 66/F III-A IgG-λ 17 MP relapse 
8 PCL 33.20 125.2 55/F III-A IgG-κ 46 none untreated/active 
 
Cells of 10 different plasma cell lines were incubated with different concentrations of lovastatin for 4 days.
MTT50 and MTT25 are the concentrations of lovastatin that decreased cell viability with 50 or 75%,
compared to solvent control-treated cells, respectively. The expression of Pgp, Bcl-2, Bax, and LRP was
determined by using flow cytometry. The ratio of the mean fluorescence intensity of the primary antibody
and the isotype control (MFR) is shown. The Bcl-2/Bax ratio was calculated by dividing the MFR of Bcl-2
and Bax. UM-6, XG-1+, and U266 plasma cell lines are dependent on IL-6 for their growth. 
MTT50 and MTT25 indicate the concentrations of lovastatin, which after a 4 day incubation, reduced cell 
viability of ex vivo purified myeloma cells with 50 and 75%, compared to solvent control-treated cells, 
respectively. The patients were classified according to the Durie-Salmon staging system54. The M-protein type 
was determined by immunofixation. Bone marrow plasma cell percentage was determined by simultaneous 
detection of CD38 and CD138 in bone marrow mononuclear cells by flow cytometric analysis. Plasma cell 
monoclonality was established by means of immunofluorescence microscopy based on heavy and light chain 
expression. MM, multiple myeloma; PCL, plasma cell leukemia; M, male; F, female; Ig, immunoglobulin; κ, 
kappa; λ, lambda; LC, light chain; autoPBSCT, autologous peripheral blood stem cell transplantation; 
alloBMT, allogeneic bone marrow transplantation; MP, melphalan and prednisone; dexa, dexamethasone; 
Thal, thalidomide; VAD, vincristine, doxorubicin, and dexamethasone.    
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8226, UM-6, and U266). In vitro incubation with lovastatin induced apoptosis in the 
plasma cell lines in a dose- and time-dependent way, as measured in the Annexin V assay 
(data not shown). The percentage of apoptotic cells was 19.2, 31.9 and 58.2% after 2 days 
and 32.4, 65.7, and 97.2% after 4 days of incubation with 40 µM lovastatin for U266, 
UM-6, and RPMI-8226 cells, respectively. Mevalonate significantly blocked induction of 
apoptosis by lovastatin in all 3 cell lines. Data from a representative experiment 
performed with UM-6 cells, are shown in Figure 3A. The Annexin V data were confirmed 
in an independent flow cytometric apoptosis assay, the Tunel assay (Figure 3B for a 
representative experiment performed with the RPMI-8226 cell line). The effect of 
lovastatin on proliferation of RPMI-8226, U266, and UM-6 plasma cell lines was 
evaluated by measuring 3H-thymidine incorporation. Figure 4A shows a concentration-
dependent decrease of plasma cell proliferation at day 4 in all 3 cell lines. As with the 
induction of apoptosis, inhibition of proliferation by lovastatin was significantly abrogated 
by addition of 100 µM mevalonate, as shown in Figure 4B for U266 cells. Thus, these 
results imply that the effect of lovastatin on plasma cell viability is the consequence of 
induction of apoptosis and inhibition of proliferation.  
 
Figure 3. Lovastatin-induced apoptosis is 
inhibited by addition of mevalonate, as was 
determined by two independent apoptosis 
assays. (A) UM-6 cells were incubated with 
solvent control, 100 µM lovastatin alone or in 
combination with 100 µM mevalonate for 4 days, 
after which apoptosis was determined by using the 
Annexin V assay. The percentages of viable 
plasma cells (Annexin V-/PI-), early apoptotic 
cells (Annexin V+/PI-) and late apoptotic cells 
(Annexin V+/PI+) in each dot plot are indicated in 
the corresponding quadrants. (B) RPMI-8226 cells 
were incubated with solvent control, 100 µM 
lovastatin in the presence or absence of 
mevalonate (100 µM) for 4 days, after which 
DNA strand breaks were detected by using the 
TUNEL assay. In the overlay diagram, the filled histogram represents the cells treated with lovastatin alone, the 
histogram with the bold line the cells treated with mevalonate and lovastatin and the histogram with the thin line 
cells treated with solvent control. 
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Figure 4. Lovastatin inhibits proliferation of plasma cell lines, which was abrogated by addition of 
mevalonate. (A) RPMI-8226, U266, and UM-6 cells were incubated with various concentrations of lovastatin or 
solvent control for 4 days, and proliferation was determined by 3H-thymidine incorporation during the last 16 
hours of culture. Data were from 3 experiments performed in triplo. Data are presented as mean ± s.e.m. (B) 
Inhibition of proliferation of U266 cells by lovastatin was abrogated by addition of 100 µM mevalonate. Data 
were from 3 experiments performed in triplo. Data are presented as mean ± s.e.m. *: P < 0.001. 
 
 
Correlation between expression of MDR-related proteins and lovastatin sensitivity   
The plasma cell lines differed in their sensitivity to lovastatin-induced cell death. 
Therefore, we investigated a possible correlation between lovastatin sensitivity and IL-6-
dependent growth and expression of the anti-apoptotic protein Bcl-2, the pro-apoptotic 
protein Bax, the membrane efflux pump Pgp, and the human major vault protein LRP 
(lung resistance-related protein) in 10 different plasma cell lines. No difference in 
lovastatin sensitivity was found between IL-6-dependent (XG-1+, UM-6, and U266) and -
independent plasma cell lines (Table 1). Moreover addition of exogenous IL-6 (5 ng/ml) 
did not protect against lovastatin-induced cell death (data not shown). All cell lines 
expressed different levels of intracellular Bcl-2 and Bax, and with the exception of the 
doxorubicin-resistant cell lines RPMI-DOX40 and RPMI-DOX6, the plasma cell lines 
hardly expressed Pgp and had low or undetectable intracellular LRP expression (Table 1). 
There was no significant correlation between Bcl-2, Bax, Bcl-2/Bax-ratio, or LRP 
expression and lovastatin sensitivity. However, lovastatin sensitivity significantly 
correlated with Pgp expression (R= –0.733 and –0.697; P = 0.016 and 0.025 for MTT50 
and MTT25, respectively). DOX6 and DOX40 are doxorubicin-resistant variants of the 
RPMI-8226 plasma cell line. In these lines doxorubicin resistance positively correlated 
with the expression of Pgp. The most doxorubicin resistant cell line (DOX40) was most 
sensitive for lovastatin treatment, followed by DOX6 and the RPMI-8226.  
 
Dexamethasone synergizes with lovastatin in reducing plasma cell viability   
The combined effect of lovastatin and dexamethasone on cell viability was examined by 
using the MTT assay in 3 dexamethasone-sensitive plasma cell lines (U266, L363, and 
XG-1+). In all cell lines, lovastatin had a synergistic effect with dexamethasone in 
reducing cell viability. A representative experiment with XG-1+ cells is shown in Figure 
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5. Dexamethasone (5 µM) alone reduced cell viability by 27.5%, lovastatin (1 µM) alone 
by 11.4%, while the combination of both decreased the percentage of viable cells by 
54.5%. In the other 2 cell lines, U266 and L363, a synergistic effect between 
dexamethasone (0.5 and 5 µM) and lovastatin (1-10 µM) was found (data not shown).  
Figure 5. Dexamethasone synergizes with lovastatin in reducing plasma cell viability. Cells from the XG-1+ 
plasma cell line were incubated with different lovastatin concentrations (0-5 µM) in combination with 
dexamethasone (0.5 or 5 µM) or solvent control for 4 days. Cell viability was determined by using the MTT 
assay as compared to cells treated without lovastatin and dexamethasone. Data were from 3 experiments 
performed in triplo. Data are presented as mean ± s.e.m. 
 
 
Lovastatin down-regulates Bcl-2 expression only in the U266 cell line  
High levels of Bcl-2 protein expression are associated with in vitro resistance to 
dexamethasone 36. In colon carcinoma cell lines, lovastatin reduced expression of the anti-
apoptotic protein Bcl-2 and increased expression of the pro-apoptotic protein Bax 15. To 
determine whether the synergism between dexamethasone and lovastatin in inducing 
plasma cell cytotoxicity was related to changes in the protein expression of Bcl-2 and Bax 
by lovastatin, Western blotting was performed. Cells from plasma cell lines (XG-1+, 
U266, and L363) were incubated for 2 or 4 days with different concentrations of 
lovastatin in the presence or absence of mevalonate. Lovastatin reduced Bcl-2 protein 
expression only in U266 cells (shown for day 4 in Figure 6A), but not in the other two cell 
lines tested (shown for XG-1+ in Figure 6B). Bax and α-actin levels remained unchanged. 
Mevalonate prevented lovastatin-induced Bcl-2 down-regulation in U266 cells. In 2 out of 
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8 patients lovastatin treatment resulted in a decreased Bcl-2 protein expression, without 
changing Bax or α-actin expression levels (data not shown). 
 
Figure 6. Down-regulation of Bcl-2, but not Bax protein levels in the U266 cell line, which was abrogated 
by mevalonate.  U266 cells were incubated for 4 days with solvent control or 10 or 30 µM lovastatin in the 
presence or absence of 100 µM mevalonate. XG-1+ cells were incubated for 4 days with solvent control or the 
same doses lovastatin. After protein isolation, Bcl-2 and Bax were determined by Western blot analysis. Blots 
were reprobed with anti-actin to confirm the presence of equal amounts of protein in each lane. The data 
presented are representative of 3 independent experiments. 
 
 
Lovastatin and protein isoprenylation 
Lovastatin depletes the cellular pool of mevalonate by inhibition of HMG-CoA reductase 
and potentially impairs isoprenylation and a subsequent membrane localization of small 
GTPases like Ras. The effect of Lovastatin on Ras localization was evaluated by 
incubating U266 cells with different doses of lovastatin in the absence or presence of 
mevalonate for 2 days. Membrane and cytosol protein fractions were isolated and 
analyzed by Western blot. In the untreated cells, Ras was predominantly membrane 
associated (Figure 7). Lovastatin induced a dose-dependent shift of Ras from the 
membrane to the cytosolic protein fraction. Co-incubation with mevalonate prevented this 
effect of lovastatin on Ras localization. The localization of non-isoprenylated control 
proteins, ICAM-1 (membrane protein) and γ-adaptin (cytosolic protein) was not affected 
by lovastatin treatment (Figure 7). Identical results were obtained with the RPMI-8226 
and UM-6 plasma cell lines (data not shown). These results show that Lovastatin 
treatment of plasma cells impairs membrane localization of Ras, probably via inhibition of 
isoprenylation.    
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Figure 7. Lovastatin induces a shift of membrane-associated Ras to cytosol localized Ras, which is 
abrogated by the addition of mevalonate. U266 cells were incubated with solvent control, 10, or 30 µM 
lovastatin in the presence or absence of 100 µM mevalonate. After a 2 day incubation, protein was separated in 
membrane and cytosolic fractions. Ras was identified by Western blot analysis. The blots were reprobed with 
anti-ICAM-1 and anti-γ-adaptin, to confirm a well-performed separation and the presence of equal amounts of 
protein in each lane. The data are representative of 3 independent experiments. 
 
 
Discussion 
 
Lovastatin is a HMG-CoA reductase inhibitor, which, because of its inhibition of hepatic 
cholesterol synthesis, is prescribed as a cholesterol-lowering drug. In this report we 
demonstrated for the first time that lovastatin induced cell death in ex vivo purified plasma 
cells from myeloma patients and cell lines at concentrations that can be achieved in vivo 
37, which was mediated by induction of apoptosis and by inhibition of proliferation. 
Furthermore, lovastatin in combination with dexamethasone displayed a synergistic effect 
in inducing cell death.  
Lovastatin sensitivity differed among the plasma cell lines and the purified 
myeloma samples. In plasma cell lines we examined possible correlations between 
lovastatin sensitivity and IL-6-dependent growth and expression of well-known multiple 
myeloma multidrug resistance-related proteins 38 such as P-glycoprotein (Pgp) 39-41, lung 
resistance protein (LRP) 42,43, and Bcl-2 family proteins 36,44,45. There was no obvious 
relationship between IL-6-independent or -dependent plasma cell growth and lovastatin 
sensitivity. Moreover, addition of exogenous IL-6 did not protect against lovastatin-
induced cell death. No correlation was found between lovastatin sensitivity and LRP, Bax, 
or Bcl-2 expression, but cell lines with a high Pgp expression were more sensitive to 
lovastatin than cell lines, which did not express Pgp. This is in agreement with previously 
published in vitro studies performed in neuroblastoma, myeloid leukemia, and two 
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myeloma cell lines 46-48. The correlation between lovastatin sensitivity and Pgp expression 
indicates that lovastatin can be used for the treatment of myeloma patients with multidrug-
resistant disease related to Pgp overexpression.  
Induction of apoptosis and inhibition of proliferation of myeloma plasma cells by 
lovastatin was reversed by addition of mevalonate. Mevalonate is an intermediate in the 
synthesis of cholesterol, but also of the isoprenoids farnesylpyrophosphate and 
geranylgeranylpyrophosphate 1. Ras and Ras-related proteins depend on the covalent 
attachment of these isoprenoids to their C-terminus for their proper localization to the cell 
membrane 2. Plasma membrane localization of Ras is necessary for the conversion of its 
inactive GDP- to its active GTP-bound state 49, following activation of transmembrane 
receptors by growth factors such as the myeloma growth and survival factor IL-6 22-24. 
GTP-bound Ras subsequently activates downstream signaling proteins, which regulate 
growth and survival 3-7. Activating Ras mutations are described in 39% of newly 
diagnosed myeloma patients 50 and in 64 - 70% of patients with terminal disease 24,51,52. 
The presence of Ras mutations at diagnosis is also associated with a poor response to 
chemotherapy 51 and a shorter survival 50. In vitro, Ras mutations are associated with IL-6-
independent growth and protection from apoptosis induced by IL-6 withdrawal 26 or 
treatment with dexamethasone and doxorubicin 27. Importantly, lovastatin inhibits cell 
proliferation both in cell lines with wild type and mutant Ras 53. Our results demonstrate 
that treatment of plasma cells with lovastatin resulted in a depletion of membrane-
localized Ras and an accumulation of cytosolic Ras, probably by inhibition of 
isoprenylation. This effect was abrogated by mevalonate. The cytotoxic effect of 
lovastatin on plasma cells may be the consequence of interference with the isoprenylation 
of Ras and its subsequent involvement in signaling cascades and thereby abrogating 
proliferation and cell survival signals. This is consistent with experiments, which show 
that lovastatin disrupted oncogenic Ras signaling through MAPK, causing apoptosis and 
inhibiting proliferation 20,28. Current experiments focus on the characterization of 
isoprenylated target proteins that regulate plasma cell survival and proliferation. 
In multiple myeloma high levels of the anti-apoptotic protein Bcl-2 are associated 
in vitro with protection against IL-6-deprived apoptosis 44 and resistance to cytotoxic 
drugs and dexamethasone 36. In colon cancer cells lovastatin treatment resulted in a 
decreased Bcl-2 and an increased Bax protein expression 15. The results presented in this 
paper showed that lovastatin and dexamethasone had a synergistic effect in inducing cell 
death in plasma cell lines. However, lovastatin treatment reduced Bcl-2 protein levels only 
in the U266 cell line. In L363 and XG-1+ cells, Bcl-2 levels remained unchanged. This 
implies that although down-regulation of Bcl-2 in U266 cells may contribute to the 
observed synergistic effect between lovastatin and dexamethasone in the induction of 
plasma cell cytotoxicity, other mechanisms may account for the synergistic response in 
the other two cell lines. The same observation was made in ex vivo purified plasma cells; 
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only in 2 out of 8 patients did lovastatin treatment reduce Bcl-2 protein expression, 
without changing Bax and α-actin expression levels.  
Serum peak levels in the range of 0.1 to 4 µM were achieved in individuals, who 
received high-doses of lovastatin (30 mg/kg/day). These dosages were well tolerated, but 
as a mono-therapy had little effect in reducing tumor load in patients with solid tumors 37. 
However, tumor cells from patients with acute myeloid leukemia (AML) were more 
sensitive to lovastatin compared to solid tumors. Dosages of lovastatin that are easily 
reached in vivo, induced cell death of freshly isolated AML cells and decreased the colony 
forming potential of AML primary cultures, with minimal effects on normal bone marrow 
and normal bone marrow progenitors 19. In this paper we demonstrate that concentrations 
that can be achieved in vivo, also effectively killed plasma cell lines and ex vivo purified 
myeloma tumor cells from patients in vitro. Furthermore, we show that lovastatin at low 
concentrations (0-10 µM) displayed a synergistic effect with dexamethasone in inducing 
cell death. These results agree with earlier published findings, which show that lovastatin 
enhanced antitumor activity of several chemotherapeutical agents in solid tumors 12-18.  
In conclusion, lovastatin reduced cell viability in plasma cell lines and ex vivo 
purified plasma cells from myeloma patients. Dexamethasone synergized with low 
concentrations of lovastatin in reducing plasma cell viability. Induction of apoptosis in 
myeloma cell lines by lovastatin was independent of expression of MDR-related proteins 
like Bcl-2, Bax, and LRP, but cells expressing Pgp were more sensitive to lovastatin. 
Together, our data indicate that lovastatin as single agent or combined with 
dexamethasone or dexamethasone-containing regimens, should be evaluated in multiple 
myeloma.  
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Abstract 
 
HMG-CoA reductase is the rate-limiting enzyme of the mevalonate pathway leading to the 
formation of cholesterol and isoprenoids like farnesylpyrophosphate (FPP) and 
geranylgeranylpyrophosphate (GGPP). Inhibition of HMG-CoA reductase by lovastatin 
induced apoptosis in plasma cell lines and tumor cells from patients with multiple 
myeloma. Here we show that co-treatment with mevalonate or geranylgeranyl moieties, 
but not farnesyl groups, rescued myeloma cells from lovastatin-induced apoptosis. Also 
inhibition of geranylgeranylation by specific inhibition of geranylgeranyl transferase I 
(GGTase I) resulted in induction of apoptosis of myeloma cells. Apoptosis triggered by 
inhibition of geranylgeranylation was associated with reduction of Mcl-1 protein 
expression, collapse of the mitochondrial transmembrane potential, expression of the 
mitochondrial membrane protein 7A6, cytochrome c release from mitochondria into the 
cytosol, and stimulation of caspase-3 activity. These results imply that protein 
geranylgeranylation is critical for the regulation of myeloma tumor cell survival, possibly 
through the regulation of Mcl-1 expression. Our results show that pharmacological agents 
such as lovastatin or GGTase inhibitors may be useful in the treatment of multiple 
myeloma.  
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Introduction 
  
Prenylation is a class of lipid modification involving the covalent attachment of 
hydrophobic isoprenoid molecules to target proteins 1. The enzymes farnesyl transferase 
(FTase) and geranylgeranyl transferase (GGTase) catalyze the transfer and subsequent 
binding of farnesyl and geranylgeranyl isoprenoid moieties from farnesylpyrophosphate 
(FPP) and geranylgeranylpyrophosphate (GGPP), respectively, to a cysteine-containing 
motif located at or near the C-terminus of a target protein. Prenylation is essential for 
membrane attachment 1 and the subsequent participation of prenylated proteins in diverse 
signaling pathways regulating cell growth and survival 2-5. Proteins that require 
geranylgeranylation or farnesylation for their function include GTP-binding proteins such 
as the Rho family members Rac-1, RhoA, and Cdc42 (geranylgeranylation) 6 and Ras 
(farnesylation) 1,5. Oncogenic Ras mutations have been found in several human cancers 
including multiple myeloma 7,8. Based on in vitro studies indicating that inhibition of 
farnesylation has antimyeloma activity 9-12, clinical studies have been initiated to evaluate 
the efficacy of FTase inhibitors in myeloma treatment 13. 
Multiple myeloma is a so far incurable neoplastic disease of the B-cell lineage, 
characterized by the presence of monoclonal plasma cells in the bone marrow. Although 
chemotherapy is initially effective in most patients with myeloma, they all eventually 
develop multidrug-resistant disease. Recently, we described that lovastatin effectively 
decreases the viability of myeloma cells from cell lines and patients’ samples, including 
patients with drug-resistant disease 14. In addition, low concentrations of lovastatin 
synergized with dexamethasone in inducing plasma cell cytotoxicity 14. Lovastatin is a 
potent competitive inhibitor of the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A 
(HMG-CoA) reductase and is widely used for the treatment of hypercholesterolemia 15. 
HMG-CoA reductase is the rate-limiting enzyme of the mevalonate pathway and catalyzes 
the reduction of HMG-CoA to mevalonate, which is an intermediate in the synthesis of 
FPP and GGPP 16. The apoptotic effect of lovastatin on myeloma plasma cells was 
reversed by the addition of mevalonate 14. This suggests that downstream metabolites of 
mevalonate play a role in the regulation of lovastatin-induced apoptosis.  
Recent reports imply that anti-apoptotic and pro-apoptotic Bcl-2 family proteins 
are important regulators of cell survival and resistance to cytotoxic drugs. The anti-
apoptotic members of the Bcl-2 family, such as Bcl-2, Bcl-XL and Mcl-1 protect against 
apoptosis by the formation of heterodimers with pro-apoptotic Bcl-2 family members, such 
as Bax and Bad 17,18. This prevents the collapse of the mitochondrial transmembrane 
potential and the release of cytochrome c from mitochondria, which may facilitate a 
change in Apaf-1 structure to allow procaspase-9 recruitment, processing and activation. 
Activated caspase-9 then activates effector caspases such as caspase-3 17,18. Our work and 
that of others has shown that Bcl-2 protects myeloma cells against cytotoxic drugs and 
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contributes to chemoresistance 19-22. Bcl-XL is upregulated in myeloma cells at the time of 
relapse and correlates with a decreased response rate to subsequent chemotherapy 23. 
Recently it was reported that a threshold level of Mcl-1 expression is required to prevent 
apoptosis and maintain viability of myeloma cells, marking Mcl-1 as a critical survival 
factor for myeloma cells 24-26.     
In this study, we examined the importance of protein farnesylation and 
geranylgeranylation for the regulation of survival of myeloma tumor cells. We 
demonstrate that geranylgeranylation is essential for myeloma tumor cell survival through 
the regulation of Mcl-1 protein expression. 
 
 
Materials and methods 
 
Reagents 
Lovastatin and simvastatin were obtained from Merck & Co., Inc (Rahway, NJ, USA) and 
were chemically activated by alkaline hydrolysis prior to use as described previously 27.  
Pravastatin Sodium was purchased from Bristol-Meyers Squibb (New Brunswick, NJ, 
USA) and dissolved in PBS (20 mM). Atorvastatin Calcium was obtained from Pfizer 
GmbH (Freiburg, Germany) and dissolved in ethanol containing 3% DMSO (Riedel-de 
Haen, Seelze, Germany) (10 mM). Mevalonate and farnesol (FOH) were purchased from 
Sigma (St Louis, MO, USA) and geranylgeraniol (GGOH) was obtained from ICN 
Biomedicals, BV (Zoetermeer, The Netherlands). FOH and GGOH are metabolized to 
FPP and GGPP in the cells, respectively 28. FTI-277 and GGTI-298 were obtained from 
Calbiochem (Schwallbach, Germany). 
 
Cell lines and patients  
Plasma cell lines RPMI-8226 and U266 were obtained from the American Tissue Culture 
Collection (ATCC) and L363 from the German Collection of Microorganisms and Cell 
Cultures (GCMC). These cell lines were cultured in the absence of exogenous IL-6 29. The 
IL-6-dependent plasma cell line XG-1 was a kind gift of Dr B. Klein (Institute for 
Molecular Genetics, Montpellier, France) 30. Cell lines were cultured in RPMI-1640 
(GIBCO, Breda, The Netherlands) supplemented with 10% fetal calf serum (FCS) 
(Integro, Zaandam, The Netherlands), 100 IU/ml penicillin, 100 µg/ml streptomycin and 
10 µM β-mercaptoethanol (growth medium). The IL-6-dependent cell line XG-1 was 
cultured in the continuous presence of exogenous IL-6 (1.25 ng/ml rhIL-6 (Roche, 
Almere, The Netherlands). 
Myeloma plasma cells were obtained from bone marrow aspirates taken from the 
posterior iliac crest in 4 patients and from peripheral blood in one patient with plasma cell 
leukemia after obtaining informed consent. The plasma cell percentage in the patient 
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samples varied from 12-96% of the mononuclear cells as determined by co-expression of 
CD38 (anti-CD38-FITC, Immunotech, Marseille, France) and CD138 (anti-CD138-PE, 
Immunotech) by flow cytometric analysis (FACSCalibur, Becton Dickinson, 
Erembodegem, Belgium (BDIS)). Except for patient 2, who had 96% myeloma cells in 
her bone marrow, tumor cells were purified ex vivo from mononuclear cells obtained by 
Ficoll-Paque (Amersham; Pharmacia BiotechAB, Uppsala, Sweden) density 
centrifugation, by magnetic cell sorting (MACS) based on CD138 expression. To this end, 
mononuclear cells were subsequently labeled with anti-CD138 (Immunotech) and rat anti-
mouse IgG1 microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany) and then 
separated using a high gradient magnetic separation column placed in a strong magnetic 
field (Miltenyi), exactly following the instructions of the manufacturer. Samples obtained 
in this way contained >95% myeloma plasma cells as determined by analysis of 
CD38/CD138 co-expression. For experiments, myeloma cells were resuspended in RPMI-
1640 (GIBCO) supplemented with 10% fetal calf serum (FCS) (Integro), 100 IU/ml 
penicillin, 100 µg/ml streptomycin, and 10 µM β-mercaptoethanol. 
   
Cell viability 
Viability of cells was examined by means of the 3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium bromide (MTT) assay as described previously 14. In short, cells were 
seeded in a concentration of 0.3 x 106/ml for the myeloma cell lines or 1 X 106/ml for the 
tumor cells of patients in a 96-well flat bottom plate (100 µl/well) (Nunc, Roskilde, 
Denmark) and treated with lovastatin (for concentrations see legends) alone or in the 
presence of mevalonate, FOH or GGOH. Fixed concentrations of mevalonate (100 µM), 
FOH (10 µM), or GGOH (10 µM) were used. These concentrations proved to be optimal 
in rescuing myeloma cells from lovastatin-induced apoptosis (data not shown). Inhibition 
of FTase and GGTase I was accomplished by treating cells with FTI-277 and GGTI-298, 
respectively (for concentrations see legends). After 2 or 4 days, 25 µl of MTT (5 mg/ml) 
was added to each well. After an incubation of 2 hours at 37oC the reaction was stopped 
by the addition of 100 µl 20% sodium dodecyl sulphate (SDS; Boehringer Mannheim, 
Mannheim, Germany) / 0.025 M HCl / 0.35 M HAc in a mixture of (1:1; v/v) N,N-
dimethylformamide (Merck, Darmstadt, Germany) and distilled water. After an overnight 
incubation at 37oC the optical density of the samples was determined at 570 nm.  
 
Apoptosis detection by Annexin V staining   
Myeloma cells (1.5 X 105 in 0.5 ml) were incubated with lovastatin (for concentrations 
see legends) alone or in the presence of mevalonate (100 µM), FOH (10 µM) or GGOH 
(10 µM) in a 48-well plate (Nunc). Inhibition of FTase and GGTase I was accomplished 
by treating cells with FTI-277 and GGTI-298 (for concentrations see legends), 
respectively. After 2 or 4 days, cells were harvested, washed in ice-cold PBS and directly 
  
Inhibition of protein geranylgeranylation induces apoptosis in myeloma plasma cells  
98 
stained with Annexin V-FITC (Nexins Research, Kattendijke, The Netherlands) and 
propidium iodide (PI). After 10 minutes of incubation at room temperature in the dark, 
cells were analyzed by flow cytometry (FACSCalibur, BDIS) as described previously 14. 
Apoptotic cells were defined as early apoptotic cells (Annexin V positive and PI negative) 
and late apoptotic cells (Annexin V positive and PI positive). 
 
Apoptosis detection by APO2.7 staining 
Myeloma cells (1.5 X 105 in 0.5 ml) were incubated with lovastatin (for concentrations 
see legends) alone or in the presence of mevalonate (100 µM), FOH (10 µM) or GGOH 
(10 µM) in a 48-well plate (Nunc). Cells were washed in PBS with 2.5% FCS and 
permeabilized in 100 µg/ml Digitonin (Sigma) in PBS, and incubated for 20 minutes on 
ice. Cells were washed and resuspended in 80 µl PBS with 2.5% FCS and 20 µl APO2.7-
PE (Immunotech), and incubated for 15 minutes at room temperature in the dark. After a 
washing step, cells were analyzed by flow cytometry (FACSCalibur, BDIS). 
 
Caspase-3 activity  
The caspase-3 activity assay (Roche) was used to determine caspase-3 activity. Briefly, 
cells were washed in ice-cold PBS and then resuspended in lysis buffer (1 X DTT) and 
incubated for 1 minute on ice. Supernatants were obtained after centrifugation at 14 000 
r.p.m. for 1 minute at room temperature. Supernatant was added to anti-caspase-3 coated 
wells and incubated at 37oC for 1 hour. After 3 washing steps, substrate solution (Ac-
DEVD-AFC) was added and the wells were incubated for 2 hours at 37oC. Fluorescence 
was measured with an excitation filter 400 nm and an emission filter 505 nm. 
 
Cytochrome c ELISA 
A cytochrome c ELISA kit (MBL, Watertown, MA, USA) was used to quantitate 
cytochrome c that was released from mitochondria into the cytosol. Briefly, cells were 
washed three times with ice-cold PBS and resuspended at the concentration of 5 X 106 
cells/ml in 10 mM Tris-HCl (pH 7.5), 0.3 M sucrose, and a cocktail of protease inhibitors 
(Boehringer Mannheim). Cells were homogenized by douncing 10 times in a Dounce 
homogenizer with a sandpaper-polished pestle. After a centrifugation step at 4oC for 60 
minutes at 14 000 r.p.m. the cytosolic fraction was present in the supernatant. Sixty µl of 
the 1:5 diluted cytosolic fraction was mixed with 60 µl conjugate reagent. Hundred µl of 
the mixture was added to anti-cytochrome c coated wells and incubated for 60 minutes at 
room temperature. After 4 washing steps, substrate solution was added and the wells were 
incubated for 15 minutes at room temperature. After addition of stop solution, the 
absorbance of each well was read at 450 nm. 
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Measurement of mitochondrial transmembrane potential 
Changes in mitochondrial transmembrane potential (∆ψm) were evaluated by staining with 
40 nM 3,3’-dihexyloxacarbocyanine iodide (DiOC6[3]; Molecular Probes, Leiden, The 
Netherlands). Cells were incubated with DiOC6[3] in PBS for 15 minutes at 37oC, washed 
and resuspended in PBS. The cells were then analyzed on a flow cytometer 
(FACSCalibur, BDIS). 
 
Western blotting 
Cells (1 X 106 cells in 1.5 ml) were incubated for 2 or 4 days with lovastatin (for 
concentrations see legends) in the presence or absence of mevalonate (100 µM), FOH (10 
µM) or GGOH (10 µM). Inhibition of FTase and GGTase I was accomplished by treating 
cells with FTI-277 and GGTI-298 (for concentrations see legends), respectively. After 
harvesting, whole cell lysates were made by washing cells twice in ice-cold PBS and then 
resuspending them in lysis buffer (10 mM Tris-HCl (pH 7.6), 150 mM NaCl, 1% Triton 
X-100 and a cocktail of protease inhibitors (Boehringer Mannheim)) at 4oC for 20 
minutes. Insoluble material was removed by centrifugation at 14 000 r.p.m. for 6 minutes 
at 4oC. When membrane and cytosolic protein fractions were analyzed, cells were 
suspended in extraction solution (10% glycerol, 20 mM Hepes, 1 mM MgCl2, 1 mM 
EDTA, 1 mM DTT and a cocktail of protease inhibitors (Boehringer Mannheim)). The 
lysate was sonificated twice for 5 seconds and centrifuged at 4oC for 30 minutes at 48 000 
g. The supernatant contained the proteins of the cytosolic fraction. The insoluble material 
was subsequently resuspended in solubilization buffer (1% NP-40, 20 mM Hepes, 20 mM 
MgAc, 5 mM NaF, 0.2 mM EDTA, 0.8 mM EGTA, 1 mM DTT and a cocktail of protease 
inhibitors). After 2 rounds of sonification for 10 seconds, an incubation for 30 minutes at 
4oC and a centrifugation step at 4 oC for 30 minutes at 48 000 g, proteins of the membrane 
fraction were present in the supernatant. 
Protein concentrations were determined by the BCA assay (Pierce, Rockford, IL, 
USA). Samples containing equal amounts of protein were mixed with 2 X Laemmli 
sample buffer (0.125 M Tris pH 6.9 with 4% SDS, 20% Glycerol and 10% β-
mercaptoethanol) and boiled for 5 minutes. Proteins were subsequently fractionated in 
10% SDS-PAGE at room temperature and electrically transferred from the gel to PVDF-
membrane (Biorad). After blocking in 0.1% Tween-20, 5% skimmed powder milk, 2% 
BSA in 10 mM Tris and 150 mM NaCl, the membranes were incubated with anti-Bcl-2 
(Dako, Glostrup, Denmark), anti-Mcl-1 (Santa Cruz Biotechnology Inc, Santa Cruz, CA, 
USA), anti-Bcl-XL (Santa Cruz), anti-Bax (Immunotech), anti-Rap1a (Santa Cruz), or 
anti-HDJ-2 (DnaJ) (Neomarkers, Lab Vision, Fremont, CA, USA). Antibody binding was 
visualized with enhanced chemoluminescence (Amersham) detection with hyperfilm ECL 
(Amersham) after incubation with a horseradish peroxidase (HRP)-conjugated secondary 
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antibody (Dako). Finally, the membranes were extensively washed in PBS and reprobed 
with anti-α-actin (Sigma) as a control for equal loading of protein. Relative amounts of 
protein were determined by densitometry and expressed as a percentage of the solvent 
control. 
 
 
Results 
 
Inhibition of prenylation by lovastatin, FTI-277, and GGTI-298 in myeloma cell lines 
The effect of lovastatin, FTase inhibitor FTI-277, and GGTase I inhibitor GGTI-298 on 
prenylation in myeloma cell lines was determined by analysis of the migratory behaviour 
during electrophoresis of DnaJ, a protein prenylated exclusively by FTase 31,32, and of 
Rap1a, a protein prenylated exclusively by GGTase I 33. Inhibition of prenylation of these 
proteins can be monitored by immunoblotting, because the unprenylated forms of these 
proteins display reduced mobility in SDS-PAGE relative to their prenylated versions. All 
experiments were performed with the myeloma cell lines RPMI-8226, L363, U266, and 
XG-1. For brevity, only representative results from the cell line RPMI-8226 are shown in 
Figure 1A. In solvent control-treated myeloma cell lines DnaJ and Rap1a were in the 
processed, prenylated, forms. Treatment with lovastatin inhibited the processing of DnaJ 
and of Rap1a in a dose-dependent way, resulting in unprenylated protein forms with 
reduced electrophoretic mobility (Figure 1A). The effect of lovastatin on prenylation was 
reversed by the addition of mevalonate (shown for 30 µM lovastatin and 100 µM 
mevalonate). Treatment with lovastatin (30 µM) in the presence of GGOH (10 µM), 
which is metabolized to GGPP in the cells 28, restored geranylgeranylation of Rap1a, but 
had no effect on the inhibition of the farnesylation of DnaJ. In contrast, FOH (10 µM), 
which is metabolized to FPP 28, restored DnaJ farnesylation, but not Rap1a 
geranylgeranylation. Inhibition of FTase by FTI-277 disrupted the processing of DnaJ in a 
dose-dependent way. Similarly, a dose-dependent mobility shift of Rap1a was observed 
on exposure to GGTI-298. The specificity of these prenylation inhibitors is illustrated by 
the lack of inhibition of Rap1a prenylation by FTI-277, and, likewise, the lack of 
inhibition of DnaJ prenylation by GGTI-298 (Figure 1B). 
Prenylation is crucial for the membrane attachment of proteins. This is shown in 
Figure 1C for RhoA, which is geranylgeranylated by GGTase I. Lovastatin reduced the 
amount of RhoA present in the membrane protein fraction and increased the amount 
present in the cytosolic protein fraction when compared with the solvent control. Co-
treatment of cells with mevalonate or GGOH, but not FOH, prevented the cytosolic 
accumulation and restored the membrane localization of RhoA.  
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Figure 1. Effect of lovastatin, FTI-277, and GGTI-298 on farnesylation and geranylgeranylation. (A) 
RPMI-8226 cells were treated for 2 days with solvent control, or lovastatin (30 µM) alone or in the presence of 
mevalonate (meva; 100 µM), GGOH (10 µM), or FOH (10 µM). For the dose-response, RPMI-8226 cells were 
treated with solvent control or lovastatin (1, 2, 3, 4, 5, 10, 30, 50, 100 µM). After protein isolation, prenylation 
status of DnaJ and Rap1a was determined by Western blot analysis. The faster-migrating band represents 
prenylated protein, the slower band represents unprenylated protein. The data shown are representative of at least 
three independent experiments. (B) RPMI-8226 cells were treated for 2 days with solvent control, FTI-277 (2.5, 
5, 10, 15, 20, or 30 µM), or GGTI-298 (2.5, 5, 10, 15, 20, or 30 µM). After protein isolation, prenylation status 
of DnaJ and Rap1a was determined by Western blot analysis. The data shown are representative of at least three 
independent experiments. (C) RPMI-8226 cells were exposed to solvent control, or lovastatin (30 µM) alone or 
in the presence of mevalonate (100 µM), GGOH (10 µM), or FOH (10 µM). After a 2 day incubation, protein 
was separated in membrane and cytosolic fractions. RhoA was identified by Western blot analysis. The data are 
representative of three independent experiments.  
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Depletion of intracellular pools of geranylgeranylpyrophosphate induces apoptosis in 
myeloma cell lines  
Previously we have shown that lovastatin reduces cell viability in myeloma cell lines and 
in ex vivo purified myeloma tumor cells 14. Reduction of cell viability was abrogated by 
the addition of mevalonate. This suggests that the effect of lovastatin resulted from 
inhibition of mevalonate formation and not from non-specific cell toxicity. Here we 
examined the effect of the simultaneous exposure of cells to lovastatin and the isoprenoids 
GGOH or FOH, which are metabolites downstream of mevalonate. A dose-response 
analysis revealed a reduction of cell viability by lovastatin beginning at a concentration of 
1 µM for XG-1 cells, 2 µM for RPMI-8226 and L363 cells, and 3 µM for U266 cells. 
Lovastatin sensitivity varied among the myeloma cell lines, with MTT50 (concentration 
that reduces cell viability with 50%) ranging from 1.86 µM (XG-1) to 10.17 µM (U266) at 
day 4 (Figure 2). GGOH (10 µM), but not FOH (10 µM), prevented lovastatin-induced 
reduction of myeloma cell viability (Figure 2). This demonstrates that inhibition of protein 
geranylgeranylation by lovastatin results in reduction of cell viability.  
Figure 2. Lovastatin reduces cell viability in plasma cell lines, which is restored by GGOH. Plasma cell 
lines (A) RPMI-8226, (B) L363, (C) XG-1, and (D) U266 were treated for 4 days with solvent control, or 
different concentrations of lovastatin (5, 10, 30, 50, 100 µM) alone or in the presence of mevalonate (meva; 100 
µM), GGOH (10 µM), or FOH (10 µM). The percentage of viable cells, relative to the solvent control-treated 
cells, was measured by using MTT assay. Experiments were performed three times in triplicate. Data are 
presented as mean ± s.e.m. 
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Then it was investigated whether the reduction of cell viability was mediated by 
induction of apoptosis by using the Annexin V assay. Lovastatin induced apoptosis in a 
dose-dependent way in the U266, L363, RPMI-8226, and XG-1 cell lines. Mevalonate and 
GGOH prevented lovastatin-induced apoptosis. FOH was without effect (RPMI-8226 and 
XG-1) or had only partial protective effects (L363 and U266) (Figure 3 A and B). These 
data were confirmed by the TUNEL (terminal deoxynucleotidyl transferase [TdT]-
mediated deoxyuracil triphosphate [dUTP] nick-end labeling) assay (data not shown).  
Figure 3. Lovastatin induces apoptosis in plasma cell lines by depletion of intracellular pools of GGPP. (A) 
RPMI-8226 cells were treated for 4 days with solvent control, or lovastatin (30 µM) alone or in combination 
with mevalonate (meva; 100 µM), GGOH (10 µM), or FOH (10 µM). The percentage of apoptotic cells was 
examined by using the Annexin V assay.  The percentages of viable plasma cells (Annexin V-/PI-), early 
apoptotic cells (Annexin V+/PI-), and late apoptotic cells (Annexin V+/PI+) in each dot plot are indicated in the 
corresponding quadrants. Results are representative of three experiments performed in triplicate. (B) RPMI-
8226, L363, XG-1, and U266 cells were treated for 4 days with solvent control, or different concentrations of 
lovastatin (5,10, 40, 100, 150 µM) in combination with mevalonate (meva; 100 µM), GGOH (10 µM), or FOH 
(10 µM), after which apoptosis was determined by the Annexin V assay. Shown is the sum of the percentages of 
early and late apoptotic cells. Experiments were performed three times in triplicate. Data are presented as mean ± 
s.e.m. 
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Identical results were obtained with other inhibitors of HMG-CoA reductase 
including simvastatin and atorvastatin. Cells from the different myeloma cell lines were 
most sensitive to simvastatin, followed by lovastatin and atorvastatin. However, the 
hydrophilic HMG-CoA reductase inhibitor pravastatin had no effect (data not shown). 
 
Inhibition of geranylgeranyl transferase I induces apoptosis in myeloma cell lines 
The importance of protein geranylgeranylation versus farnesylation for the regulation of 
survival of myeloma cells was further evaluated by treating cell lines with different 
concentrations of FTI-277 or GGTI-298 for 2 or 4 days. Cell viability was examined by 
MTT assay. GGTI-298 and FTI-277 reduced cell viability in a dose- and time-dependent 
way in the 4 plasma cell lines analyzed (Figure 4A). However, GGTI-298 had, by far, the 
most pronounced effect on cell viability when compared to FTI-277. The reduction of cell 
viability at day 2 and 4 by GGTI-298 (20 µM) in the cell lines varied from 52.9 to 86.2% 
and 40.4 to 98.7%, whereas the reduction by FTI-277 (20 µM) varied from 22.1 to 43.7% 
and 0 to 57.0%, respectively. The reduction of cell viability by GGTI-298 was mediated 
by induction of apoptosis (Figure 4B). In all cell lines, treatment with GGTI-298 (20 µM) 
increased the percentage of apoptotic cells when compared with the solvent control. In 
contrast, FTI-277 (20 µM) induced low to moderate apoptosis in XG-1 and L363 cells, 
and did not induce apoptosis in U266 and RPMI-8226 cells.  
 
Inhibition of geranylgeranylation reduces Mcl-1 protein levels 
Inhibition of geranylgeranylation either by depletion of intracellular pools of GGPP or by 
inhibition of GGTase I, induces apoptosis in myeloma cell lines. To investigate how 
inhibition of geranylgeranylation results in apoptosis, the expression levels of several Bcl-
2 family proteins were determined by Western blot analysis in cells treated with lovastatin 
in combination with mevalonate, FOH, or GGOH. Lovastatin treatment resulted in a 
down-regulation of Mcl-1 protein levels at both day 2 and 4 in RPMI-8226, L363, U266, 
and XG-1 cells when compared with solvent control-treated cells (Figure 5). The Mcl-1 
down-regulation by lovastatin preceded (U266 cells) or was concomitant (RPMI-8226, 
L363, and XG-1 cells) with apoptosis induction. Co-treatment of cells with mevalonate or 
GGOH restored Mcl-1 protein expression. Co-inbubation of myeloma cell lines with FOH 
was without effect. Lovastatin treatment also resulted in a reduction of Bcl-XL protein 
levels in U266, L363, and XG-1 cells and an increase in Bax protein levels in RPMI-8226 
and XG-1 cells. However, the altered expression levels of Bcl-XL and Bax were relatively 
late effects and observed only after 4 days of treatment. Bcl-XL was detected as a doublet 
of mass 29-31 kD, which represent two conformations of Bcl-XL that migrate differently 
in SDS-page 23. Lovastatin did not alter the expression levels of Bcl-2. However, there 
was a time-dependent up-regulation of the pro-apoptotic 23 kD Bcl-2 form, which could 
be visualized after long exposure of the film when compared with Bcl-2. Bcl-XS 
expression was not detected in the different plasma cell lines. Mevalonate and GGOH 
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prevented lovastatin-mediated reduction of Bcl-XL, and the increase of Bax and the pro-
apoptotic Bcl-2 form. In contrast, FOH was without effect. Similar results were obtained 
with simvastatin and atorvastatin, whereas pravastatin had no effect (data not shown).  
Similar to lovastatin, GGTI-298 also reduced Mcl-1 protein levels after 2 days in 
all 4 plasma cell lines tested (Figure 6). Furthermore, GGTI-298 treatment resulted in an 
increase of the pro-apoptotic 23 kD Bcl-2 form and reduced Bcl-XL expression levels in 
L363 and XG-1 cell lines. FTI-277 did not alter Mcl-1, Bcl-XL, Bax, or Bcl-2 protein 
expression and did not consistently change expression of the pro-apoptotic 23 kD Bcl-2 
form. 
Figure 4. Inhibition of GGTase I by GGTI-298 reduces cell viability and induces apoptosis. (A) Plasma cell 
lines RPMI-8226, L363, XG-1, and U266 were treated for 2 or 4 days with solvent control, different 
concentrations of the farnesyl transferase inhibitor FTI-277 (2.5, 5, 10, 15, 20, 30 µM), or with different 
concentrations of the geranylgeranyl transferase I inhibitor GGTI-298 (2.5, 5, 10, 15, 20, 30 µM). The 
percentage of viable cells, relative to the solvent control-treated cells, was measured by using MTT assay. 
Experiments were performed three times in triplicate. Data are presented as mean ± s.e.m. (B) Plasma cell lines 
RPMI-8226, L363, XG-1, and U266 were treated for 2 or 4 days with solvent control, FTI-277 (20 µM), or with 
GGTI-298 (20 µM). The percentage of apoptotic cells was determined by Annexin V assay. Shown is the sum of 
the percentages of early and late apoptotic cells. Experiments were performed three times in triplicate. Data are 
presented as mean ± s.e.m. 
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Figure 5. Lovastatin reduces Mcl-1 protein levels by depletion of intacellular pools of GGPP. Plasma cell 
lines (A) RPMI-8226, (B) L363, (C) XG-1, and (D) U266 were treated for 2 or 4 days with solvent control, or 
lovastatin (5 µM for XG-1 and 30 µM for RPMI-8226, U266, and L363) alone or in combination with 
mevalonate (meva; 100 µM), FOH (10 µM), or GGOH (10 µM). After protein isolation, Mcl-1, Bcl-XL, Bcl-2, 
and Bax were determined by Western blot analysis. Furthermore, the pro-apoptotic 23 kD Bcl-2 form was 
detected after long exposure of the film. The data shown are representative of at least three independent 
experiments. The percentage of apoptotic cells was determined by Annexin V assay. Shown is the sum of the 
percentages of early and late apoptotic cells. Experiments were performed three times in triplicate. Data are 
presented as mean ± s.e.m. 
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Figure 6. GGTI-298 reduces Mcl-1 protein levels. Plasma cell lines RPMI-8226, L363, XG-1, and U266 were 
treated for 2 days with solvent control, FTI-277 (20 µM), or GGTI-298 (20 µM). After protein isolation, Mcl-1, 
Bcl-XL, Bcl-2, and Bax expression levels were determined by Western blot analysis. Furthermore, the pro-
apoptotic 23 kD Bcl-2 form was detected after long exposure of the film. The data shown are representative of at 
least three independent experiments. 
 
 
Inhibition of geranylgeranylation results in reduction of the mitochondrial 
transmembrane potential, APO2.7 staining, release of cytochrome c, and caspase 
activation 
Members of the Bcl-2 family are involved in the regulation of the mitochondrial 
transmembrane potential, release of cytochrome c, and caspase-3 activation 17,18. 
Treatment of RPMI-8226, L363, U266, and XG-1 cells with lovastatin resulted in loss of 
the mitochondrial transmembrane potential as shown in Figure 7A for RPMI-8226 cells. 
The collapse was time- (data not shown) and dose-dependent (Figure 7B). APO2.7 reacts 
with a mitochondrial membrane protein (7A6 antigen) that is exposed in cells undergoing 
apoptosis. Lovastatin increased the percentage of APO2.7-positive cells in a time- (data 
not shown) and dose-dependent way (Figure 7 A and B). This together with the loss of the 
mitochondrial transmembrane potential suggests that mitochondrial changes were induced 
by lovastatin.  
Collapse of the mitochondrial transmembrane potential results in the release of 
several pro-apoptogenic factors such as cytochrome c from the mitochondria into the 
cytosol 17,18. Treatment of myeloma cell lines with lovastatin resulted in an increase of 
cytosolic cytochrome c as shown for RPMI-8226 cells in Figure 7C. 
Cytosolic cytochrome c promotes activation of caspases through the cytochrome 
c/Apaf-1/caspase-9 pathway 17,18. To determine whether lovastatin-induced cytochrome c 
release resulted in activation of caspase-3, cell lysates were analyzed for caspase-3 
activity. Treatment of plasma cell lines with lovastatin resulted in activation of caspase-3 
as shown for RPMI-8226 cells in Figure 7D. Bcl-2 is a known substrate of caspase-3 34,35. 
Exposure of cell lines to lovastatin stimulates caspase-3 activity, which, in turn, results in 
the generation of the Bcl-2 cleavage product that promotes apoptosis. The time-dependent 
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increase of the pro-apoptotic 23 kD Bcl-2 form was demonstrated by Western blot 
analysis (Figure 5).  
Importantly, incubation of the plasma cell lines with lovastatin in the presence of 
mevalonate or GGOH, markedly prevented the collapse of the mitochondrial 
transmembrane potential, APO2.7 staining, the release of cytochrome c from 
mitochondria, and the activation of caspase-3 (as shown for myeloma cell line RPMI-
8226 in Figure 7A-D). In contrast, co-treatment of cells with FOH had no effect when 
compared to cells treated with lovastatin alone. 
 
Inhibition of geranylgeranylation induces apoptosis in ex vivo purified tumor cells 
from myeloma patients 
Studies were then conducted to determine the effect of lovastatin in purified tumor cells 
from multiple myeloma patients (n=5). Except for patient 2 who had 96% myeloma cells 
in her bone marrow, tumor cells were purified from mononuclear cells by MACS based 
on the expression of CD138. The percentage of tumor cells was >95%. Treatment of ex 
vivo purified myeloma cells with 30 µM lovastatin resulted in the reduction of myeloma 
cell viability in all patients (Table 1). Moreover, as in cell lines treatment of ex vivo 
purified myeloma tumor cells with lovastatin reduced Mcl-1 protein levels (Table 1).  
Similar to the effects in plasma cell lines, addition of mevalonate or GGOH resulted in 
complete inhibition of lovastatin-induced reduction of cell viability and lovastatin-induced 
apoptosis. However, co-incubation of cells with FOH had no effect. Co-treatment of 
tumor cells with mevalonate or GGOH restored Mcl-1 protein expression, whereas FOH 
was without effect. Figure 8 shows representative examples from 2 myeloma patients. 
Only in tumor cells from patient 2, lovastatin treatment additionally reduced Bcl-XL 
protein expression (>50% reduction when compared to the solvent control) and resulted in 
the increase of the pro-apoptotic Bcl-2 cleavage product.  
 
 
Table 1. Effect of lovastatin on expression of Bcl-2 family proteins and viability in 
purified tumor cells derived from myeloma patients 
Patient Mcl-1 Bcl-XL Bcl-2 Bax Viability 
1 3.7 86.8 103.1 76.7 18.4 
2 4.8 33.0 144.9 181.5 18.9 
3 21.8 69.7 103.7 92.5 60 
4 2.3 112.0 95.0 98.7 23.7 
5 3.3 82.5 101.5 76.9 4.6 
Purified myeloma cells were treated with solvent control or 30 µM lovastatin for 4 days. After protein isolation, 
Mcl-1, Bcl-XL, Bcl-2, and Bax were detected by Western blot analysis. Protein levels were quantitated by 
densitometry analysis of the protein bands and expressed as a percentage of the solvent control values. The 
percentage of viable cells, relative to the solvent control-treated cells, was measured by using MTT assay. 
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Figure 7. Lovastatin 
treatment results in collapse 
of the mitochondrial 
transmembrane potential, 
APO2.7 staining, release of 
cytochrome c into the 
cytosol, and caspase-3 
activation by depletion of 
GGPP. (A) RPMI-8226 cells 
were treated for 4 days with 
solvent control, or lovastatin 
(30 µM) alone or in 
combination with mevalonate 
(meva; 100 µM), FOH (10 
µM), or GGOH (10 µM). 
Collapse of the mitochondrial 
transmembrane potential was 
determined by staining the 
cells with DiOC6[3]. The 
fraction of cells with low 
(DiOC6[3]low) and the fraction 
of cells with intact 
(DiOC6[3]high) mitochondrial 
transmembrane potential are 
indicated in gate M1 and M2, 
respectively. APO2.7 staining 
was determined by flow 
cytometry in Digitonin-
permeabilized cells. The 
fraction of cells staining with 
APO2.7-PE (M2) and the 
fraction of cells not staining 
with APO2.7-PE (M1) are 
indicated. Results are 
representative of 3 
experiments performed in triplicate (B) RPMI-8226 cells were treated for 4 days with solvent control, or 
different concentrations of lovastatin (5, 10, 30, 50, 100, 150 µM) alone or in combination with mevalonate 
(meva; 100 µM), FOH (10 µM), or GGOH (10 µM). Collapse of the mitochondrial transmembrane potential was 
determined by staining the cells with DiOC6[3]. Shown is the percentage of cells with low mitochondrial 
transmembrane potential (gate M1). APO2.7 staining was determined by flow cytometry in Digitonin-
permeabilized cells. Shown is the percentage of cells staining with APO2.7-PE (gate M2). Experiments were 
performed three times in triplicate. Data are presented as mean ± s.e.m. (C) RPMI-8226 cells were exposed to 
solvent control, or lovastatin (30 µM) alone or in combination with mevalonate (meva; 100 µM), FOH (10 µM), 
or GGOH (10 µM) for 2 days, at which time the cells were harvested and cytochrome c present in the cytosolic 
fraction was determined by ELISA. Experiments were performed three times in duplicate. Data are presented as 
mean ± s.e.m. (D) RPMI-8226 cells were exposed to solvent control, or lovastatin (30 µM) alone or in 
combination with mevalonate (meva; 100 µM), FOH (10 µM), or GGOH (10 µM) for 2 days, at which time the 
cells were harvested and caspase-3 activation was assessed as described in "Materials and Methods." 
Experiments were performed three times in duplicate. Data are presented as mean ± s.e.m. 
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Figure 8. Treatment of ex vivo purified myeloma cells with lovastatin results in reduction of cell viability 
and induction of apoptosis by reducing Mcl-1 protein levels. Plasma cells from myeloma patient 1 were 
purified from bone marrow mononuclear cells by MACS based on CD138 expression. Plasma cell percentage 
was 97% after purification. Patient 2 had 96% myeloma cells in her bone marrow mononuclear cells and 
therefore purification was not necessary. Tumor cells derived from patients 1 and 2 were treated for 4 days with 
solvent control, or lovastatin (30 µM) alone or in the presence of mevalonate (meva; 100 µM), FOH (10 µM), or 
GGOH (10 µM). (A) The percentage of viable cells, relative to the solvent control-treated cells, was measured 
by using MTT assay. Experiments were performed once in triplicate. Data are presented as mean ± s.e.m. (B) 
The percentage of apoptotic cells was determined by the Annexin V assay. The percentages of viable myeloma 
cells (Annexin V-/PI-), early apoptotic cells (Annexin V+/PI-), and late apoptotic cells (Annexin V+/PI+) in 
each dot plot are indicated in the corresponding quadrants. (C) After protein isolation, Mcl-1, Bcl-XL, Bcl-2, and 
Bax expression levels were determined by Western blot analysis. Furthermore, the pro-apoptotic 23 kD Bcl-2 
form was detected after long exposure of the film.  
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Discussion 
 
In this study we demonstrated that inhibition of protein geranylgeranylation induced 
apoptosis in myeloma plasma cells. Inhibition of geranylgeranylation was established in 
two independent ways, by depletion of intracellular pools of GGPP by lovastatin and by 
specific inhibition of GGTase I activity. Incubation of myeloma cells with lovastatin 
effectively depleted pools of FPP and GGPP resulting in a dose-dependent inhibition of 
protein farnesylation and geranylgeranylation. This was demonstrated by analysis of the 
migratory behaviour of DnaJ and Rap1a during electrophoresis. Addition of FOH, which 
is converted to FPP in cells 28, to lovastatin-treated myeloma cells restored farnesylation 
of DnaJ and addition of GGOH, which is converted to GGPP 28, restored 
geranylgeranylation of Rap1a. In addition, geranylgeranylation and farnesylation were 
specifically blocked in a dose-dependent way by GGTase I and FTase inhibitors GGTI-
298 and FTI-277, respectively. In functional assays, addition of GGOH, but not FOH, 
rescued myeloma cells from lovastatin-induced apoptosis. However, GGOH was less 
effective than mevalonate in the rescue of myeloma cell survival. This suggests that 
depletion of other metabolites downstream of mevalonate may also contribute partly to the 
effects of lovastatin. The GGTase I inhibitor GGTI-298 also induced apoptosis in 
myeloma cells in a time- and dose-dependent way. Both inhibition of geranylgeranylation 
by lovastatin and GGTI-298 preceded the reduction of cell viability. Rescue of 
farnesylation by addition of FOH to lovastatin-treated cells was without effect. 
Furthermore, although the FTase inhibitor FTI-277 completely blocked farnesylation, it 
was less effective in the induction of apoptosis, when compared with GGTI-298. These 
results point to an important role for geranylgeranylated proteins in the regulation of 
apoptosis in myeloma plasma cells. 
The induction of apoptosis by inhibition of geranylgeranylation either by 
lovastatin or GGTI-298 was preceded or was concomitant with a consistent reduction of 
Mcl-1 protein expression in all myeloma cell lines and patients’ samples. Down-
regulation of Mcl-1 protein expression at day two was accompanied by disruption of the 
mitochondrial transmembrane potential, increased APO2.7 staining, cytochrome c release, 
and activation of caspase-3; suggesting that apoptosis was carried out via the intrinsic 
cell-death pathway. In some cell lines and patients’ samples a reduction of Bcl-XL 
expression levels or an induction of Bax or the pro-apoptotic 23 kD Bcl-2 form was 
found. However, this was not a consistent finding or only observed 4 days after inhibition 
of geranylgeranylation. The observed temporal sequence in the regulation of expression of 
apoptosis regulating proteins, suggests for the first time that down-regulation of Mcl-1 is 
the key event in the induction of apoptosis by inhibition of geranylgeranylation. 
In multiple myeloma, Mcl-1 is one of the key-regulators of apoptosis 24-26. 
Specific depletion of Mcl-1 by antisense oligodeoxynucleotides resulted in rapid cell 
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death, whereas overexpression of Mcl-1 in myeloma cells delayed the activation of 
caspases in a manner consistent with the hypothesis that a threshold level of Mcl-1 is 
required for myeloma cell survival 24-26. In addition, Mcl-1 promotes cell viability under a 
variety of apoptosis-inducing conditions including exposure to cytotoxic agents and the 
withdrawal of required growth factors 36. Similarly, high levels of Mcl-1 have been 
correlated with failure to achieve complete remission to chemotherapy in CLL 37. At 
present, it is unclear which pathway(s) are involved in the down-regulation of Mcl-1 
protein expression in myeloma cells after lovastatin treatment or GGTase I inhibition. 
Studies using a variety of cell types imply that multiple pathways, including PI-3K, 
JAK/STAT3, and MEK/ERK, are involved in the regulation of Mcl-1 transcription 38. 
However, recent studies performed by Zhang et al 39 suggest that Mcl-1 regulation in 
myeloma is more complex and may be independent from the above mentioned signaling 
pathways.  
Statins have been shown to induce apoptosis in other tumor cell lines and ex vivo 
purified tumor cells 14,40-42. Similar to myeloma, in acute myeloid leukemia (AML) 40, 
lung adenocarcinoma 41, and in pulmonary smooth muscle cells 42, the effect of lovastatin 
could be attributed to inhibition of geranylgeranylation. Identical results as presented here 
for myeloma, were obtained with lymphoma cell lines and purified tumor cells from 
patients with B-cell non-Hodgkin’s lymphoma (manuscript in preparation). In addition to 
the induction of apoptosis, recent studies have shown that statins also enhance new bone 
formation by stimulating osteoblast differentiation and activity 43 and inhibit bone 
resorption by inhibition of osteoclast formation and function 44. This action may be 
beneficial in myeloma patients with bone disease. Furthermore, in various cell types 
HMG-CoA reductase inhibitors inhibit expression of cytokines including the important 
myeloma growth factor IL-6 45. This indicates that in addition to induction of apoptosis by 
Mcl-1 down-regulation, these pleiotropic properties of statins may have important 
additional clinical implications in the treatment of multiple myeloma. 
At present it is unclear which geranylgeranylated target protein(s) are involved in 
the regulation of myeloma tumor cell apoptosis. Possible geranylgeranylated target 
proteins include RhoA, Cdc42, and Rac-1. These small GTP-binding proteins are involved 
in important cellular functions, such as organization of the cytoskeleton 46. In addition, 
they are also involved in regulation of apoptosis and proliferation 6,47-49 through the 
activation of various signaling pathways including PI-3K 50,51, several serine/threonine 
kinases 52, NF-kappaB 53,54, and SAPK/JNK 55,56. Furthermore, Rac-1, RhoA, and Cdc42 
have been demonstrated to have transforming and oncogenic potential in cell lines 57-60. 
Whether one of the above mentioned GTP-binding proteins is involved in the regulation 
of myeloma cell survival or apoptosis is currently under investigation.  
In summary, we demonstrated that inhibition of geranylgeranylation rather than 
inhibition of farnesylation reduces cell viability of myeloma plasma cells by induction of 
apoptosis. Apoptosis triggered by inhibition of geranylgeranylation was associated with 
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reduction of Mcl-1 protein expression, which, in turn, resulted in the collapse of the 
mitochondrial transmembrane potential, cytochrome c release from mitochondria into the 
cytosol, and stimulation of caspase-3 activity. These results show that geranylgeranylation 
of proteins is a key event in the regulation of myeloma tumor cell survival. Furthermore, 
our results suggest that pharmacologic agents such as lovastatin or GGTase inhibitors may 
be useful in the treatment of multiple myeloma. 
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Abstract 
 
Lovastatin inhibits HMG-CoA reductase resulting in the depletion of mevalonate and the 
isoprenoid molecules farnesylpyrophosphate (FPP) and geranylgeranylpyrophosphate 
(GGPP). Lovastatin blocked the transition from G1 to S phase of the cell cycle by the 
specific depletion of GGPP in myeloma cell lines and ex vivo purified myeloma cells. 
Furthermore, inhibition of geranylgeranyl transferase I activity was more effective in the 
inhibition of myeloma cell growth when compared to inhibition of farnesyl transferase 
activity. This indicates that protein geranylgeranylation is important for myeloma cell 
proliferation and cell cycle progression through G1. Geranylgeranylated target proteins 
involved in the control of proliferation include Rac-1, Cdc42, and RhoA. Inhibition of 
Rho, Rac, and Cdc42 GTPases by toxin B reduced proliferation, without affecting cell 
viability, but specific inhibition of Rho GTPases by C3 exoenzyme had no effect. This 
suggests a role for Rac and/or Cdc42 GTPases in myeloma cell growth. Rac-1 activity 
was found in all myeloma cell lines and was suppressed by lovastatin through the 
depletion of intracellular pools of GGPP. IL-6 rapidly stimulated Rac-1 activity, 
indicating a role for Rac-1 in the signal transduction cascade of IL-6 leading to myeloma 
cell proliferation. Specific reduction of Rac protein levels by antisense 
oligodeoxynucleotides reduced spontaneous proliferation of primary myeloma cells. 
Furthermore, dominant-negative Tat-Rac-1 reduced myeloma cell proliferation, while 
constitutively active Tat-Rac-1 enhanced proliferation. These data imply that Rac-1 is 
involved in the regulation of myeloma cell growth.  
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Introduction 
 
Multiple myeloma is characterized by the proliferation and accumulation of monoclonal 
plasma cells in the bone marrow. The proteins interleukin-6 (IL-6) and insulin-like growth 
factor I (IGF-I) 1-8 function as growth factors for myeloma cells and promote cell survival. 
Binding of IL-6 to the IL-6 receptor triggers the activation of at least 3 signaling 
pathways; the JAK-STAT pathway 9,10, the phosphatidylinositol-3 kinase (PI-3K) pathway 
8,11, and the mitogen-activated protein kinase (MAPK) pathway 12. Activation of the JAK-
STAT 10 and PI-3K 11 pathways has been implicated in the protection against apoptosis, 
whereas activation of the PI-3K 8,11 and MAPK 12 pathways induces proliferation in 
myeloma cell lines. IGF-I stimulation leads to activation of both the MAPK and the PI-3K 
pathways in myeloma cells, however the PI-3K pathway was demonstrated to be the 
major regulator of both apoptosis and proliferation, with only minimal contributions to 
either by the MAPK cascade 6-8,13. Activation of Akt by PI-3K may be responsible for the 
proliferative and anti-apoptotic effects of PI-3K in myeloma, since expression of a 
dominant-negative Akt gene in myeloma cells or pharmacologic inhibition of Akt resulted 
in a decreased number of cells in S phase and an increase in apoptosis 14,15. Various 
elements downstream of Akt have been implicated in the control of myeloma cell growth 
and survival including the Forkhead family of transcription factors 11,13 and p70S6 kinase 
13. Furthermore, NF-κB, which is constitutively active in myeloma cells promotes survival 
and proliferation through the induction of progression of cells from the G1 phase of the 
cell cycle to S phase 16-18.        
GTPases of the Ras and Rho families cycle between an inactive GDP-bound 
form, and a GTP-bound form with affinity for various effector proteins that control signal 
transduction cascades regulating multiple cellular processes including migration, 
cytoskeletal reorganization, stimulation of cell proliferation, and survival. Activating Ras 
mutations are frequently detected in myeloma 19-21 and contribute to reduced apoptosis 22-
24, increased cell proliferation 22,23, and an adverse clinical outcome 19,20. Rac-1, Cdc42, 
and RhoA have been implicated in the regulation of cell cycle progression through G1 
phase of the cell cycle. Constitutively activated mutants of Rac-1, Cdc42, and RhoA 
caused G1 progression and stimulation of DNA synthesis in fibroblasts 25-27. Furthermore, 
expression of active forms of Rac-1, Cdc42, and RhoA can transform fibroblasts 28 and 
activation of Rac-1, RhoA, and Cdc42 is required for full Ras transforming activity 29-33. 
The role of Rac, Cdc42, and RhoA in multiple myeloma is currently unknown. 
Participation of Ras and Rho family proteins in signaling pathways depends on 
the proper subcellular localization to the plasma membrane, which is facilitated by a series 
of posttranslational modifications of the carboxyl-terminus 34-36. This includes the addition 
of a farnesyl lipid derived from farnesylpyrophosphate (FPP) or a geranylgeranyl lipid 
derived from geranylgeranylpyrophosphate (GGPP) to a conserved cysteine residue at or 
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near the carboxyl-terminus of target proteins including Ras (farnesylation) and Rho family 
proteins such as Rac-1, Cdc42, and RhoA (geranylgeranylation). These reactions are 
catalyzed by farnesyl transferase (FTase) and geranylgeranyl transferase I (GGTase I). 
The mevalonate pathway produces many critical substances in cells, including cholesterol 
and the isoprenoid molecules FPP and GGPP. The rate-limiting step of this pathway is the 
conversion of HMG-CoA to mevalonate and is catalyzed by HMG-CoA reductase 37. 
HMG-CoA reductase inhibitors such as lovastatin are widely used to treat patients with 
hypercholesterolemia 38. 
In this report we show that inhibition of protein geranylgeranylation either by 
depletion of GGPP by lovastatin or by specific inhibition of GGTase I activity inhibits 
proliferation of myeloma cells. Furthermore, our data suggest that the geranylgeranylated 
GTP-binding protein Rac-1 is involved in the control of myeloma cell growth.  
 
 
Materials and methods 
 
Reagents 
Lovastatin and simvastatin were obtained from Merck & Co., Inc (Rahway, NJ, USA) and 
were chemically activated by alkaline hydrolysis prior to use as described previously 39. 
Mevalonate and farnesol (FOH) were purchased from Sigma (St Louis, MO, USA) and 
geranylgeraniol (GGOH) was obtained from ICN Biomedicals, BV (Zoetermeer, The 
Netherlands). FOH and GGOH are metabolized to FPP and GGPP in the cells, 
respectively 40. FTI-277 and GGTI-298 were obtained from Calbiochem (Schwallbach, 
Germany). Tat-Rac-1 Q61L and Tat-Rac-1 N17 vectors were a kind gift of Dr S. Dowdy 
(Howard Hughes Medical Institute, Dept. of Pathology, Washington University School of 
Medicine, St Louis, Missouri 63110, USA). The Clostridium botulinum C3 exoenzyme 
was purchased from List Biological Laboratories, Inc. (Campbell, CA) and Clostridium 
difficile toxin B was obtained from Sigma. A rabbit polyclonal antiserum against Cdk2 
was purchased from Santa Cruz (Santa Cruz Biotechnology Inc, Santa Cruz, CA, USA). 
Mouse monoclonal antibodies recognizing RhoA and Rac-1 were obtained from Santa 
Cruz and Pierce (Rockford, IL, USA), repectively. Mouse monoclonal antibodies 
recognizing p21Cip1 and p27Kip1 were from Pharmingen (Becton Dickinson, 
Erembodegem, Belgium (BDIS)).  
 
Cell lines 
Plasma cell lines RPMI-8226 and U266 were obtained from the American Tissue Culture 
Collection (ATCC) and L363 from the German Collection of Microorganisms and Cell 
Cultures (GCMC). The IL-6 dependent plasma cell line XG-1 was a kind gift of Dr B. 
Klein (Institute for Molecular Genetics, Montpellier, France) 41. Cell lines were cultured 
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in RPMI-1640 (GIBCO, Breda, The Netherlands) supplemented with 10% fetal calf serum 
(FCS) (Integro, Zaandam, The Netherlands), 100 IU/ml penicillin, 100 µg/ml 
streptomycin and 10 µM β-mercaptoethanol (growth medium). The IL-6-dependent cell 
line XG-1 was cultured in the continuous presence of exogenous IL-6 (1.25 ng/ml rhIL-6 
(Roche, Almere, The Netherlands). 
 
Isolation of myeloma tumor cells 
Myeloma plasma cells were obtained from bone marrow aspirates taken from the posterior 
iliac crest in 8 patients and from peripheral blood in one patient with plasma cell leukemia 
(patient 4) after obtaining informed consent. The plasma cell percentage in the patient 
samples varied from 15-96% of the mononuclear cells as determined by co-expression of 
CD38 (anti-CD38-FITC, Immunotech, Marseille, France) and CD138 (anti-CD138-PE, 
Immunotech) by flow cytometric analysis (FACSCalibur, BDIS). Except for patient 3, 
who had 96% myeloma cells in her bone marrow, tumor cells were purified ex vivo from 
mononuclear cells obtained by Ficoll-Paque (Amersham; Pharmacia BiotechAB, Uppsala, 
Sweden) density centrifugation, by magnetic cell sorting (MACS; Miltenyi Biotec, 
Bergisch Gladbach, Germany) based on CD138 expression as described previously 42. 
Samples obtained in this way contained >95% myeloma plasma cells as determined by 
analysis of CD38/CD138 co-expression. For experiments, myeloma cells were 
resuspended in RPMI-1640 (GIBCO) supplemented with 10% fetal calf serum (FCS) 
(Integro), 100 IU/ml penicillin, 100 µg/ml streptomycin, and 10 µM β-mercaptoethanol. 
 
Cell viability  
Viability of cells was examined by means of the 3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium bromide (MTT) assay as described previously 43. In short, cells were 
seeded in a concentration of 0.3 X 106/ml for the myeloma cell lines or 1 X 106/ml for the 
tumor cells of patients in a 96-well flat bottom plate (100 µl/well) (Nunc, Roskilde, 
Denmark) and treated with different concentrations of lovastatin (for concentrations see 
legends) alone or in the presence of mevalonate (100 µM), FOH (10 µM), or GGOH (10 
µM). Fixed concentrations of mevalonate (100 µM), FOH (10 µM), or GGOH (10 µM) 
were used. These concentrations proved to be optimal in rescuing myeloma cells from 
lovastatin-induced inhibition of proliferation. Inhibition of FTase and GGTase I was 
accomplished by treating cells with FTI-277 and GGTI-298, respectively (for 
concentrations see legends). After 2 or 4 days, 25 µl of MTT (5 mg/ml) was added to each 
well. After an incubation of 2 hours at 37oC the reaction was stopped by the addition of 
100 µl 20% sodium dodecyl sulphate (SDS; Boehringer Mannheim, Mannheim, 
Germany) / 0.025 M HCl / 0.35 M HAc in a mixture of (1:1; v/v) N,N-
dimethylformamide (Merck, Darmstadt, Germany) and distilled water. After an overnight 
incubation at 37oC the optical density of the samples was determined at 570 nm.  
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Apoptosis detection by Annexin V staining   
Myeloma cells (1.5 X 105 in 0.5 ml) were incubated with different concentrations of 
lovastatin (for concentrations see legends) alone or in the presence of mevalonate (100 
µM), FOH (10 µM), or GGOH (10 µM) in a 48-well plate (Nunc). Inhibition of FTase and 
GGTase I was accomplished by treating cells with FTI-277 and GGTI-298, respectively 
(for concentrations see legends). After 2 or 4 days, cells were harvested and apoptosis was 
determined by using the Annexin V assay as described previously 43. Apoptotic cells were 
defined as early apoptotic cells (Annexin V positive and PI negative) and late apoptotic 
cells (Annexin V positive and PI positive). 
 
Cell proliferation  
Cells (3 X 104) were seeded in 96-well flat bottom plates (Nunc) in 100 µl growth 
medium with different concentrations of lovastatin (for concentrations see legends) alone 
or in the presence of mevalonate (100 µM), FOH (10 µM), or GGOH (10 µM). Inhibition 
of FTase and GGTase I was accomplished by treating cells with different concentrations 
of FTI-277 (0-30 µM) and GGTI-298 (0-30 µM), respectively. After 32 and 80 hours, 3H-
thymidine (Amersham, Little Chalfont, UK) (1 µCi/well) was added for the remaining 16 
hours of the assay. 3H-thymidine incorporation was analyzed by liquid scintillation 
counting as described previously 43. 
 
Cell cycle analysis 
Myeloma cells (1 X 106 in 1.5 ml) were incubated with different concentrations of 
lovastatin (for concentrations see legends) in the presence or absence of mevalonate (100 
µM), FOH (10 µM), or GGOH (10 µM) in a 48-well plate (Nunc) for 2 days. Inhibition of 
FTase and GGTase I was accomplished by treating cells for 2 days with FTI-277 (20 µM) 
and GGTI-298 (20 µM), respectively (for concentrations see legends). Cells were then 
pulsed with 10 µM bromodeoxyuridine (BrdU) for 30 minutes at 37oC, after which the 
cells were washed twice with ice-cold PBS containing 1% bovine serum albumin (BSA). 
Cells were subsequently fixed with 70% ethanol for 30 minutes at 4oC. After the ethanol 
was washed away, the cells were treated with 2 M HCl containing 0.5% Triton-X-100 for 
30 minutes at room temperature, followed by neutralization with 1M natrium tetraborate 
(pH 8.5). Following washing, cells were resuspended in PBS containing 0.5% Tween-20 
and 1% BSA and then incubated with anti-BrdU-FITC (Becton and Dickinson) for 30 
minutes at room temperature. After washing with PBS containing 0.5% Tween-20 and 1% 
BSA, cells were stained with propidium iodide in PBS (5 µg/ml) and analyzed by flow 
cytometry. 
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Cdk2 kinase assay 
Cells (1.67 X 106 cells in 2.5 ml) were incubated for 2 days with lovastatin (30 µM) alone 
or in the presence of mevalonate (100 µM), FOH (10 µM), or GGOH (10 µM). After 
harvesting, whole cell lysates were made by washing cells in ice-cold PBS and then 
resuspending them in ELB buffer (150 mM NaCl, 50 mM HEPES pH 7.5, 5 mM EDTA, 
0.1% NP-40 with a cocktail of protease inhibitors (Boehringer Mannheim)) for 30 minutes 
at 4oC. Insoluble material was removed by centrifugation at 14 000 r.p.m. for 15 minutes 
at 4oC. Supernatants were then precleared with protein A-Sepharose CL-4B beads 
(Amersham, Little Chalfont, UK) for 30 minutes at 4oC. Following a short 14 000 r.p.m. 
centrifugation, protein A-Sepharose CL-4B beads (Amersham) and 0.4 µg of anti-Cdk2 
antibody (Santa Cruz) were added to the precleared supernatants and Cdk2 was 
immunoprecipitated overnight at 4oC. The precipitates were washed three times with ELB 
buffer and twice with kinase buffer (20 mM HEPES pH 7.5 with 5 mM MgCl2 and 2.5 
mM MnCl2). The precipitates were then dried with an insulin syringe and incubated in 
kinase buffer containing 2.5 µCi (γ-32P) ATP (Amersham), 10 µg histone H1 (Roche, 
Basel, Switzerland) and 50 µM ATP (Sigma) for 30 minutes at 30oC. Samples were then 
mixed with 2 X Laemmli sample buffer (0.125 M Tris pH 6.9 with 4% SDS, 20% 
Glycerol and 10% β-mercaptoethanol) and boiled for 5 minutes. Proteins were separated 
on a 10% SDS-PAGE gel and the gel was dried in a gel dryer (Biorad, Hercules, CA, 
USA) for 60 minutes at 80oC. The phosphorylated histone H1 was visualized using 
hyperfilm ECL (Amersham). 
 
Treatment of cells with C. botulinum C3 exoenzyme and C. difficile toxin B 
Cells were washed in PBS and resuspended in buffer (114 mM KCl, 15 mM NaCl, 5.5 
mM MgCl2, 10 mM Tris) in the presence of solvent control or 50 µg/ml C.botulinum C3 
exoenzyme for 1 hour at room temperature as described previously 44,45. Cells were 
washed and resuspended in medium. C.difficile toxin B (50 ng/ml) was directly 
administered to the cells. Toxin B and C3 exoenzyme were used at concentrations, which 
inhibited proliferation of various cell lines as shown previously 44-46.   
 
Incubation of cells with oligodeoxynucleotides  
A 16-mer phosphorothioated antisense Rac oligodeoxynucleotide (5’-ACT TGA TGG 
CCT GCA T-3’), complementary to a sequence shared by Rac-1 and Rac-2 genes and 
starting at the initiation codon, was synthesized by Isogen (Maarssen, The Netherlands) 
47,48. Reverse polarity ODNs (sequence; 5’-ATG CAG GCC ATC AAG T-3’ were used as 
a control. The ODNs were dissolved in Iscove’s Modified Dulbecco’s medium (IMDM) 
and stored at –80oC until use. ODNs were administered to cells in free form in the absence 
of cationic lipids. 
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Tat-Rac-1 protein isolation 
Polyhistidine-tagged Tat-Rac-1 Q61L and Tat-Rac-1 N17 constructs were expressed in 
BL21 bacteria (Novagen, Madison, WI, USA). Expression and isolation of Tat-Rac-1 
Q61L and Tat-Rac-1 N17 were performed similarly as has been described by Hall et al 49, 
except that the isolation of the proteins was performed under non-reducing conditions. 
Briefly, expression of Tat-Rac-1 Q61L and Tat-Rac-1 N17 in bacteria was induced by 
IPTG for 3-4 hours at 37oC, before the bacteria pellet was solubilized in lysis buffer (50 
mM NaH2PO4, 300 mM NaCl, 10 mM imidazole, 10% glycerol, 1 mM PMSF, pH 8.0). 
Lysozyme (1 mg/ml) and DNase (5 µg/ml) were added to the bacteria solution and 
incubated for 30 minutes on ice. The solution was sonicated 6-8 times for 10 seconds 
each, and centrifuged twice at 15 000 r.p.m. for 20 minutes. The supernatant containing 
the fusion protein was added to Ni-NTA beads and rotated for 30 minutes at 4oC. The 
beads were incubated with lysis buffer, twice with wash buffer 1 (50 mM NaH2PO4, 300 
mM NaCl, 20 mM imidazole, 0.5% Tween-20, 10% glycerol, pH 8.0), and 3-4 times with 
wash buffer 2 (50 mM NaH2PO4, 300 mM NaCl, 20 mM imidazole, 10% glycerol, pH 
8.0). Protein was eluted from the beads with elution buffer (50 mM NaH2PO4, 300 mM 
NaCl, 500 mM imidazole, 10% glycerol, pH 8.0). LPS was removed from the protein 
elution by a method described previously 50. In short, 0.1 volume of LPS removal buffer 
(50 mM NaH2PO4, 300 mM NaCl, 10% glycerol, 10% Triton-X114, pH 7.5) was added 
and rotated at 4oC for 10 minutes. After transferring the solution to 37oC for 5 minutes, it 
was centrifuged at 3 000 r.p.m. for 5 minutes. Upper layer was transferred to a new tube 
and the procedure was repeated 4 times and 2 times with the LPS removal buffer without 
Triton-X114. Imidazole, and last traces of Triton-X114, were removed from the resultant 
protein solution by dialyzing two times against PBS (pH 7.4) containing 10% glycerol for 
at least 4 hours at 4oC each time, using Slide-A-Lyzer dialysis cassette (extra strength; 3-
12 ml; MW cut off 10 kD; Pierce). Protein concentration was measured and purity of Tat-
Rac-1 Q61L and Tat-Rac-1 N17 was approximately 95%, as determined by sodium 
dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and subsequent 
Coomassie blue staining. Protein expression of Tat-Rac-1 Q61L and Tat-Rac-1 N17 was 
confirmed by SDS-PAGE and immunoblotting using anti-HA and anti-Rac-1 antibodies. 
Protein solution was aliquoted and frozen at –80oC.  
 
Detection of Rac-1 activity 
Rac-1 activity was determined by using the EZ-Detect Rac-1 activation kit (Pierce). Cells 
were treated for 2 days with lovastatin (for concentrations see legends) alone or in the 
presence of mevalonate (100 µM), FOH (10 µM), or GGOH (10 µM). Prior to stimulation 
of cell lines with IL-6, cells were cultured overnight in serum-free RPMI-1640 medium. 
After purification of myeloma cells from patients, cells were washed 2 times in serum-free 
medium, resuspended in serum-free medium, and incubated for 1 hour at 37oC. Cell lines 
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and purified tumor cells from myeloma patients were stimulated with 10 ng/ml IL-6. 
Equal numbers of cells (10-15 X 106) were washed in ice-cold PBS and then resuspended 
in 1 ml lysis buffer (25 mM Tris HCl, pH 7.5, 150 mM NaCl, 5mM MgCl2, 1% NP-40, 1 
mM DTT and 5% glycerol) at 4oC for 5 minutes. The supernatant, which was obtained 
after a centrifugation step at 16 000 g for 15 minutes at 4oC, was added to a spin column 
containing an immobilized glutathione disc and 20 µg GST-Pak1-PBD. After an 
incubation of the reaction mixture at 4oC for 60 minutes with gentle rocking, the columns 
were centrifuged at 7 200 g for 2 minutes. The resin was washed four times with lysis 
buffer and then 50 µl 2 x SDS sample buffer containing 5% β-mercaptoethanol was added 
to the resin. The samples were boiled at 100oC for 5 minutes. After a centrifugation step at 
7 200 g for 2 minutes, the samples were electrophoresed on a gel.  
 
Western blotting 
Cells (1 X 106 cells in 1.5 ml) were incubated for 2 or 4 days with lovastatin (for 
concentrations see legends) in the presence or absence of mevalonate, FOH, or GGOH. 
Inhibition of FTase and GGTase I was accomplished by treating cells with FTI-277 and 
GGTI-298, respectively (for concentrations see legends). Cell lysates were made as 
described previously 51 and protein concentrations were determined by the BCA assay 
(Pierce). Samples containing equal amounts of protein were mixed with 2 X Laemmli 
sample buffer (0.125 M Tris pH 6.9 with 4% SDS, 20% Glycerol and 10% β-
mercaptoethanol) and boiled for 5 minutes. Proteins were subsequently fractionated in 
10% SDS-PAGE at room temperature and electrically transferred from the gel to PVDF-
membrane (Biorad). After blocking in 0.1% Tween-20, 5% skimmed powder milk, 2% 
BSA in 10 mM Tris and 150 mM NaCl, the membranes were incubated with anti-p27Kip1, 
p21Cip1, Cdk2, RhoA, or Rac-1. Antibody binding was visualized with enhanced 
chemoluminescence (Amersham) detection with hyperfilm ECL (Amersham) after 
incubation with a horseradish peroxidase (HRP)-conjugated secondary antibody (Dako). 
Finally, the membranes were extensively washed in PBS and reprobed with anti-α-actin 
(Sigma) as a control for equal loading of protein. Relative amounts of protein were 
determined by densitometry. 
 
 
Results 
 
Depletion of GGPP inhibits proliferation by inducing G1 arrest in myeloma cell lines 
Lovastatin inhibits the conversion of HMG-CoA to mevalonate, and thereby the synthesis 
of the isoprenoids FPP and GGPP. We have previously shown that the depletion of FPP 
and GGPP in myeloma cells results in inhibition of protein farnesylation and 
geranylgeranylation, respectively 52, and that geranylgeranylated proteins play an 
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important role in the regulation of myeloma cell survival 52. To investigate the effect of 
depletion of FPP and GGPP on myeloma cell proliferation, myeloma cell lines were 
incubated for 2 or 4 days with different concentrations of lovastatin alone or in the 
presence of mevalonate (100 µM), FOH (10 µM), or GGOH (10 µM). Lovastatin 
inhibited proliferation of RPMI-8226 and L363 cells, and the IL-6-dependent U266 and 
XG-1 cell lines in a dose- and time-dependent way as determined by detection of 3H-
thymidine incorporation (Figure 1A). Inhibition of proliferation by 30 µM lovastatin 
varied from 64.1-98.2% at day 2, while proliferation was reduced by more than 95% in all 
4 cell lines tested at day 4. Addition of mevalonate to lovastatin-treated cell lines restored 
cell proliferation. This indicates that lovastatin inhibits proliferation through the decrease 
of mevalonate production as a consequence of the specific inhibition of HMG-CoA 
reductase and not through non-specific cell toxicity. FPP and GGPP are metabolites of 
mevalonate and are donors of farnesyl and geranylgeranyl molecules, which are attached 
to a variety of proteins including small GTPases. FOH and GGOH are metabolized to FPP 
and GGPP in the cells 40. GGOH restored proliferation in lovastatin-treated myeloma 
cells. In contrast, FOH had no effect or only partial protective effects (Figure 1A). Cell 
cycle analysis showed that lovastatin treatment for 2 days caused accumulation of cells in 
G1 phase of the cell cycle and a loss of cells in S phase in a dose-dependent way as shown 
for U266 cells in Figure 1B. At day 2, there was no significant increase in apoptosis in 
U266 cells, as determined by the absence of a sub-G1 population. Addition of mevalonate 
or GGOH, but not FOH prevented the G1 to S phase cell cycle arrest (Figure 1C). 
Addition of mevalonate, GGOH, or FOH to myeloma cells in the absence of lovastatin 
had no effect on cell cycle distribution. Lovastatin-induced G1/S phase growth arrest was 
accompanied by the up-regulation of the cyclin dependent kinase (Cdk) inhibitors p21Cip1 
and/or p27Kip1. Lovastatin increased p21Cip1 protein levels in U266 (shown in Figure 1D), 
XG-1, and RPMI-8226 cells and p27Kip1 levels in RPMI-8226 and L363 cells. To evaluate 
whether the induction of the Cdk inhibitors resulted in the inhibition of kinase activity, we 
measured the phosphorylation of histone H1 in anti-Cdk2 immunoprecipitates. In all 4 
myeloma cell lines, Cdk2 activity was significantly reduced after treatment with lovastatin 
for 2 days, whereas Cdk2 protein levels did not change. Mevalonate and GGOH, but not 
FOH prevented the up-regulation of the Cdk inhibitors and the decrease in Cdk2 activity 
as shown for U266 cells in Figure 1D. 
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Figure 1. Lovastatin reduces proliferation of myeloma cell lines through the depletion of GGPP. (A) L363, 
RPMI-8226, XG-1, and U266 cells were treated for 2 or 4 days with solvent control, or different concentrations 
of lovastatin (1, 5, 10, 30, 50, 100, 150 µM) alone or in combination with mevalonate (meva; 100 µM), FOH (10 
µM), or GGOH (10 µM). Proliferation was determined by 3H -thymidine incorporation during the last 16 hours 
of culture. Data were from three experiments performed in triplicate. Data are presented as mean ± s.e.m. (B and 
C) U266 cells were treated with solvent control (0), or lovastatin (5, 10, 30, 100, or 150 µM) alone or in 
combination with mevalonate (M; 100 µM), FOH (F; 10 µM), or GGOH (G; 10 µM) for 2 days, at which time 
the cells were harvested and cell cycle distribution was determined by BrdU assay. The percentages of cells in 
G1 phase, G2/M phase, and S phase of the cell cycle are shown. Results are representative of three experiments 
performed in triplicate. (D) U266 cells were treated for 2 days with solvent control or lovastatin (30 µM) alone 
or in the presence of mevalonate (100 µM), FOH (10 µM), or GGOH (10 µM). After protein isolation p21Cip1, 
p27Kip1, and Cdk2 were determined by Western blot analysis. In addition, cell lysates were immunoprecipitated 
(IP) with anti-Cdk2, and kinase activity was determined using histone H1 as substrate. The data shown are 
representative of at least three independent experiments. 
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Depletion of GGPP inhibits proliferation of purified tumor cells derived from 
myeloma patients 
Similar to myeloma cell lines, lovastatin inhibited both spontaneous and IL-6-induced 
proliferation of purified myeloma tumor cells (n=7) in a dose- and time- (data not shown) 
dependent way as determined by detection of 3H-thymidine incorporation (Figure 2A-C). 
Reduction of spontaneous proliferation induced by 30 µM lovastatin varied between 61.9-
99.8% and 73.0-99.9% at day 2 and 4, respectively. Addition of exogenous IL-6 enhanced 
myeloma cell proliferation, as shown in Figure 2A for two myeloma patients’ samples. 
Lovastatin reduced myeloma cell proliferation both in the presence and in the absence of 
exogenous IL-6 (n=2). Proliferation was restored by addition of mevalonate or GGOH to 
lovastatin-treated myeloma tumor cells, whereas FOH had no effect (n=4), as shown in 
Figure 2B for two representative myeloma patients’ samples. Also in primary myeloma 
cells, Cdk2 activity was reduced by lovastatin and activity was restored by addition of 
mevalonate to lovastatin-treated cells (n=3), as shown in Figure 2C for a representative 
myeloma patient sample. The inhibition of Cdk2 activity was accompanied by up-
regulation of p21Cip1 protein levels in myeloma cells (Figure 2C). These data clearly 
suggest that lovastatin-reduced myeloma cell proliferation is the result of depletion of 
intracellular pools of GGPP leading to inhibition of protein geranylgeranylation.  
 
Inhibition of GGTase I activity reduces proliferation of myeloma cells 
We have previously shown that in myeloma cells GGTI-298 is a specific inhibitor of 
GGTase I, whereas FTase activity is specifically inhibited by FTI-277 52. To confirm that 
geranylgeranylation is critical for the regulation of myeloma cell proliferation, we 
incubated myeloma cell lines with FTI-277 and GGTI-298 for 2 or 4 days. GGTI-298 
inhibited proliferation in a dose- and time-dependent way (Figure 3A). FTI-277 had no 
effect or inhibited proliferation only to a small extent when compared to GGTI-298. Cell 
cycle analysis showed that GGTI-298 treatment for 2 days caused myeloma cells to arrest 
at the G1 phase of the cell cycle and reduced the number of cells in S phase (Figure 3B). 
 
Rho family members are involved in the regulation of myeloma cell proliferation 
These data support the involvement of geranylgeranylated proteins in myeloma cell 
growth. Potential geranylgeranylated target proteins are the Rho family members RhoA, 
Rac-1, and Cdc42, which are involved in a host of cellular processes including cell 
proliferation. To discriminate between these proteins, we studied the effect of toxin B and 
C3 exoenzyme. C. difficile toxin B specifically glucosylates and inactivates Rho, Rac, and 
Cdc42 GTPases 46,53. Treatment of myeloma cell lines with toxin B for 2 or 4 days 
reduced the number of viable cells in a dose- (data not shown) and time-dependent way 
(Table 1).  
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Figure 2. Lovastatin reduces proliferation of purified myeloma cells from patients through depletion of 
GGPP. Plasma cells from myeloma patients were purified from bone marrow mononuclear cells by MACS 
based on CD138 expression. Plasma cell percentage was >95% after purification. (A) Myeloma tumor cells were 
treated for 4 days with lovastatin (30 µM) or solvent control in the presence or absence of IL-6 (10 ng/ml). (B) 
Myeloma cells were treated for 4 days with solvent control, or lovastatin (30 µM) alone or in combination with 
mevalonate (meva; 100 µM), FOH (10 µM), or GGOH (10 µM). (C) Myeloma cells were treated for 2 days with 
solvent control, or lovastatin (30 µM) alone or in combination with mevalonate (meva; 100 µM). Proliferation 
was determined by 3H-thymidine incorporation during the last 16 hours of culture. Experiments were performed 
once in triplicate. Data are presented as mean ± s.e.m. After protein isolation p21Cip1, p27Kip1, and Cdk2 were 
determined by Western blot analysis. In addition, cell lysates were immunoprecipitated (IP) with anti-Cdk2, and 
kinase activity was determined using histone H1 as substrate. 
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This was caused by a dose- (data not shown) and time-dependent inhibition of myeloma 
cell proliferation, since the percentage of apoptotic cells was not affected by toxin B 
(Table 1) as shown for XG-1 cells in Figure 4A. C. botulinum C3 exoenzyme selectively 
inactivates Rho GTPases by ADP-ribosylating asparagine 41 54-56. Treatment of myeloma 
cells with C3 exoenzyme (50 µg/ml) for 2 or 4 days had no effect on the number of viable 
cells, and did not inhibit proliferation or induce apoptosis as shown for the XG-1 cell line, 
which was the most sensitive cell line to toxin B, in Figure 4B. In addition, introduction of 
C3 exoenzyme into cells using reversible permeabilization of myeloma cells with 
streptolysin-O had also no effect (data not shown). These data suggest that in myeloma 
cells, Rac and/or Cdc42 small GTPases rather than Rho proteins are involved in the 
regulation of myeloma cell proliferation.   
Figure 3. Inhibition of geranylgeranyl transferase I activity inhibits proliferation of myeloma cell lines. 
(A) L363, RPMI-8226, XG-1, and U266 cells were treated for 2 or 4 days with solvent control, or different 
concentrations of FTI-277 (2.5, 5, 10, 15, 20, 30 µM) or GGTI-298 (2.5, 5, 10, 15, 20, 30 µM) for 2 or 4 days. 
Proliferation was determined by 3H-thymidine incorporation during the last 16 hours of culture. Data were from 
three experiments performed in triplicate. Data are presented as mean ± s.e.m. (B) U266 cells were treated with 
solvent control, FTI-277 (20 µM), or GGTI-298 (20 µM) for 2 days, at which time the cells were harvested and 
cell cycle distribution was determined by BrdU assay. The percentages of cells in G1 phase, G2/M phase, and S 
phase of the cell cycle are shown. Results are representative of three experiments performed in triplicate.     
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Table 1. Effect of C. difficile toxin B on viability, proliferation, and apoptosis of myeloma 
cell lines  
 
Figure 4. Toxin B inhibits proliferation, but has no effect on the survival of myeloma cell lines. (A) XG-1 
cells were treated for 2 or 4 days with solvent control or Clostridium difficile toxin B (50 ng/ml). (B) XG-1 cells 
were treated for 2 or 4 days with solvent control or Clostridium botulinum C3 exoenzyme (50 µg/ml). The 
percentage of viable cells, relative to the solvent control, was measured by using MTT assay. Proliferation was 
determined by 3H-thymidine incorporation during the last 16 hours of culture. The percentage of apoptotic cells 
was determined by Annexin V assay. Shown is the percentage of early and late apoptotic cells. Experiments 
were performed three times in triplicate. Data are presented as mean ± s.e.m.  
 
 
Lovastatin reduces Rac-1 activity in myeloma cell lines 
We analyzed in myeloma cell lines whether lovastatin, through inhibition of 
geranylgeranylation, reduced Rac-1 activity. The activation of Rac-1 was measured by 
specifically coprecipitating the GTP-bound form of Rac-1 using a recombinant fusion 
 L363 RPMI-8226 XG-1 U266 
 Day 2 Day 4 Day 2 Day 4 Day 2 Day 4 Day 2 Day 4 
Number of viable 
cells (%control) 53.1 39.6 93.1 79.8 42.9 13.7 85.8 59.6 
         
Proliferation 
(%control) 61.5 65.2 93.8 83.7 39.8 22.7 39.6 36.3 
         
% of apoptotic  
cells 31.9/36.8 42.8/41.6 30.2/33.4 48.1/50.5 30.2/38.1 41.5/48.8 10.9/12.7 11.3/16.7 
 Myeloma cell lines were treated for 2 or 4 days with solvent control or toxin B (50 ng/ml). The number of
viable cells was determined by MTT assay, the percentage of apoptotic cells was evaluated by Annexin
V/PI assay, and proliferation was determined by 3H-thymidine incorporation. The number of viable cells
and proliferation are shown as a percentage of solvent control-treated cells. The percentage of apoptotic
cells is shown for solvent control-(left) and toxin B-treated cells (right). 
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protein of GST and amino acid residues 59-145 of PAK-1β, including the Rac binding 
domain (GST-PAK). Rac-1 was activated in all myeloma cell lines tested as shown for 
XG-1 cells in Figure 5A. Lovastatin reduced Rac-1 activity to near background levels. 
Rac-1 activity was restored by addition of mevalonate or GGOH to lovastatin-treated 
cells, whereas FOH had no effect.  
Figure 5. Lovastatin inhibits Rac-1 activity, and IL-6 induces activation of Rac-1 in myeloma cell lines and 
purified tumor cells from patients. (A) XG-1 cells were treated for 2 days with solvent control, or lovastatin (5 
µM) alone or in combination with mevalonate (meva; 100 µM), FOH (10 µM), or GGOH (10 µM). Rac-1 
activation state was examined using GST-PAK pull-down assays. Results are representative of three experiments 
performed in triplicate. (B) XG-1 cells were stimulated with IL-6 for 1, 5, and 15 minutes. Prior to stimulation 
with IL-6, XG-1 cells were cultured overnight in serum-free RPMI-1640 medium. Rac-1 activation state was 
examined using GST-PAK pull-down assays. Results are representative of three experiments performed in 
triplicate. (Ci) Plasma cells from myeloma patient 8 were purified from bone marrow mononuclear cells by 
MACS based on CD138 expression. Plasma cell percentage was >95% after purification. Purified myeloma 
tumor cells were incubated for 1 hour at 37oC in serum-free RPMI-1640 medium, and then incubated with 10 
ng/ml IL-6 for 15 minutes. Rac-1 activation state was examined using GST-PAK pull-down assays. (Cii) 
Purified myeloma cells from patient 8 were incubated for 2 days in growth medium in the presence or absence of 
IL-6. Proliferation was determined by 3H-thymidine incorporation during the last 16 hours of culture. 
Experiments were performed once in triplicate. Data are presented as mean ± s.e.m. 
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primary cells. Similar to cell lines, IL-6-induced proliferation coincided with a significant 
increase in Rac-1-GTP levels (Figure 5C).   
 
Antisense Rac suppresses myeloma cell proliferation 
The role of Rac in the regulation of proliferation was investigated in purified tumor cells 
from a myeloma patient using antisense oligodeoxynucleotides (ODNs) complementary to 
a sequence shared by Rac-1 and Rac-2 genes. Myeloma cells were incubated for 4 days 
with solvent control, Rac antisense ODNs, or reverse polarity control ODNs prior to 
detection of Rac protein levels and measurement of proliferation. Rac protein levels were 
not affected by reverse polarity ODNs, whereas these were markedly decreased by Rac 
antisense ODNs when compared with the solvent control-treated cells. The down-
regulation of Rac was sequence-specific since Rac antisense ODNs did not alter 
expression levels of RhoA (Figure 6A). Antisense-mediated Rac down-regulation 
significantly reduced the spontaneous proliferation of ex vivo purified myeloma cells 
(Figure 6B). In contrast, reverse polarity control ODNs had no effect when compared with 
solvent control-treated cells. Myeloma cell survival was not altered by Rac antisense 
ODNs (data not shown).  
Figure 6. Rac antisense ODNs reduce myeloma cell proliferation. Plasma cells from myeloma patient 9, were 
purified from bone marrow mononuclear cells by MACS based on CD138 expression. Plasma cell percentage 
was >95% after purification. Purified myeloma tumor cells were incubated for 4 days with solvent control, 
reverse polarity Rac ODNs (RP Rac), or antisense Rac ODNs (AS Rac). (A) After protein isolation, Rac-1 and 
RhoA were determined by Western blot analysis. Numbers below blots represent the ratios of the optical density 
of a band relative to the optical density of the band from solvent control-treated cells. (B) Proliferation was 
determined by 3H-thymidine incorporation during the last 16 hours of culture. Experiments were performed once 
in triplicate. Data are presented as mean ± s.e.m.   
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Dominant-negative Tat-Rac-1 reduces proliferation, whereas constitutively active 
Tat-Rac-1 enhances proliferation of myeloma cells 
Previous studies have shown that Tat fusion proteins rapidly enter cells following their 
addition to cell culture medium 49,57, and therefore Tat fusion proteins offer a novel 
method for transduction of proteins into cells. In this study, Tat-HA was fused with 
dominant-negative or constitutively active Rac-1. The effect of dominant-negative Tat-
Rac-1 N17 or constitutively active Tat-Rac-1 Q61L on myeloma cell proliferation was 
analyzed in U266 and XG-1 cells. Myeloma cells were incubated with the Tat-Rac-1 
proteins for 2 or 4 days after which proliferation was determined by detection of 3H-
incorporation. Transduction of myeloma cells with dominant-negative Tat-Rac-1 N17 
decreased proliferation when compared with solvent control-treated cells. In contrast, cells 
transduced with constitutively active Tat-Rac-1 Q61L showed increased proliferation 
(Figure 7A). However, both dominant-negative and constitutively active Tat-Rac-1 
protein had no effect on viability of myeloma cells as determined by the Annexin V/PI 
assay (Figure 7B). 
Figure 7. Dominant-negative Tat-Rac-1 inhibits proliferation and constitutively active Tat-Rac-1 induces 
proliferation of myeloma cells. U266 and XG-1 cells were treated for 2 or 4 days with solvent control, 
dominant-negative Tat-Rac-1 N17 (18.7 µg/ml), or constitutively active Tat-Rac-1 Q61L (18.7 µg/ml). (A) 
Proliferation was determined by 3H-thymidine incorporation during the last 16 hours of culture. Data were from 
three experiments performed in triplicate. Data are presented as mean ± s.e.m. (B) The percentage of apoptotic 
cells was determined by Annexin V assay. Shown is the percentage of early and late apoptotic cells. Experiments 
were performed three times in triplicate. Data are presented as mean ± s.e.m. 
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Discussion 
 
In this study we investigated the importance of protein prenylation in the control of 
myeloma cell growth. In a previous study we showed that inhibition of HMG-CoA 
reductase by statins induced apoptosis in myeloma cells via down-regulation of the anti-
apoptotic protein Mcl-1 52. In these experiments addition of geranylgeranyl isoprenoids, 
but not farnesyl isoprenoids, rescued myeloma cells from statin-induced apoptosis. 
Furthermore, specific inhibition of GGTase I activity, but not FTase activity, also resulted 
in myeloma cell death. These results implied that geranylgeranylated proteins are involved 
in statin-induced apoptosis. In this paper we show for the first time that 
geranylgeranylated proteins regulate myeloma cell growth. Analysis of potential candidate 
geranylgeranylated proteins suggests that the GTPase Rac-1 is involved in the control of 
myeloma proliferation without affecting apoptosis.  
We have previously shown that inhibition of HMG-CoA reductase in myeloma 
cells inhibited both farnesylation and geranylgeranylation of target proteins by depletion 
of the isoprenoids FPP and GGPP in a time- and dose-dependent fashion. Inhibition of 
geranylgeranylation coincided with induction of apoptosis and these effects could be 
prevented by addition of mevalonate or GGOH, which is metabolized to GGPP in cells 40. 
Studies performed with lung adenocarcinoma 58 and in mouse fibroblasts 59 implicated 
that inhibition of geranylgeranylation resulted in inhibition of proliferation by arrest in the 
G1 phase of the cell cycle. Here we show that lovastatin blocks Cdk2 activity, in 
association with enhanced expression of Cdk inhibitors p21Cip1 and/or p27Kip1, and inhibits 
myeloma cell proliferation in a time- and dose-dependent way through the accumulation 
of cells in the G1 phase of the cell cycle. Addition of GGOH restored Cdk2 activity, the 
G1 to S phase cell cycle progression, and proliferation. FOH, which is metabolized to FPP 
in cells 40, completely restored farnesylation 52, but had no or only minor effects on 
myeloma cell proliferation. Furthermore, specific inhibition of GGTase I activity was 
more effective in reducing myeloma cell proliferation when compared with inhibition of 
FTase. This indicates that farnesylated proteins are not involved in the regulation of 
myeloma proliferation or are unable to support proliferation in the absence of 
geranylgeranylated proteins. These data support a role for geranylgeranylated proteins in 
the progression of myeloma cells from G1 to the S phase of the cell cycle.     
Geranylgeranylated target proteins that regulate proliferation include Rac-1, 
RhoA, and Cdc42. Clostridium difficile toxin B glycolysates and inactivates Rho, Cdc42 
and Rac GTPases 46,53. Toxin B did not induce apoptosis, but inhibited the proliferation of 
myeloma cells. Clostridium botulinum C3 exoenzyme which ADP-ribolysates and 
inactivates Rho GTPases 54-56, had no effect on myeloma cell growth or survival. This 
suggests that reduced cell growth by inhibition of geranylgeranylation is likely due to, at 
least in part, inhibition of Rac and/or Cdc42 protein activity. Furthermore, these data 
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indicate that the regulation of proliferation by these geranylgeranylated proteins is 
independent of effects on survival. Since Rac-1 is required for proliferation, but not 
survival of BCR/ABL-expressing myeloid precursor cells 60 and plays a role in the 
regulation of invasion and metastasis of lymphoma tumor cells 61, we investigated the role 
of Rac-1 in myeloma in this study. Rac-1 is a regulator of diverse cellular processes 
including the control of cytoskeleton organization, membrane trafficking, cellular 
adhesion, and gene expression. In addition, Rac-1 plays an essential role in cell cycle 
progression through G1 25,62. Studies in fibroblasts with activated Rac-1 mutants showed 
that activation of Rac-1 alone was sufficient to initiate cell cycle progression 25,26, while 
dominant-negative versions of Rac-1 blocked serum-induced DNA synthesis 25.  
Rac-1 activity was observed in all myeloma cell lines tested. Depletion of GGPP 
by lovastatin reduced Rac-1 activity in myeloma cell lines. We also investigated whether 
the myeloma growth factor IL-6 stimulated Rac-1 activity. Both in myeloma cell lines and 
in purified myeloma cells from patients Rac-1 activity was induced by IL-6. The role of 
Rac-1 in the regulation of myeloma cell survival and proliferation was investigated by 
using both Tat-Rac-1 mutants and Rac antisense ODNs. Specific reduction of Rac protein 
levels by antisense ODNs reduced spontaneous proliferation of myeloma cells. 
Furthermore, we demonstrated that dominant-negative Tat-Rac-1 reduced proliferation, 
whereas constitutively active Tat-Rac-1 stimulated proliferation of myeloma cell lines 
including IL-6-dependent XG-1 cells. These data suggest that in myeloma cells IL-6 
induces proliferation, at least in part, through Rac-1-dependent pathways. Several studies 
have indicated that the Ras-Raf-MEK-ERK 12,63,64 and PI-3K/Akt 8,11,14,64 pathways are 
involved in IL-6-induced proliferation. Rac-1 may be a downstream effector of Ras and/or 
PI-3K signaling pathways in myeloma cells, since both Ras 29,31,65,66 and PI-3K 66-71 
mediate Rac-1 activation. In addition, in myeloma cells IL-6 induces tyrosine 
phosphorylation of Vav 72, which is a GDP/GTP exchange factor (GEF) for members of 
the Rho family of GTPases, including Rac-1 73-75. Phosphorylation of Vav and products of 
PI-3K activation have been proposed to contribute to the GEF activation of Vav. We are 
currently investigating which IL-6-triggered signaling pathways lead to the activation of 
Rac-1 in myeloma. Interestingly, dominant-negative Tat-Rac-1, constitutively active Tat-
Rac-1, and Rac antisense ODNs did not affect myeloma cell survival. This suggests that 
Rac-1-dependent pathways play an important role in the control of myeloma cell growth, 
but not in myeloma cell viability.  
In conclusion, our findings indicate that protein geranylgeranylation is essential 
for myeloma cell proliferation through the induction of G1/S progression. We have 
identified the geranylgeranylated GTP-binding protein Rac-1 as an important regulator of 
myeloma tumor cell proliferation. Furthermore, we provide evidence that IL-6-mediated 
Rac-1 activation is necessary for IL-6-dependent myeloma cell growth. However, Rac-1 
activity was not required for myeloma cell survival. These results suggest that inhibition 
of protein geranylgeranylation may be a new treatment strategy in multiple myeloma. 
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Abstract 
 
Purpose: Prenylation is essential for membrane localization and participation of 
proteins in various signaling pathways. The following study was conducted to examine 
the importance of protein farnesylation and geranylgeranylation for the regulation of 
lymphoma cell survival and proliferation.  
Experimental design: Lymphoma cells were treated with the HMG-CoA 
reductase inhibitor lovastatin, which inhibits protein farnesylation and 
geranylgeranylation by the depletion of intracellular pools of farnesylpyrophosphate and 
geranylgeranylpyrophosphate. In addition, farnesyl transferase and geranylgeranyl 
transferase (GGTase I) activity were specifically inhibited by FTI-277 and GGTI-298, 
respectively.  
Results: Only inhibition of geranylgeranylation by lovastatin resulted in the 
reduction of cell viability in lymphoma cell lines and purified tumor cells from lymphoma 
patients in a time- and dose-dependent way. The reduction in the number of viable cells 
was mediated by both induction of apoptosis and inhibition of proliferation. In addition, 
GGTI-298 was more effective in the induction of apoptosis and inhibition of proliferation, 
when compared with FTI-277. Apoptosis induced by inhibition of protein 
geranylgeranylation was associated with a reduction of Mcl-1 protein levels, collapse of 
the mitochondrial transmembrane potential, and caspase-3 activation. Inhibition of 
proliferation resulted from the induction of a G1 arrest. Furthermore, lovastatin at low 
concentrations sensitized lymphoma cells to dexamethasone, including cells resistant to 
this drug.  
Conclusion: These results indicate that protein geranylgeranylation is critical for 
the regulation of lymphoma tumor cell survival and proliferation, and that 
pharmacological agents such as lovastatin or GGTase inhibitors, alone or in combination 
with other drugs, may be useful in the treatment of lymphoma.  
 
 
Abbreviations 
 
The abbreviations used are: FPP, farnesylpyrophosphate; GGPP, 
geranylgeranylpyrophosphate; GGTase I, geranylgeranyl transferase I; FTase, farnesyl 
transferase; AML, acute myeloid leukemia; FOH, farnesol; GGOH, geranylgeraniol; FCS, 
fetal calf serum; NHL, non-Hodgkin’s lymphoma; B-CLL, B cell chronic lymphocytic 
leukemia; MTT, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide; SDS, 
sodium dodecyl sulphate; BrdU, bromodeoxyuridine; BSA, bovine serum albumin; PI, 
propidium iodide; DiOC6[3], 3,3’-dihexyloxacarbocyanine iodide; s.e.m., standard error 
of the mean. 
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Introduction 
 
The rate-limiting step of the mevalonate pathway is the conversion of HMG-CoA to 
mevalonate and is catalyzed by the enzyme HMG-CoA reductase 1. Mevalonate is an 
intermediate in the synthesis of cholesterol, essential for membrane integrity; of dolichol, 
required for glycoprotein synthesis; of polyisoprenoids side chains of heme A and 
ubiquinone, involved in oxidative respiration; and of isopentyl-adenine, present in some 
tRNAs. Furthermore, mevalonate is also a precursor of the isoprenoids FPP and GGPP 1. 
These isoprenoids are used for the post-translational modification of proteins including 
Ras (farnesylation) 2,3 and the Rho familiy members Rac-1, RhoA, and Cdc42 
(geranylgeranylation) 4. FTase and GGTase transfer farnesyl and geranylgeranyl moieties 
from FPP and GGPP, respectively, to the thiol group of conserved cysteine residues at or 
near the C-terminus of target proteins. Prenylation is essential for membrane association 2 
and participation of proteins in various signaling pathways regulating growth and survival 
3,5-7. Lovastatin is a potent competitive inhibitor of HMG-CoA reductase and thereby 
prevents the conversion of HMG-CoA to mevalonate and the synthesis of the other 
products of the mevalonate pathway. We and others have previously shown that lovastatin 
induces apoptosis and inhibits proliferation in various cancer cell lines 8-12 and in purified 
tumor cells derived from multiple myeloma 12 and AML patients 11. 
NHL and B-CLL are characterized by initial sensitivity to cytotoxic drugs in the 
majority of the patients. However, multidrug-resistant disease will ultimately develop in 
many of these patients. Recent studies have shown that defects in apoptotic pathways 
contribute significantly to resistance of cancer cells to chemotherapeutic agents 13. Anti-
apoptotic signaling pathways such as PI-3K/Akt 14-20 or NF-kappaB 21, and expression of 
anti-apoptotic Bcl-2 familiy members including Bcl-2 22-27, Mcl-1 17,28-30, and Bcl-XL 31, 
are involved in the regulation of lymphoma tumor cell survival and protection against 
cytotoxic drugs. Therefore, interference with such pathways may induce apoptosis in 
lymphoma tumor cells or restore chemosensitivity in chemoresistant tumor cells. 
This report shows that inhibition of protein geranylgeranylation by depletion of 
GGPP by lovastatin or by inhibition of GGTase I activity, induces apoptosis and inhibits 
proliferation in lymphoma cell lines and tumor cells from patients. In addition, we found 
that lovastatin enhanced the sensitivity of lymphoma cells to dexamethasone. Altogether 
our results indicate that interference with the geranylgeranylation of proteins involved in 
survival and proliferation, may be a new treatment strategy in lymphoma. 
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Materials and methods 
 
Reagents 
Lovastatin and simvastatin were obtained from Merck & Co., Inc (Rahway, NJ, USA) and 
were chemically activated by alkaline hydrolysis prior to use as described previously 32.  
Pravastatin Sodium was purchased from Bristol-Meyers Squibb (New Brunswick, NJ, 
USA) and dissolved in PBS (20 mM). Atorvastatin Calcium was obtained from Pfizer 
GmbH (Freiburg, Germany) and dissolved in ethanol containing 3% DMSO (Riedel-de 
Haen, Seelze, Germany) (10 mM). Mevalonate and FOH were purchased from Sigma (St 
Louis, MO, USA) and GGOH was obtained from ICN Biomedicals, BV (Zoetermeer, The 
Netherlands). FOH and GGOH were metabolized in cells to FPP and GGPP, respectively 
33. FTI-277 and GGTI-298 were obtained from Calbiochem (Schwallbach, Germany). 
 
Cell lines 
The follicular lymphoma cell line DoHH2 was obtained from the German Collection of 
Microorganisms and Cell Cultures (GCMC) and the follicular lymphoma cell line SU-
DHL-6 34, was kindly provided by Dr J. Jansen (University Medical Center Nijmegen, 
The Netherlands). The Burkitt’s lymphoma cell lines Raji, Ramos, and Daudi were 
purchased from the American Tissue Culture Collection. Cell lines were cultured in 
RPMI-1640 (GIBCO, Breda, The Netherlands) supplemented with 10% FCS (Integro, 
Zaandam, The Netherlands), 100 IU/ml penicillin, 100 µg/ml streptomycin and 10 µM β-
mercaptoethanol (growth medium).  
 
Patients 
After obtaining informed consent, mononuclear cells were obtained by Ficoll-Paque 
(Amersham; Pharmacia BiotechAB, Uppsala, Sweden) density centrifugation of 
peripheral blood from 13 patients suffering from leukemic NHL, B-CLL or hairy cell 
leukemia, of bone marrow from one patient with follicular lymphoma, and of pleural fluid 
from one patient with mantle cell lymphoma. Clinical characteristics of the patients are 
shown in Table 1. Tumor cells from patients 3 and 9 were purified from bone marrow 
mononuclear cells (patient 3) or from peripheral blood mononuclear cells (patient 9) by 
MACS, based on CD19 expression. To this end, mononuclear cells were subsequently 
labeled with anti-CD19 (Becton Dickinson, Erembodegem, Belgium (BDIS)) and rat anti-
mouse IgG1 microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany) and then 
separated using a high gradient magnetic separation column placed in a strong magnetic 
field (Miltenyi), following the instructions of the manufacturer. Purity after MACS 
selection of these samples was >95%.  
Tumor cells from patient 7 were purified from an axillary lymph node. The organ 
was cut into small pieces with a scalpel blade and incubated with 1 mg/ml collagenase IV 
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(Sigma) and 0.1 mg/ml DNase I (Sigma) for one hour at 37oC, 5% CO2. The cell 
suspension was subsequently filtered through an open-filter chamber (NPBI, Emmer-
Copascuum, The Netherlands) and mononuclear cells were obtained by Ficoll-Paque 
density centrifugation.  
Percentage and monoclonality of the malignant cells was established by flow 
cytometry (FACSCalibur, BDIS) by analysis of the light chain distribution within the 
surface bound immunoglobulins on CD19 positive cells or the CD4/CD8 ratio within CD3 
positive T cells in case of patient 11. Percentages of clonal cells present in the samples 
after density centrifugation or MACS selection (patients 3 and 9) ranged from 75 to 
99.4% of the nucleated cells (Table 3). For experiments, tumor cells were resuspended in 
growth medium (see above). 
 
Table 1. Clinical characteristics  
 
 
 
 
 
 
Cell viability   
Viability of cells was examined by means of the MTT assay as described previously 12. In 
short, cells were seeded in a concentration of 0.3 X 106/ml for the lymphoma cell lines or 
1 X 106/ml for the tumor cells of patients in a 96-well flat bottom plate (100 µl/well) 
(Nunc, Roskilde, Denmark) and treated with different concentrations of lovastatin (for 
concentrations see legends) alone or in the presence of mevalonate, FOH, or GGOH. 
Fixed concentrations of mevalonate (100 µM), FOH (10 µM), or GGOH (10 µM) were 
used. These concentrations proved to be optimal in rescuing myeloma cells from 
Patient Age/Sex Diagnosis Stage Disease status 
1 64/M FL grade I IVA untreated 
2 43/M FL grade I IVA refractory 
3 70/M FL grade I IVA  refractory 
4 71/F FL grade I IVA refractory 
5 59/M FL grade I IVA responsive disease 
6 45/M FL grade III IIIA refractory 
7 66/F MCL IVA refractory  
8 67/M MCL IVA refractory 
9 47/F MCL IVB refractory 
10 49/M MZL IVA responsive disease 
11 67/F PTL IVA untreated 
12 59/M Richter IVA refractory 
13 59/M B-CLL Rai II untreated 
14 59/M B-CLL Rai III untreated 
15 62/F B-CLL Rai IV refractory 
16 73/M HCL  untreated 
 The lymphoproliferative disorders were diagnosed according to the REAL
classification. The NHL and CLL patients were classified according to the Ann
Arbor and Rai classification. F, female; M, male; FL, Follicular lymphoma;
MCL, Mantle cell lymphoma; MZL, Marginal zone lymphoma; PTL, Peripheral
T-cell lymphoma; Richter, Richter’s syndrome; B-CLL, B-cell chronic
lymphocytic leukemia; HCL, Hairy cell leukemia. 
  
Inhibition of protein geranylgeranylation in lymphoma tumor cells 
148 
lovastatin-induced apoptosis (data not shown). After 2 or 4 days, 25 µl of MTT (5 mg/ml) 
was added to each well. After an incubation of 2 hours at 37oC the reaction was stopped 
by the addition of 100 µL 20% SDS (Boehringer Mannheim, Mannheim, Germany) / 
0.025 M HCl / 0.35 M HAc in a mixture of (1:1; v/v) N,N-dimethylformamide (Merck, 
Darmstadt, Germany) and distilled water. After an overnight incubation at 37oC the 
optical density of the samples was determined at 570 nm.  
 
Cell proliferation  
Cells (3 X 104) were seeded in 96-well flat bottom plates (Nunc) in 100 µl growth 
medium with lovastatin (for concentrations see legends) alone or in the presence of 
mevalonate (100 µM), FOH (10 µM), or GGOH (10 µM). Inhibition of FTase and 
GGTase I was accomplished by treating cells with FTI-277 and GGTI-298, respectively 
(for concentrations see legends). After 32 and 80 hours, 3H-thymidine (Amersham, Little 
Chalfont, UK) (1 µCi/well) was added for the remaining 16 hours of the assay. 3H-
thymidine incorporation was analyzed by liquid scintillation counting as described 
previously 12. 
 
Cell cycle analysis 
Lymphoma cells (1 X 106 in 1.5 ml) were incubated with different concentrations of 
lovastatin (for concentrations see legends) in the presence or absence of mevalonate (100 
µM), FOH (10 µM), or GGOH (10 µM) in a 48-well plate (Nunc) for 2 days. Cells were 
then pulsed with 10 µM BrdU for 30 minutes at 37oC, after which the cells were washed 
twice with ice-cold PBS containing 1% BSA. Cells were subsequently fixed with 70% 
ethanol for 30 minutes at 4oC. After the ethanol was washed away, the cells were treated 
with 2 M HCl containing 0.5% Triton-X-100 for 30 minutes at room temperature, 
followed by neutralization with 1M natrium tetraborate (pH 8.5). Following washing, cells 
were resuspended in PBS containing 0.5% Tween-20 and 1% BSA and incubated with 
anti-BrdU-FITC (BDIS) for 30 minutes at room temperature. After washing with PBS 
containing 0.5% Tween-20 and 1% BSA, cells were stained with propidium iodide in PBS 
(5 µg/ml) and analyzed by flow cytometry. 
 
Apoptosis detection by Annexin V staining   
Lymphoma cells (1.5 X 105 in 0.5 ml) were incubated with different concentrations of 
lovastatin (for concentrations see legends) alone or in the presence of mevalonate (100 
µM), FOH (10 µM), or GGOH (10 µM) in a 48-well plate (Nunc). Inhibition of FTase and 
GGTase I was accomplished by FTI-277 and GGTI-298, respectively (for concentrations 
see legends). After 2 or 4 days, cells were harvested, washed in ice-cold PBS and directly 
stained with Annexin V-FITC (Nexins Research, Kattendijke, The Netherlands) and PI. 
After 10 minutes of incubation at room temperature in the dark, cells were analyzed by 
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flow cytometry as described previously 12. Apoptotic cells were defined as early apoptotic 
cells (Annexin V positive and PI negative) and late apoptotic cells (Annexin V positive 
and PI positive).  
 
Caspase-3 activity  
The caspase-3 activity assay (Roche) was used to determine caspase-3 activity. Briefly, 
cells were washed in ice-cold PBS and then resuspended in lysis buffer (1X DTT) and 
incubated for 1 minute on ice. Supernatants were obtained after centrifugation at 14 000 
r.p.m. for 1 minute at room temperature. Supernatant was added to anti-caspase-3 coated 
wells and incubated at 37oC for 1 hour. After 3 washing steps, substrate solution (Ac-
DEVD-AFC) was added and the wells were incubated for 2 hours at 37oC. Fluorescence 
was measured with an excitation filter 400 nm and an emission filter 505 nm. 
 
Measurement of mitochondrial transmembrane potential 
Changes in mitochondrial transmembrane potential (∆ψm) were evaluated by staining with 
40 nM DiOC6[3] (Molecular Probes, Leiden, The Netherlands). Cells were incubated with 
DiOC6[3] in PBS for 15 minutes at 37oC, washed and resuspended in PBS. The cells were 
then analyzed on a flow cytometer (FACSCalibur, BDIS). 
  
Western blotting 
Cells (1 X 106 cells in 1.5 ml) were incubated for 2 days with lovastatin (for 
concentrations see legends) in the presence or absence of mevalonate (100 µM), FOH (10 
µM), or GGOH (10 µM). Inhibition of FTase and GGTase I was accomplished by FTI-
277 and GGTI-298, respectively (for concentrations see legends). After harvesting, whole 
cell lysates were made by washing cells twice in ice-cold PBS and then resuspending 
them in lysis buffer (10 mM Tris-HCl (pH 7.6), 150 mM NaCl, 1% Triton X-100 and a 
cocktail of protease inhibitors) at 4oC for 20 minutes. Insoluble material was removed by 
centrifugation at 14 000 r.p.m. for 6 minutes at 4oC. Protein concentrations were 
determined by the BCA assay (Pierce, Rockford, IL, USA). Samples containing equal 
amounts of protein were mixed with 2 X Laemmli sample buffer (0.125 M Tris pH 6.9 
with 4% SDS, 20% Glycerol and 10% β-mercaptoethanol) and boiled for 5 minutes. 
Proteins were subsequently fractionated in 10% SDS-PAGE at room temperature and 
electrically transferred from the gel to PVDF-membrane (Biorad). After blocking in 0.1% 
Tween-20, 5% skimmed powder milk, 2% BSA in 10 mM Tris and 150 mM NaCl, the 
membranes were incubated with anti-Bcl-2 (Dako, Glostrup, Denmark), anti-Mcl-1 (Santa 
Cruz Biotechnology Inc, Santa Cruz, CA, USA), anti-Bcl-XL (Santa Cruz) or anti-Bax 
(Dako), anti-Rap1a (Santa Cruz), or anti-HDJ-2 (DnaJ) (Neomarkers, Lab Vision, 
Fremont, CA, USA). Antibody binding was visualized with enhanced chemoluminescence 
(Amersham) detection with hyperfilm ECL (Amersham) after incubation with a 
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horseradish peroxidase-conjugated secondary antibody (Dako). Finally, the membranes 
were extensively washed in PBS and reprobed with anti-α-actin (Sigma) as a control for 
equal loading of protein. Relative amounts of protein were determined by densitometry 
and expressed as a percentage of the solvent control. 
 
Statistics  
Data analysis was performed using the SPSS statistical software package (SPSS Inc, 
Chicago, IL, USA). A two-sided Student’s t-test or a Welch’s t-test in case of unequal 
variances was used to determine differences between groups. Differences were considered 
statistically significant when P < 0.05. Data are plotted as means ± s.e.m. 
 
 
Results 
 
Lovastatin reduces cell viability of lymphoma cell lines  
The lymphoma cell lines (DoHH2, Raji, Daudi, Ramos, and SU-DHL-6) were incubated 
with different concentrations of lovastatin for 2 or 4 days. Lovastatin reduced viability in 
a dose- and time-dependent way. Representative examples from the DoHH2 and Raji cell 
lines are shown in Figure 1A and B. DoHH2 was the most sensitive cell line to lovastatin, 
whereas SU-DHL-6 was most resistant to lovastatin. The concentration of lovastatin that 
reduced viability with 50% (MTT50) and 75% (MTT25) ranged from 4.7 to 45.7 and 9.7 
to 118 µM at day 2, respectively. At day 4, MTT50 varied between 4.4 and 29.3 and 
MTT25 between 7.9 and 46.6 µM (Table 2). 
 
 
 
 
 
Table 2. Effect of lovastatin on cell viability in 5 lymphoma cell lines 
MTT50 and MTT25 represent the concentrations of lovastatin, which after a 2 (t2) or 4 (t4) day
incubation reduced cell viability of purified lymphoma tumor cells with 50% and 75%, compared to
the solvent control-treated cells, respectively. 
Cell line MTT50 t2 (µM) MTT25 t2 (µM) MTT50 t4 (µM) MTT25 t4 (µM) 
DoHH2 4.7 9.7 4.4 7.9 
Raji 20.6 110.9 14.0 25.1 
Daudi 29.2 118.4 18.5 27.4 
Ramos 27.4 60.1 19.5 27.2 
SU-DHL-6 45.7 87.5 29.3 46.6 
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Figure 1. Lovastatin reduces cell viability in cell lines and in purified tumor cells from lymphoma patients 
in a time- and dose-dependent way. Cell lines (A) DoHH2, (B) Raji, (C) purified tumor cells from patient 1 
(FL, follicular lymphoma), and (D) purified tumor cells from patient 7 (MCL, mantle cell lymphoma) were 
treated for 2 or 4 days with solvent control or with different concentrations of lovastatin (1-150 µM). The 
percentage of viable cells, relative to the solvent control-treated cells, was measured by using MTT assay. 
Experiments were performed three times in triplicate in case of cell lines and one time in triplicate in case of 
purified tumor cells from patients. Data are presented as mean ± s.e.m. In some cases the s.e.m. was smaller than 
the symbol. 
 
 
Lovastatin reduces cell viability of tumor cells from NHL patients 
Studies were then conducted to determine the effect of lovastatin in purified tumor cells 
from lymhoma patients (n=16). Tumor cells were purified from peripheral blood (n=13), 
bone marrow (n=1), pleural fluid (n=1), or from an axillary lymph node (n=1). Tumor cell 
percentage was >75% after purification (Table 3). The purified tumor cells were incubated 
with different concentrations of lovastatin for 2 or 4 days. Similar to cell lines, lovastatin 
reduced cell viability in a dose- and time-dependent way in tumor cells from all patients. 
Figure 1C and D show representative examples of dose-response data from 2 patients. 
Lovastatin sensitivity differed among the lymphoma patients' samples. MTT50 and 
MTT25 were in the range of 1.9 to >150 and 3.1 to >150 at day 2, respectively. At day 4 
MTT50 varied from 0.72 to 118 and MTT25 from 1.8 to 142 µM (Table 3). No obvious 
correlations were observed between lymphoma type or prior therapy and the effects of 
lovastatin on cell viability. Patients 1, 11, 13, 14, and 16 had not received treatment at the 
moment that the in vitro experiments were performed. Patients 1, 13, and 16 responded to 
subsequent chemotherapy, whereas patients 11 and 14 were lost to follow-up. There was 
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no difference between patients with chemosensitive or chemoresistant disease and 
lovastatin sensitivity. 
 
 
Lovastatin inhibits protein prenylation  
The effect of lovastatin on prenylation in DoHH2 and Raji cell lines was determined by 
analysis of the migratory behaviour during electrophoresis of DnaJ, a protein prenylated 
exclusively by FTase 35,36, and of Rap1a, a protein prenylated exclusively by GGTase I 37 
(Figure 2A). Inhibition of prenylation of these proteins can be monitored by 
immunoblotting, because the unprenylated forms of these proteins display reduced 
mobility in SDS-PAGE relative to their prenylated versions. In solvent control-treated 
cells DnaJ and Rap1a were in the processed, prenylated forms. Lovastatin inhibited the 
farnesylation of DnaJ and geranylgeranylation of Rap1a. Addition of mevalonate restored 
the processing of DnaJ and Rap1a. Treatment with lovastatin in the presence of GGOH 
(10 µM), which is metabolized to GGPP in the cells 33, restored geranylgeranylation of 
Rap1a, but had no effect on the inhibition of the farnesylation of DnaJ. In contrast, FOH 
(10 µM), which is metabolized to FPP 33, restored DnaJ farnesylation, but not Rap1a 
geranylgeranylation. 
Table 3. Effect of lovastatin on cell viability of purified tumor cells from patients with 
lymphoproliferative disorders  
Patient Source Purity (%) MTT50 t2 (µM) MTT25 t2 (µM) MTT50 t4 (µM) MTT25 t4 (µM) 
1 PB 90.2 6.4 116 3.2 16.3 
2 PB 87.2   4.4 8.8 
3 BM 99.4* n.r. n.r. 16.9 57.0 
4 PB 89.2  144 n.r. 118 142 
5 PB 88.5  146 n.r.   
6 PF 82.0  42.3 124 8.4 19.1 
7 LN 93.4  70.6 90.4 18.2 24.4 
8 PB 94.5 101 148 17.5 27.6 
9 PB 97.8* 14.7 18.8   
10 PB 75.0 92.5 n.r. 10.3 129 
11 PB 96.0  n.r. n.r. 14.3 77.6 
12 PB 84.0    7.0 14.7 
13 PB 94.6 3.3 49.6 4.3 71.9 
14 PB 77.5    4.4 15.0 
15 PB 94.2 1.9 3.1 0.72 1.8 
16 PB 75.0  108 n.r. 41.5 91.2    
 Purity indicates the percentage of tumor cells in patients’ samples and was determined by detection of CD19
and membrane immunoglobulin light chain (sκ/sλ) detection in case of a B-cell malignancy or by detection of
CD3/CD4/CD8 in case of a T-cell malignancy by flow cytometric analysis. * indicates that selection was
performed by MACS based on CD19 expression. MTT50 and MTT25 represent the concentrations of
lovastatin, which after a 2 (t2) or 4 (t4) day incubation reduced cell viability of purified lymphoma tumor cells
with 50% and 75%, compared to the solvent control-treated cells, respectively. n.r., indicates that MTT50 or
MTT25 values could not be calculated, because the concentration response curves reached a plateau. PB,
peripheral blood; BM, bone marrow; PF, pleural fluid; LN, axillary lymph node. 
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Figure 2. Lovastatin inhibits protein farnesylation and geranylgeranylation, and induces apoptosis by 
depletion of intracellular pools of GGPP. (A) DoHH2 and Raji cells were treated for 2 days with solvent 
control, or lovastatin (30 µM) alone or in the presence of mevalonate (meva; 100 µM), GGOH (10 µM), or FOH 
(10 µM). After protein isolation, processing of DnaJ and Rap1a was determined by Western blot analysis. The 
faster-migrating band represents mature and processed protein, the slower band represents unprenylated, 
unprocessed protein. The data shown are representative of at least three independent experiments. (B) DoHH2 
cells were treated for 4 days with solvent control, or lovastatin (30 µM) alone or in combination with mevalonate 
(meva; 100 µM), GGOH (10 µM), or FOH (10 µM). The percentage of apoptotic cells was examined by using 
the Annexin V assay.  The percentages of viable plasma cells (Annexin V-/PI-), early apoptotic cells (Annexin 
V+/PI-), and late apoptotic cells (Annexin V+/PI+) in each dot plot are indicated in the corresponding quadrants. 
Results are representative of three experiments performed in triplicate. (C) DoHH2 and Raji cells were treated 
for 4 days with solvent control, or lovastatin (5, 10, 40, 100, 150 µM) in combination with mevalonate (meva; 
100 µM), GGOH (10 µM), or FOH (10 µM), after which apoptosis was determined by Annexin V assay. Shown 
is the sum of the percentages of early and late apoptotic cells. Experiments were performed three times in 
triplicate. Data are presented as mean ± s.e.m. In some cases the s.e.m. was smaller than the symbol. 
 
 
Lovastatin induces apoptosis by depletion of geranylgeranylpyrophosphate 
DoHH2, Raji, Daudi, Ramos, and SU-DHL-6 cells were treated with lovastatin alone or in 
combination with mevalonate (100 µM), FOH (10 µM), or GGOH (10 µM) and apoptosis 
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was assessed by using the Annexin V assay. Lovastatin treatment resulted in an increase 
of the percentage of apoptotic cells in a time- and dose-dependent way as shown for 
DoHH2 and Raji in Figure 2 B and C. Treatment of cells with mevalonate or GGOH 
prevented lovastatin-induced apoptosis. However, addition of FOH had no effect. Similar 
to lovastatin, other hydrophobic HMG-CoA reductase inhibitors including simvastatin and 
atorvastatin also induced apoptosis, which could be abrogated by addition of mevalonate 
or GGOH, but not FOH. However, the hydrophilic inhibitor pravastatin was without effect 
(data not shown). This indicates that inhibition of geranylgeranylation by depletion of 
intracellular pools of GGPP by inhibition of HMG-CoA reductase induces apoptosis in 
lymphoma cell lines. 
 
Apoptosis induction by lovastatin is associated with Mcl-1 protein reduction, collapse 
of the mitochondrial transmembrane potential, and caspase-3 activation 
Expression levels of Bcl-2 family proteins were determined in DoHH2 and Raji cells 
treated with lovastatin (30 µM) alone or in combination with mevalonate (100 µM), FOH 
(10 µM), or GGOH (10 µM) by Western blot analysis. Lovastatin treatment resulted in a 
significant reduction of Mcl-1 expression levels (Figure 3A). Only in DoHH2 cells, 
lovastatin reduced Bcl-XL and increased Bax protein expression. Although Bcl-2 protein 
levels remained unaltered, there was an increase of the pro-apoptotic 23 kD Bcl-2 form, 
which could be visualized after long exposure of the film when compared with Bcl-2. 
Importantly, mevalonate and GGOH prevented the reduction of Mcl-1 and Bcl-XL 
expression, and the increase of Bax and the pro-apoptotic Bcl-2 form. In contrast, FOH 
was without effect.  
Members of the Bcl-2 family are involved in the regulation of the mitochondrial 
transmembrane potential, release of cytochrome c, and caspase-3 activation 38,39. 
Treatment of DoHH2 and Raji cells with lovastatin resulted in loss of the mitochondrial 
transmembrane potential as shown in Figure 3 B and C for DoHH2 cells. The collapse 
was time- (data not shown) and dose-dependent (Figure 3C). To determine whether 
lovastatin treatment resulted in activation of caspase-3, cell lysates were analyzed for 
caspase-3 activity. Treatment of DoHH2 and Raji cells with lovastatin resulted in 
activation of caspase-3 as shown for DoHH2 cells in Figure 3D. Bcl-2 is a known 
substrate of caspase-3 40,41. Exposure of cell lines to lovastatin stimulates caspase-3 
activity, which, in turn, results in the generation of the Bcl-2 cleavage product that 
promotes apoptosis. The increase of the pro-apoptotic 23 kD Bcl-2 form was 
demonstrated by Western blot analysis (Figure 3A).  
Treatment of DoHH2 and Raji cells with lovastatin in the presence of mevalonate 
or GGOH prevented the collapse of the mitochondrial transmembrane potential and the 
activation of caspase-3. However, incubation of cells with lovastatin in combination with 
FOH had no effect, when compared with lovastatin alone (Figure 3B-D). 
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Figure 3. Depletion of GGPP by lovastatin is associated with Mcl-1 protein reduction, collapse of the 
mitochondrial transmembrane potential, and caspase-3 activation. (A) Lymphoma cell lines DoHH2 and 
Raji were treated for 2 days with solvent control, or lovastatin (30 µM) alone or in combination with mevalonate 
(meva; 100 µM), FOH (10 µM), or GGOH (10 µM). After protein isolation, Mcl-1, Bcl-XL, Bcl-2, and Bax 
were determined by Western blot analysis. Furthermore, the pro-apoptotic 23 kD Bcl-2 form was detected after 
long exposure of the film. The data shown are representative of at least three independent experiments. (B) 
DoHH2 cells were treated for 4 days with solvent control, or lovastatin (30 µM) alone or in combination with 
mevalonate (meva; 10 µM), FOH (10 µM), or GGOH (10 µM). Collapse of the mitochondrial transmembrane 
potential was determined by staining the cells with DiOC6[3]. Results are representative of 3 experiments 
performed in triplicate. The fraction of cells with low (DiOC6[3]low) and the fraction of cells with intact 
(DiOC6[3]high) mitochondrial transmembrane potential are indicated in gate M1 and M2, respectively. (C) 
DoHH2 cells were treated for 4 days with solvent control, or different concentrations of lovastatin (10, 30, 50, 
100, 150 µM) alone or in combination with mevalonate (meva; 100 µM), FOH (10 µM), or GGOH (10 µM). 
Collapse of the mitochondrial transmembrane potential was determined by staining the cells with DiOC6[3]. 
Shown is the percentage of cells with low mitochondrial transmembrane potential. Experiments were performed 
three times in triplicate. Data are presented as mean ± s.e.m. In some cases the s.e.m. was smaller than the 
symbol. (D) DoHH2 cells were exposed to solvent control, or lovastatin (30 µM) alone or in combination with 
mevalonate (meva; 100 µM), FOH (10 µM), or GGOH (10 µM) for 2 days, at which time the cells were 
harvested and caspase-3 activation was assessed as described in "Materials and Methods." Experiments were 
performed three times in duplicate. Data are presented as mean ± s.e.m. 
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Synergism between lovastatin and dexamethasone in the induction of lymphoma cell 
death   
Cell lines were treated with dexamethasone (0, 5, 10, 50, or 100 µM) or doxorubicin (0, 
10, 25, 50, 100, 200, or 500 nM) alone or in combination with lovastatin (0-30 µM). The 
combination of lovastatin with doxorubicin produced a significant additive effect (data not 
shown). Furthermore, low concentrations of lovastatin potently sensitized both 
dexamethasone-sensitive (DoHH2, SU-DHL-6, Ramos) and dexamethasone-resistant 
(Raji, Daudi) lymphoma cells to dexamethasone in a synergistic fashion (Figure 4).  
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Figure 4. Lovastatin synergizes with dexamethasone in
reducing cell viability. (A) DoHH2, (B) Raji, (C) Daudi,
(D) SU-DHL-6, and (E) Ramos cells were incubated with
different concentrations of dexamethasone (0-100 µM) in
combination with lovastatin (lova; 2, 5, 10, 20, or 30 µM)
or solvent control for 4 days. Cell viability was determined
by using MTT assay as compared to cells treated without
dexamethasone and lovastatin. Results are representative of
at least three experiments performed in triplicate. Data are
presented as mean ± s.e.m. In some cases the s.e.m. was
smaller than the symbol. *Significantly higher reduction of
cell viability than the sum of the effects observed in the
corresponding lovastatin- and dexamethasone-treated
groups (P < 0.05). 
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Depletion of GGPP inhibits proliferation by induction of a G1 arrest 
DoHH2, Raji, Daudi, Ramos, and SU-DHL-6 were treated with lovastatin (0-150 µM) 
alone or in combination with mevalonate (100 µM), FOH (10 µM), or GGOH (10 µM). 
Proliferation was examined by measuring 3H-thymidine incorporation. Lovastatin 
inhibited proliferation in a time- (data not shown) and dose-dependent way as shown for 
DoHH2 and Raji at day 4 in Figure 5A. Mevalonate and GGOH, but not FOH restored 
proliferation in lovastatin-treated lymphoma cell lines. Cell cycle analysis revealed that 
lovastatin-treatment increased the number of cells in the G1 phase of the cell cycle, 
whereas the number of cells in the S phase decreased (Figure 5B). The blockade of cell 
cycle progression responsible for the inhibition of proliferation of lymphoma cells was 
abrogated by addition of mevalonate or GGOH, whereas FOH was without effect (Figure 
5B). 
Figure 5. Depletion of GGPP by lovastatin inhibits proliferation by the induction of a G1 block. (A) 
DoHH2 and Raji cells were treated for 4 days with solvent control, or different concentrations of lovastatin (1, 5, 
10, 30, 50, 100, 150 µM) alone or in combination with mevalonate (meva; 100 µM), FOH (10 µM), or GGOH 
(10 µM). Proliferation was determined by 3H-thymidine incorporation during the last 16 hours of culture. Data 
were from three experiments performed in triplicate. Data are presented as mean ± s.e.m. In some cases the 
s.e.m. was smaller than the symbol. (B) DoHH2 cells were treated with solvent control, or lovastatin (lova; 10 or 
30 µM) alone or in combination with mevalonate (meva; 100 µM), FOH (10 µM), or GGOH (10 µM) for 2 days, 
at which time the cells were harvested and cell cycle distribution was determined by BrdU assay. The percentage 
of apoptotic cells (1) and the percentages of cells in G1 phase (2), G2/M phase (3), and S phase (4) of the cell 
cycle in each dot plot are indicated in the corresponding quadrants. Results are representative of three 
experiments performed in triplicate. 
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Depletion of GGPP reduces cell viability, down-regulates Mcl-1 expression levels, 
and inhibits proliferation in purified tumor cells from lymphoma patients 
Purified tumor cells from lymphoma patients were incubated with lovastatin alone or in 
combination with mevalonate (100 µM), FOH (10 µM), or GGOH (10 µM). Similar to the 
effects in cell lines, addition of mevalonate and GGOH to purified tumor cells from 
patients (n=4) abrogated lovastatin-induced reduction of cell viability, whereas FOH had 
no effect. This is shown for a representative patient (patient 15) in Figure 6A. Mcl-1 
levels were determined in cells from 3 patients. In all cases, Mcl-1 protein levels were 
decreased when the cells were incubated with lovastatin. The reduction was 54.3% for 
patient 3, 35.1% for patient 7, and 98.4% for patient 15. Bcl-XL, Bcl-2, and Bax protein 
levels remained unchanged. Mcl-1 protein expression was recovered when mevalonate or 
GGOH were added to lovastatin-treated cells. FOH had no effect, as shown for patient 15 
in Figure 6B. In addition, proliferation of purified tumor cells (n=2) was restored by 
addition of mevalonate or GGOH, but not FOH. A representative example from patient 7 
is shown in Figure 6C.  
 
some cases the s.e.m. was smaller than the symbol. (B) Tumor cells derived from patient 15 were treated for 4
days with solvent control, or lovastatin (30 µM) alone or in the presence of mevalonate (meva; 100 µM), FOH
(10 µM), or GGOH (10 µM). After protein isolation, Mcl-1, Bcl-XL, Bcl-2, and Bax were determined by
Western blot analysis. (C) Tumor cells derived from patient 7 were treated for 4 days with solvent control, or
different concentrations of lovastatin (5, 10, 30, 50, 100, 150 µM) alone or in the presence of mevalonate
(meva; 100 µM), FOH (10 µM), or GGOH (10 µM). Proliferation was determined by 3H-thymidine
incorporation during the last 16 hours of culture. Experiments were performed once in triplicate. Data are
presented as mean ± s.e.m. In some cases the s.e.m. was smaller than the symbol. 
 
Figure 6. Treatment of purified tumor cells from
lymphoma patients with lovastatin reduces cell
viability, down-regulates Mcl-1 protein
expression levels, and inhibits proliferation by
reduction of intracellular pools of GGPP. (A)
Tumor cells derived from patient 15 were treated
for 4 days with solvent control, or different
concentrations of lovastatin (5, 10, 30, 50, 100, 150
µM) alone or in the presence of mevalonate (meva;
100 µM), FOH (10 µM), or GGOH (10 µM). The
percentage of viable cells, relative to the solvent
control-treated cells, was measured by using MTT
assay. Experiments were performed once in
triplicate. Data are presented as mean ± s.e.m. In  
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Figure 7. Inhibition of GGTase I by GGTI-298 inhibits protein geranylgeranylation resulting in Mcl-1 
down-regulation and induction of apoptosis.  DoHH2 and Raji cells were treated for 2 or 4 days with solvent 
control, the farnesyl transferase inhibitor FTI-277 (20 µM), or with the geranylgeranyl transferase I inhibitor 
GGTI-298 (20 µM). (A) After protein isolation at day 2, processing of DnaJ and Rap1a was determined by 
Western blot analysis. The faster-migrating band represents prenylated protein, the slower band represents 
unprenylated, unprocessed protein. The data shown are representative of at least three independent experiments. 
(B) The percentage of apoptotic cells was determined by Annexin V assay. Shown is the sum of the percentages 
of early and late apoptotic cells. Experiments were performed three times in triplicate. Data are presented as 
mean ± s.e.m. (C) After protein isolation at day 2, Mcl-1, Bcl-XL, Bcl-2, and Bax were determined by Western 
blot analysis. Furthermore, the pro-apoptotic 23 kD Bcl-2 form was detected after long exposure of the film. The 
data shown are representative of at least three independent experiments. 
 
 
Inhibition of GGTase I reduces Mcl-1 protein expression and induces apoptosis 
The importance of geranylgeranylation for the regulation of apoptosis and proliferation 
was further evaluated by using specific inhibitors of FTase (FTI-277) and GGTase I 
(GGTI-298). FTI-277 (20 µM) inhibited the farnesylation of DnaJ and GGTI-298 (20 µM) 
inhibited the geranylgeranylation of Rap1a in DoHH2 and Raji cells. The specificity of 
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these prenylation inhibitors is illustrated by the lack of inhibition of Rap1a prenylation by 
FTI-277, and, likewise, the lack of inhibition of DnaJ prenylation by GGTI-298 (Figure 
7A). Treatment of DoHH2 and Raji cells with GGTI-298 (20 µM) resulted in the 
induction of apoptosis in a time-dependent way (Figure 7B). The effect of FTI-277 (20 
µM) on induction of apoptosis was significantly less pronounced when compared with 
GGTI-298. Apoptosis induced by GGTI-298 treatment was associated with reduction of 
Mcl-1 protein expression (Figure 7C). Furthermore, in DoHH2 cells, Bcl-XL expression 
levels were reduced. Bax and Bcl-2 levels remained unchanged, however, GGTI-298 
treatment led to an increase of the 23 kD pro-apoptotic Bcl-2 form. In contrast, inhibition 
of FTase activity by FTI-277 had no effect on expression of Mcl-1, Bcl-XL, Bax, Bcl-2, 
and the pro-apoptotic Bcl-2 form (Figure 7C).  
 
Inhibition of GGTase I inhibits proliferation 
The effect of FTI-277 (0-30 µM) and GGTI-298 (0-30 µM) on proliferation of DoHH2 
and Raji cells was examined by measuring 3H-thymidine incorporation. Inhibition of 
GGTase I activity by GGTI-298 reduced proliferation in a time- and dose-dependent way 
(Figure 8 A and B). Inhibition of FTase activity by FTI-277 did not result in inhibition of 
proliferation or inhibited proliferation only to a small extent, when compared with GGTI-
298 (Figure 8 A and B). 
Figure 8. Inhibition of GGTase I by GGTI-298 inhibits proliferation. (A) DoHH2 and (B) Raji cells were 
treated for 2 or 4 days with solvent control, different concentrations of FTI-277 (2.5, 5, 10, 15, 20, 30 µM), or 
with different concentrations of GGTI-298 (2.5, 5, 10, 15, 20, 30 µM). Proliferation was determined by 3H-
thymidine incorporation during the last 16 hours of culture. Data were from three experiments performed in 
triplicate. Data are presented as mean ± s.e.m. In some cases the s.e.m. was smaller than the symbol. 
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Discussion 
 
Treatment of cell lines (n=6) and purified tumor cells from lymphoma patients (n=16) 
with the HMG-CoA reductase inhibitor lovastatin reduced the number of viable cells. The 
reduction in the number of viable cells was mediated by both induction of apoptosis and 
inhibition of proliferation. Addition of mevalonate to lovastatin-treated cells prevented 
apoptosis induction and restored proliferation. This indicates that the effects of lovastatin 
resulted from the inhibition of mevalonate formation, and not from non-specific cell 
toxicity. There was no significant difference in lovastatin sensitivity between tumor cells 
from pre-treated and untreated patients or from patients with chemosensitive or 
chemoresistant disease. 
Mevalonate is the precursor of various molecules including the isoprenoids FPP 
and GGPP 1. We found that geranylgeranylated protein(s) are important regulators of 
survival and proliferation in lymphoma tumor cells. Although lovastatin depletes 
intracellular pools of both GGPP and FPP resulting in inhibition of geranylgeranylation of 
Rap1a and farnesylation of DnaJ, only addition of GGOH, which is converted to GGPP in 
cells 33, abrogated the inhibition of geranylgeranylation by lovastatin and restored both 
cell viability and proliferation. In contrast, although addition of FOH, which is converted 
to FPP 33, completely restored farnesylation of DnaJ, it had no effect on viability or 
proliferation. However, in some cases GGOH was less effective than mevalonate in 
rescuing lymphoma tumor cells from apoptosis and growth arrest. This suggests that 
depletion of other metabolites downstream of mevalonate may also contribute partly to the 
effects of lovastatin. The importance of geranylgeranylation for the regulation of growth 
and survival of lymphoma cells was further confirmed by specific inhibition of FTase by 
FTI-277 and GGTase I by GGTI-298. GGTI-298 inhibited protein geranylgeranylation 
and resulted in the induction of apoptosis and inhibition of proliferation, while inhibition 
of farnesylation by FTI-277 had no or only small effects.  
The Bcl-2 family consists of pro-apoptotic proteins such as Bax, Bad, and Bak, 
and anti-apoptotic family members including Mcl-1, Bcl-XL, and Bcl-2. The balance of 
anti- and pro-apoptotic Bcl-2 family proteins determines survival or death of cells 38,39. 
The anti-apoptotic Bcl-2 family members inhibit apoptosis by forming inactivating 
heterodimers with pro-apoptotic Bcl-2 family proteins, and by preventing the collapse of 
the mitochondrial transmembrane potential and cytochrome c release from mitochondria 
into the cytosol 38,39. In the cytosol, cytochrome c and Apaf-1 can activate pro-caspase-9, 
which subsequently activates caspase-3 38,39. Mcl-1 is expressed in various types of human 
leukemia and lymphoma including CLL 28, follicular lymphoma 31,42, and anaplastic large 
cell lymphoma 43. There is increasing evidence that Mcl-1 plays a prominent role in 
lymphomagenesis 44, and in the survival 17,30,45 and chemoresistance 28,29 of lymphoma 
tumor cells. We showed that apoptosis induced by inhibition of geranylgeranylation was 
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associated with a reduction of Mcl-1 protein expression levels in lymphoma cell lines and 
patient cells, which in turn, resulted in the collapse of the mitochondrial transmembrane 
potential, and caspase-3 activation.  
Lovastatin treatment also resulted in the increase of the 23 kD pro-apoptotic Bcl-
2 form. Bcl-2 is a known substrate of caspase-3 40,41 and it is, therefore, likely that 
lovastatin-mediated stimulation of caspase-3 activity resulted in the increase of the pro-
apoptotic Bcl-2 form. The pro-apoptotic 23 kD Bcl-2 form is able to localize to 
mitochondria and to stimulate the release of cytochrome c into the cytosol 41. Therefore, 
caspase-3 dependent cleavage of Bcl-2 appears to promote further caspase activation as 
part of a positive feed-back loop. Only in DoHH2 cells, expression of the anti-apoptotic 
protein Bcl-XL was decreased and the pro-apoptotic protein Bax was increased.  Although 
the alterations in expression levels of these proteins were relatively small, when compared 
to the change in Mcl-1 expression, they may contribute partly to the induction of 
apoptosis induced by inhibition of geranylgeranylation in this cell line. 
The geranylgeranylated target protein(s) of lovastatin and GGTI-298 that mediate 
the protection against cell death and regulate the proliferation of lymphoma tumor cells 
remain to be identified. Candidates, however, include RhoA, Rac-1, R-Ras, and Cdc42, 
which are involved in important cellular functions including the regulation of apoptosis 
4,46-50. Several pathways, including PI-3K, JAK/STAT3, and MEK/ERK, can stimulate 
Mcl-1 transcription 51. Since RhoA 52,53, Rac-1 54, R-Ras 49,55, and Cdc42 56 have been 
shown to activate the PI-3K pathway, inhibition of these proteins by lovastatin or GGTI-
298 may be involved in Mcl-1 down-regulation and induction of apoptosis. Furthermore, 
RhoA, Rac-1, R-Ras, and Cdc42 have also been implicated as regulators of proliferation 
4,47,48,50,57. We showed that inhibition of geranylgeranylation resulted in a reduction of 
proliferation due to arrest in G1 phase of the cell cycle. This indicates that 
geranylgeranylated proteins are critical for G1-S transition in lymphoma tumor cells. Also 
in lung adenocarcinoma 58 and in mouse fibroblasts 37 inhibition of geranylgeranylation 
arrested cells in the G1 phase of their cycle. Rac-1 59,60, Cdc42 60-62, and RhoA 59,60 play an 
essential role in G1-S phase transition, and inhibition of processing of these proteins by 
lovastatin or GGTI-298 may, therefore, be responsible for the G1 block. Ongoing studies 
are directed at identifying the geranylgeranylated target proteins.   
Lovastatin augmented the sensitivity of both drug-sensitive and drug-resistant 
lymphoma cells to dexamethasone in a synergistic way. Moreover, additive cytotoxicity 
was observed between lovastatin and doxorubicin. Our findings are consistent with the 
ability of lovastatin to sensitize tumor cells to cytotoxic agents in other models 10,12,63-65. 
Since Mcl-1 is an important regulator of response to cytotoxic agents 28,29,66, the synergism 
between lovastatin and dexamethasone may be due, at least in part, to the lovastatin-
mediated Mcl-1 down-regulation. Importantly, cell death and chemosensitization induced 
by lovastatin were observed at concentrations that could be achieved in vivo without 
significant tissue toxicity 67.  
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In summary, we have shown that geranylgeranylation of proteins is critical for 
the survival and proliferation of lymphoma tumor cells. Inhibition of geranylgeranylation 
either by depletion of intracellular pools of GGPP through the inhibition of HMG-CoA 
reductase by lovastatin or by the specific inhibition of GGTase I activity by GGTI-298 
resulted in the induction of apoptosis and reduction of proliferation. Apoptosis induced by 
inhibition of geranylgeranylation was probably due to reduction of the anti-apoptotic Bcl-
2 familiy member Mcl-1, which, in turn, resulted in the collapse of the mitochondrial 
transmembrane potential and activation of caspase-3. The Mcl-1 down-regulation may 
also explain the chemosensitizing activity of lovastatin. Furthermore, inhibition of 
proliferation was associated with a G1 block. These data suggest that inhibition of protein 
geranylgeranylation either alone or in combination with chemotherapy warrants further 
investigation as a new therapeutic strategy in lymphoma and CLL. 
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Multiple myeloma 
Multiple myeloma is a B-lineage neoplasia and is characterized by the accumulation of 
malignant plasma cells in the bone marrow. Enhanced proliferation and defects in the 
regulation of programmed cell death account for the expansion of the malignant clone. 
Emergence of drug resistance is the primary cause of treatment failure in myeloma. 
Various studies have indicated that inhibition of drug-induced apoptosis is an important 
mechanism of drug resistance in various human cancers including myeloma. 
Understanding of mechanisms that regulate apoptosis and growth will allow for the 
development of new biologically-based therapies that overcome drug resistance and 
reduce myeloma tumor growth.  
 
This thesis has focused on the role of Bcl-2 and the mevalonate pathway in the 
maintenance of myeloma tumor cell survival and resistance to drug-induced apoptosis.  
 
Bcl-2 in myeloma  
The anti-apoptotic protein Bcl-2 is an important regulator of survival and drug resistance 
in various cancers including non-Hodgkin’s lymphoma (NHL) and acute myeloid 
leukemia (AML) 1. In myeloma, the role of Bcl-2 is unclear. Some studies suggest that in 
myeloma Bcl-2 contributes to malignant cell expansion by preventing programmed cell 
death and mediates resistance to cytotoxic drugs 2-5, whereas others claim that there is no 
correlation between Bcl-2 expression and response to treatment in vivo 6-8. In chapter 2, 
we investigated the importance of Bcl-2 in drug-induced apoptosis in myeloma using an 
antisense approach (Figure 1). G3139 (Genasense, oblimersen sodium; 5’-TCT CCC AGC 
GTG CGC CAT-3’) is a phosphorothioate 18-mer oligodeoxynucleotide (ODN) 
complementary to the first 6 codons of the Bcl-2 open reading frame. Treatment of ex vivo 
purified myeloma tumor cells with Bcl-2 antisense ODNs resulted in a sequence-specific 
reduction of Bcl-2 mRNA, followed by a sequence-specific decrease in Bcl-2 protein 
levels 9. Down-regulation of Bcl-2 resulted in enhanced sensitivity of myeloma tumor 
cells to dexamethasone or doxorubicin-induced apoptosis 9. This chemosensitizing effect 
was observed in both chemosensitive and chemoresistant myeloma cells. Treatment of 
myeloma cells with Bcl-2 antisense alone did not induce apoptosis, indicating that in 
primary myeloma tumor cells other anti-apoptotic proteins or signaling cascades confer 
protection against Bcl-2 down-regulation. These results agree with those obtained by two 
other groups and imply that Bcl-2 down-regulation by antisense ODNs decreases the 
apoptotic threshold and potentiates drug-induced apoptosis or reverses resistance to 
cytotoxic agents, indicating that Bcl-2 plays a role in drug resistance in myeloma 9-11 
(Figure 2).  
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Figure 1. Mechanism of action of Bcl-2 antisense oligodeoxynucleotides. Uptake of antisense ODNs by cells 
is through receptor-mediated endocytosis and/or fluid phase endocytosis. Bcl-2 antisense (G3139) is 
complementary to the first 6 codons of the Bcl-2 mRNA. This results in a sequence-specific hybridization of the 
Bcl-2 antisense with the target mRNAs, which prevents translation or recruits endogenous RNase H to cleave the 
mRNA backbone. The phosphorothioate DNA ODN is resistant to RNase H cleavage and can therefore 
hybridize with other Bcl-2 mRNA molecules. Altogether, this results in Bcl-2 protein down-regulation.     
 
 
 Bcl-2 protein is expressed in almost all myeloma patients, and along with its role 
in the regulation of chemosensitivity (Chapter 2) makes this anti-apoptotic protein an 
attractive target for therapy in multiple myeloma. In a phase 2 clinical trial, we studied the 
effect of Bcl-2 antisense in 10 myeloma patients that were heavily pretreated, with a 
median of 4 chemotherapy regimens prior to entering the study (chapter 3). G3139 was 
administered for 7 days as a continuous intravenous infusion of 7 mg/kg/day and VAD 
chemotherapy was started at day 4. This sequential order was chosen, since our preclinical 
studies showed that maximum inhibition of Bcl-2 protein was observed after 4 days of 
treatment of purified myeloma tumor cells with G3139 9. This may be due to the relatively 
long half-life of the Bcl-2 protein. Bcl-2 mRNA levels, however, were already reduced 
after 2 days of treatment 9. Administration of Bcl-2 antisense resulted in a moderate 
reduction of Bcl-2 protein levels in peripheral blood circulating myeloma cells, 
monocytes, B cells, and T cells. Four (40%) achieved a partial response and 3 (30%) 
patients a minor response, indicating that 70% of the patients responded to the 
combination of G3139 and VAD. Five out 7 responding patients were refractory to VAD 
chemotherapy alone, which indicates that the administration of Bcl-2 antisense can 
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overcome classical drug resistance in myeloma. The combination of Bcl-2 antisense and 
VAD chemotherapy was well tolerated, and toxicity was primarily attributable to VAD. 
The toxicity associated with administration of Bcl-2 antisense alone prior to start of VAD 
chemotherapy included inflammation at the infusion site, fatigue, and a transient reduction 
of absolute numbers of circulating thrombocytes, monocytes, B cells, and T cells. Since 
Bcl-2 expression is critical for survival of mature B and T cells 12,13, down-regulation of 
Bcl-2 may be responsible for the reduction of circulating B and T cells. Antisense-
mediated Bcl-2 down-regulation did not result in loss of the renewal potential of normal 
hematopoietic cells, allowing for the repopulation of depleted cells. This is in accordance 
with the observation that hematopoiesis was not affected in Bcl-2 knock-out mice 12,13 
suggesting that Bcl-2 is not essential for survival of pluripotent hematopoietic stem cells. 
Thrombocytopenia and fatigue have also been described in clinical studies that evaluated 
the effect of other phosphorothiate oligodeoxynucleotides, indicating that these effects 
probably resulted from non-sequence specific effects and can be attributed to the 
phosphorothioate backbone of the oligodeoxynucleotide molecule 14,15.  
 
Figure 2. Bcl-2 antisense-mediated down-regulation of Bcl-2 protein levels overcomes drug resistance and 
restores sensitivity to cytotoxic agents in myeloma cells. 
 
 
 Since Bcl-2 protein is expressed in a variety of tissues, it is remarkable that Bcl-2 
down-regulation was relatively non-toxic to normal cells. One of the questions at the start 
of this study, was indeed whether Bcl-2 antisense combined with chemotherapy would 
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selectively modulate apoptosis in the tumor cells without severe adverse effects in normal 
tissues. Pro-apoptotic Bcl-2 family proteins such as Bax are expressed in myeloma tumor 
cells. Moreover, myeloma cells express oncoproteins, like c-Myc, that deregulate the cell 
cycle, but also have pro-apoptotic effects 16. Deregulated expression of c-Myc is common 
in multiple myeloma 17,18, and although c-Myc stimulates proliferation, c-Myc also has an 
apoptosis-inducing effect 19. The oncogenic potential of c-Myc is reduced by its induction 
of apoptosis, as demonstrated in c-Myc transgenic mice 20. Lymphomagenesis was 
dramatically increased in these mice by Bcl-2, as c-Myc-induced apoptosis was blocked 
by Bcl-2 19. Furthermore, overexpression of c-Myc in serum-deprived CHO cells or 
fibroblasts induces proliferation accompanied by apoptosis, however coexpression of Bcl-
2 abrogates this c-Myc-induced programmed cell death 19,21. Thus the balance between 
pro-apoptotic proliferation effects and anti-apoptotic survival signals provided by various 
Bcl-2 family proteins seems to be critical for tumor cell viability and tumor cell growth. 
Reduction of one anti-apoptotic Bcl-2 family protein may then tip the balance directly 
towards apoptosis or sensitize tumor cells to a second apoptotic-trigger such as a cytotoxic 
drug, while sparing normal cells without deregulated oncogenes. This may explain the 
observation that, although Bcl-2 is expressed in many tissues, there was no excess tissue 
toxicity observed in our clinical study over and above what would be expected from VAD 
alone except for lymphopenia, fatigue, and inflammation around the infusion site. 
 One of the disadvantages of this antisense approach includes the need of a 
continuous intravenous infusion for 7 days, since the plasma half-life of G3139 is in the 
order of 2 hours. Current research is directed at examining the feasibility of a slow-release 
subcutaneous formulation of Bcl-2 antisense ODNs. Another strategy to target the Bcl-2 
protein includes the inhibition of Bcl-2 by small molecules that disrupt the binding of Bcl-
2 to pro-apoptotic Bcl-2 family members and thus abrogate at least part of the anti-
apoptotic function of Bcl-2 22-24. Other approaches include manipulation of signaling 
pathways that are critical for the expression of Bcl-2 protein or manipulation of post-
translational modifications to alter its activity 25-28. 
 The responses observed in our trial provide the proof of principle that Bcl-2 
protein is involved in drug resistance in vivo and that inhibition of Bcl-2 expression 
increases the in vivo therapeutic efficacy of cytotoxic agents in myeloma (Figure 2). A 
randomized phase 3 clinical study has been initiated to evaluate the clinical efficacy of 
dexamethasone alone compared with Bcl-2 antisense combined with dexamethasone in 
relapsed or refractory multiple myeloma patients.  
 
Mevalonate pathway in myeloma 
The mevalonate pathway produces a variety of products including farnesyl and 
geranylgeranyl isoprenoids, dolichol, ubiquinone, and cholesterol, which may be essential 
for cell survival and growth 29. Deregulated or elevated activity of HMG-CoA reductase 
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has been demonstrated in a variety of tumors including leukemia and lymphoma 30,31. In 
some cancer cell lines and purified tumor cells from AML patients, suppression of the 
mevalonate pathway by statins resulted in inhibition of growth and survival, and 
significantly enhanced sensitivity of tumor cells to novel drugs or conventional 
chemotherapeutic agents. Importantly, lovastatin had minimal effects on normal bone 
marrow progenitor cells 32. The role of the mevalonate pathway and its metabolites in 
myeloma, however, was unknown. In the second part of this thesis, we focused on the 
importance of the mevalonate pathway in myeloma. Blocking of the mevalonate pathway 
through the inhibition of HMG-CoA reductase by lovastatin induced apoptosis and 
inhibited proliferation even in resistant myeloma cell lines and primary myeloma cells. 
Lovastatin also sensitized myeloma cell lines to cytotoxic agents (chapter 4) 33.  
These effects were due to specific inhibition of HMG-CoA reductase since 
addition of mevalonate restored survival and proliferation in lovastatin-treated cells 33. 
This also indicates that products downstream of mevalonate were involved in apoptosis 
induction and inhibition of proliferation. We found that depletion of 
geranylgeranylpyrophosphate (GGPP) by lovastatin resulted in inhibition of protein 
geranylgeranylation, induction of apoptosis, and suppression of proliferation, whereas 
depletion of farnesylpyrophosphate (FPP) leading to inhibition of farnesylation had no or 
only minor effects. The role of protein geranylgeranylation in the regulation of myeloma 
tumor cell growth and survival was confirmed in experiments with specific inhibitors of 
geranylgeranyl transferase I (GGTase I) and farnesyl transferase (FTase) 34. Inhibition of 
GGTase I activity reduced proliferation and induced apoptosis, with only small effects of 
inhibition of FTase (chapter 5 and 6). Inhibition of geranylgeranylation by both lovastatin 
and the GGTase I inhibitor preceded the reduction of cell viability. These results 
regarding FTase inhibition agree with several recently published in vitro studies that 
showed that inhibition of farnesylation by FTase inhibitors had only small effects in 
myeloma 35-39. Furthermore, two clinical studies have evaluated the therapeutic efficacy of 
the FTase inhibitor Zarnestra (R115777) in patients with relapsed or refractory myeloma. 
Although treatment with Zarnestra suppressed FTase activity and inhibited protein 
farnesylation in bone marrow and peripheral blood mononuclear cells of myeloma 
patients, it had only modest antimyeloma activity 40,41.  
Addition of mevalonate to lovastatin-treated cells was more effective in rescuing 
cells from apoptosis and growth arrest than geranylgeranyl isoprenoids. This suggests that 
in addition to inhibition of geranylgeranylation, depletion of other metabolites 
downstream of mevalonate may also contribute to the effects of lovastatin. For instance, 
isopentenyladenine is an essential substrate for the modification of some tRNAs 29. 
Furthermore, the GGPP metabolite dolichol-phosphate is involved in N-linked 
glycosylation and plays a role in the translocation of survival receptors including insulin-
like growth factor-I (IGF-I) receptors from the intracellular compartment to the cell 
membrane. Depletion of intracellular pools of dolichol-phosphate by statins in various 
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cancer cell lines resulted in decreased trafficking of the IGF-I receptor to the cell 
membrane 42,43. The IGF-I signaling pathways have been shown to play an important role 
in the regulation of myeloma growth and survival. This suggests that in addition to 
inhibition of geranylgeranylation, depletion of dolichol-phosphate or isopentenyladenine 
by lovastatin may also contribute to the induction of apoptosis and inhibition of 
proliferation in myeloma cells. However, in add-back experiments isopentenyladenine or 
dolichol-phosphate did not abrogate lovastatin-induced apoptosis in AML cell lines 44. 
 Our data indicate an important role for geranylgeranylated proteins in the 
regulation of myeloma cell survival 34. The mechanisms of apoptosis induction through 
the inhibition of geranylgeranylation were investigated in chapter 5. In all myeloma cell 
lines and in all primary myeloma cells, it was demonstrated that inhibition of 
geranylgeranylation either by depletion of GGPP or inhibition of GGTase I activity 
reduced expression of Mcl-1 protein levels 34. This reduction preceded or was concomitant 
with induction of apoptosis, collapse of the mitochondrial transmembrane potential, and 
caspase activation suggesting that Mcl-1 down-regulation is involved in lovastatin- or 
GGTase I inhibitor-induced programmed cell death. Recently, several studies have 
demonstrated that the anti-apoptotic Bcl-2 family member Mcl-1 is a key regulator of 
survival and chemosensitivity in myeloma 10,45,46. Reduction of Mcl-1 protein induced 
apoptosis and restored sensitivity to dexamethasone 10. Furthermore, high expression of 
Mcl-1 was associated with a poor response to therapy in B-cell chronic lymphocytic 
leukemia (B-CLL) 47, AML, and acute lymphoblastic leukemia (ALL) patients 48. This 
suggests that the synergistic effect between lovastatin and dexamethasone in myeloma 
cells may be due to lovastatin-mediated reduction of Mcl-1 expression. 
 Myeloma tumor cell growth and survival is regulated by various signaling 
pathways including MAPK 49, PI-3K 50,51, JAK-STAT 52, NF-κB 53-56 signaling cascades. 
The MAPK 49, PI-3K 50,51,57, and NF-κB 55,56 signaling pathways stimulate myeloma cell 
proliferation and activation of JAK-STAT 52, PI-3K 50,51,57, and NF-κB 54,56 pathways 
promotes myeloma cell survival. Inhibition of geranylgeranylation either by depletion of 
geranylgeranyl isoprenoids through inhibition of HMG-CoA reductase or by inhibition of 
GGTase I activity suppressed myeloma proliferation due to G1 arrest (chapter 6). 
Approximately 0.5 to 1% of cellular proteins are geranylgeranylated, however only a 
small number of proteins have been identified 58, of these the geranylgeranylated proteins 
Rac-1, RhoA, and Cdc42 are implicated in the regulation of various cellular processes 
including survival and proliferation 59-63. Studies using specific inhibitors of these proteins 
suggested that Rac-1 and/or Cdc42 GTPases play a role in myeloma cell growth, but not 
survival. Although, Rho activity seems to be important for the rearrangement of the actin 
cytoskeleton in myeloma cells and for morphological changes and attachment to culture 
dishes 64, inhibition of Rho proteins did not affect myeloma cell survival or proliferation. 
This suggests that Rho may play a role in the motility and metastatic potential of myeloma 
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cells 64. Rac-1 was activated in all myeloma cell lines tested, and the important growth and 
survival factor IL-6 induced Rac-1 activity. Introduction of dominant-negative Tat-Rac-1 
protein and reduction of Rac protein levels by antisense oligodeoxynucleotides reduced 
proliferation, whereas constitutively active Tat-Rac-1 stimulated proliferation of myeloma 
cells. Both dominant-negative and constitutively active Rac-1 had no effect on myeloma 
cell survival. These data suggest that Rac-1 plays a role in myeloma cell proliferation, and 
that the suppression of proliferation by lovastatin and GGTase I inhibitors may be, at least 
in part, due to inhibition of geranylgeranylation of Rac-1. Since IL-6 stimulates Rac-1 
activity and dominant-negative Rac-1 blocks IL-6-induced growth, Rac-1 may be a 
downstream effector in IL-6-triggered signaling pathways. The effect of expression of 
constitutively active and dominant-negative Tat-Rac-1 mutants on proliferation is 
currently being evaluated in primary myeloma cells.   
 An important question to address is how Rac-1 is activated in myeloma cells. 
Various studies have shown that PI-3K stimulates Rac-1 activity probably through the 
activation of Rac GDP/GTP exchange factors (GEFs) 65-67. Alternatively, Rac-1 can be 
activated by Ras in a PI-3K-dependent or -independent way 66,68. Both PI-3K 50,51,57 and 
Ras 39 play an important role in myeloma cell growth. Activation of Akt by PI-3K in 
myeloma cells has been shown to contribute to proliferation and survival 69,70. Several 
pathways that contribute to growth are activated downstream of Ras in myeloma cells 
including PI-3K, NF-κB, and MAPK signaling cascades 39. Our data suggest that Rac-1 
may be a downstream effector of Ras and/or PI-3K signaling pathways leading to 
myeloma tumor cell proliferation.  
 Induction of apoptosis and suppression of proliferation through inhibition of 
protein geranylgeranylation were not restricted to myeloma tumor cells. Also in 
lymphoma cell lines and in purified tumor cells from patients with NHL and B-CLL 
inhibition of protein geranylgeranylation either by inhibition of the mevalonate pathway 
or by specific suppression of GGTase I activity induced apoptosis even in resistant cell 
lines and patient cells, blocked proliferation, and reversed resistance to dexamethasone 
(chapter 7).         
 These preclinical studies indicate that modulation of the mevalonate pathway 
through the inhibition of HMG-CoA reductase by statins represents a novel therapeutic 
approach in the treatment of myeloma and lymphoma, and provided the basis for the 
evaluation of simvastatin in combination with chemotherapy in a phase 1 clinical trial. In 
this study refractory NHL, B-CLL, and myeloma patients are treated with simvastatin for 
7 days, followed by VAD chemotherapy in myeloma or CHOP in NHL or CLL. The 
primary objectives of this study are to determine the safety and tolerability of simvastatin 
administered in combination with chemotherapy, and to define the maximum-tolerated 
dose of simvastatin.  
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Concluding remarks  
The identification and increased understanding of mechanisms that regulate survival, drug 
resistance, and proliferation will contribute to the development of new specific and 
effective therapeutic strategies to modulate apoptosis, growth, and drug resistance in 
multiple myeloma 71,72. With rare exceptions, malignant cell growth is the result of 
multiple genetic alterations 73. The combination of novel agents that simultaneously target 
a single pathway or that target different pathways will therefore be critical to avoid drug 
resistance and to achieve long-term remissions 74. The introduction of novel agents 
together with technologies such as gene expression profiling to identify those patients who 
are most likely to respond, will result in a more selective and potent molecular-based 
myeloma therapy that will improve patient outcome.  
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Multipel myeloom, ook wel ziekte van Kahler genoemd, behoort samen met de 
verschillende soorten leukemieën en lymfomen tot de hematologische maligniteiten. Bij 
multipel myeloom is er sprake van een kwaadaardige woekering van plasmacellen in het 
beenmerg. Plasmacellen behoren tot de witte bloedcellen en zijn verantwoordelijk voor 
een deel van de afweer tegen bacteriën en virussen door de productie van antistoffen. De 
myeloom tumorcellen en de producten van de tumorcellen zijn verantwoordelijk voor 
symptomen zoals infecties, botpijn, vermoeidheid (onder andere ten gevolge van 
bloedarmoede) en nierfunctie stoornissen. Multipel myeloom is een tot nu toe 
ongeneeslijke vorm van kanker met een overleving die varieert van minder dan 2 tot meer 
dan 80 maanden na diagnose. In Nederland wordt jaarlijks bij ongeveer 800 mensen de 
diagnose multipel myeloom gesteld en overlijdt een ongeveer even groot aantal aan deze 
ziekte. Multipel myeloom wordt over het algemeen behandeld met chemotherapie. 
Ondanks een vaak goede initiële respons op chemotherapie, reageert de meerderheid van 
de patiënten uiteindelijk niet meer op chemotherapie en is er sprake van 
chemotherapieresistente ziekte. Een beter inzicht in het ontstaan van 
chemotherapieresistentie en kennis van de regulatie van celdeling en overleving van 
myeloom tumorcellen kan bijdragen aan de ontwikkeling van nieuwe therapieën. In dit 
proefschrift werd gekeken naar de rol van Bcl-2 en de mevalonzuur route bij de regulatie 
van dit soort processen in multipel myeloom.  
 
Bcl-2 is een eiwit dat geprogrammeerde celdood (apoptose) tegen gaat en dat ook celdood 
geïnduceerd door chemotherapeutica kan remmen. De rol van Bcl-2 in multipel myeloom 
was nog grotendeels onbekend. De functie van Bcl-2 bij multipel myeloom werd 
onderzocht door middel van antisense oligodeoxynucleotiden (ODNs), dit zijn korte 
stukken enkelstrengs DNA, die in dit geval een sequentie hebben die complementair is 
aan de sequentie van het Bcl-2 messengerRNA (mRNA). Bcl-2 mRNA is een kopie van 
het Bcl-2 gen en bevat de code die nodig is voor de productie van het Bcl-2 eiwit in de 
cel. Bcl-2 antisense ODNs binden specifiek aan Bcl-2 mRNA moleculen, omdat ze een 
complementaire sequentie hebben. Dit leidt tot de vorming van een Bcl-2 antisense/Bcl-2 
mRNA duplex. De vorming van deze duplex remt de vertaling van het Bcl-2 mRNA tot 
eiwit en bovendien wordt het Bcl-2 mRNA in de duplex afgebroken door het enzym 
RNase H. In hoofdstuk 2 is beschreven dat behandeling van opgezuiverde myeloom 
tumorcellen van patiënten met Bcl-2 antisense ODNs resulteerde in een specifieke daling 
van de hoeveelheid Bcl-2 mRNA en Bcl-2 eiwit. De reductie van Bcl-2 eiwit alleen 
induceerde geen celdood, maar maakte de myeloom tumorcellen wel significant 
gevoeliger voor verschillende soorten chemotherapeutica.       
 Dit laboratorium onderzoek vormde de basis voor een klinische studie (hoofdstuk 
3). Het doel van dit onderzoek was om te bestuderen of een daling van de hoeveelheid 
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Bcl-2 eiwit de effectiviteit van chemotherapie in myeloom patiënten zou vergroten. In dit 
onderzoek werd aan uitvoerig voorbehandelde en niet meer op chemotherapie reagerende 
myeloom patiënten gedurende 7 dagen Bcl-2 antisense ODNs toegediend. Op dag 4 van 
de antisense infusie werd gestart met VAD-chemotherapiekuren. De combinatie van Bcl-2 
antisense en VAD-chemotherapie werd goed verdragen. Behandeling van patiënten met 
Bcl-2 antisense ODNs gecombineerd met VAD-kuren resulteerde in een reductie van de 
hoeveelheid tumor bij 7 van de 10 (70%) patiënten, wat zich vertaalde in een 
vermindering van de pijn en verbetering van de lichamelijke conditie. Vijf van deze 7 
responderende patiënten reageerden niet meer op VAD-kuren alleen. Dit geeft aan dat 
daling van de hoeveelheid Bcl-2 eiwit in de tumor met behulp van Bcl-2 antisense ODNs 
de gevoeligheid van de tumor voor chemotherapie kan herstellen.  
 
Het tweede deel van dit proefschrift gaat over de rol van de mevalonzuur route in multipel 
myeloom. De mevalonzuur route produceert een diversiteit aan producten waaronder 
farnesylpyrofosfaat, geranylgeranylpyrofosfaat, dolichol en ubiquinon, maar ook 
cholesterol. De snelheidsbepalende stap van de mevalonzuur route is de omzetting van 
HMG-CoA naar mevalonzuur en wordt geremd door statines zoals simvastatine en 
lovastatine. Remming van de mevalonzuur route door lovastatine in myeloom tumorcellen 
verminderde de celdeling, induceerde geprogrammeerde celdood en verhoogde de 
effectiviteit van chemotherapie (hoofdstuk 4). Vervolgens werd in hoofdstuk 5 en 6 
onderzocht op welke wijze remming van de mevalonzuur route resulteerde in celdood en 
vermindering van celdeling. Afname van de hoeveelheid geranylgeranylpyrofosfaat in de 
myeloom tumorcel bleek verantwoordelijk te zijn voor zowel de inductie van celdood als 
de remming van celdeling. Geranylgeranylpyrofosfaat moleculen worden door het enzym 
geranylgeranyl transferase gehecht aan bepaalde eiwitten. Dit proces, dat ook wel 
geranylgeranylering wordt genoemd, is een vereiste voor de bevestiging van deze eiwitten 
aan membranen, wat noodzakelijk is voor het kunnen uitoefenen van hun functie in de cel. 
Ook remming van geranylgeranylering door inhibitie van geranylgeranyl transferase 
induceerde celdood en verminderde de celdeling van myeloom tumor cellen.  
 Deze gegevens wijzen op een belangrijke rol van ge-geranylgeranyleerde 
eiwitten in de regulatie van deling en overleving van myeloom tumorcellen. Remming van 
de geranylgeranylering in myeloom tumorcellen resulteerde waarschijnlijk in celdood, 
doordat de expressie van het Bcl-2 familie eiwit Mcl-1 verlaagd werd. Mcl-1 beschermt 
net als Bcl-2 tegen geprogrammeerde celdood en een afname van dit eiwit kan direct 
leiden tot het dood gaan van myeloom tumorcellen. De toename van de effectiviteit van 
chemotherapie door lovastatine kan ook verklaard worden door de afname van de 
hoeveelheid Mcl-1 eiwit, aangezien Mcl-1 myeloom tumorcellen kan beschermen tegen 
de effecten van chemotherapie. 
 Door gebruik te maken van verschillende remmers van ge-geranylgeranyleerde 
eiwitten werd gevonden dat het eiwit Rac-1 waarschijnlijk een rol speelt bij de deling van 
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myeloom tumorcellen, maar niet bij de overleving van deze cellen. Rac-1 was geactiveerd 
in myeloom tumorcellen en de belangrijkste myeloom groeifactor interleukine-6 (IL-6) 
verhoogde de activiteit van Rac-1. Specifieke verlaging van de hoeveelheid Rac eiwit en 
behandeling van de cellen met een dominant-negatief Tat-Rac-1 eiwit leidde tot remming 
van de celdeling. Dit geeft dus aan dat het ge-geranylgeranyleerde eiwit Rac-1 betrokken 
is bij de regulatie van multipel myeloom celdeling.        
 In hoofdstuk 7 is beschreven dat geranylgeranylering van eiwitten ook belangrijk 
is voor de overleving en celdeling van tumorcellen die afkomstig zijn van patiënten met 
verschillende soorten non-Hodgkin lymfomen en chronische lymfatische leukemie. Ook 
bij deze vormen van kanker leidde remming van de mevalonzuur route en inhibitie van 
geranylgeranyl transferase tot celdood, remming van de celdeling en toename van de 
effectiviteit van cytostatica.  
 De preklinische studies zoals beschreven in de hoofdstukken 4 tot en met 7 geven 
aan dat remming van de mevalonzuur route door statines een nieuwe strategie is voor de 
behandeling van patiënten met multipel myeloom, non-Hodgkin lymfoom en chronische 
lymfatische leukemie. Dit onderzoek heeft geleid tot de initiatie van een klinische studie 
waarin de effectiviteit van simvastatine in combinatie met chemotherapie momenteel 
onderzocht wordt bij deze patiënten.  
 
Een beter begrip van mechanismen, die van belang zijn voor de regulatie van overleving, 
deling en chemotherapieresistentie van myeloom tumorcellen, kan bijdragen aan de 
ontwikkeling van nieuwe specifieke en effectieve therapieën voor de behandeling van 
multipel myeloom. In dit proefschrift werd de functie van het eiwit Bcl-2 en de 
mevalonzuur route in multipel myeloom beschreven. Deze kennis leidde tot de initiatie 
van twee klinische studies. Het uiteindelijke doel van dit soort laboratorium onderzoek en 
klinische studies is het verbeteren van de behandeling van multipel myeloom patiënten.    
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